| 1 |
Song C, Kakuta Y, Negoro K, Moroi R, Masamune A, Sasaki E, Nakamura N, Nakayama M. Collection of patient-generated health data with a mobile application and transfer to hospital information system via QR codes. Computer Methods and Programs in Biomedicine Update 2023. [DOI: 10.1016/j.cmpbup.2023.100099] [Reference Citation Analysis]
|
| 2 |
Bergamaschi G, Castiglione F, D'Incà R, Astegiano M, Fries W, Milla M, Ciacci C, Rizzello F, Saibeni S, Ciccocioppo R, Orlando A, Bossa F, Principi M, Vernia P, Ricci C, Scribano ML, Bodini G, Mazzucco D, Bassotti G, Riegler G, Buda A, Neri M, Caprioli F, Monica F, Manca A, Villa E, Fiorino G, Comberlato M, Aronico N, Della Corte C, Caccaro R, Gionchetti P, Giuffrida P, Iovino P, Lenti MV, Mengoli C, Pellegrini L, Pieraccini A, Ribaldone D, Testa A, Ubezio C, Viola A, Vecchi M, Klersy C, Di Sabatino A. Prevalence, Pathogenesis and Management of Anemia in Inflammatory Bowel Disease: An IG-IBD Multicenter, Prospective, and Observational Study. Inflamm Bowel Dis 2023;29:76-84. [PMID: 35366312 DOI: 10.1093/ibd/izac054] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 3 |
Ledder O, Turner D. Clinical Indices for Pediatric Inflammatory Bowel Disease Research. Pediatric Inflammatory Bowel Disease 2023. [DOI: 10.1007/978-3-031-14744-9_46] [Reference Citation Analysis]
|
| 4 |
Miyaguchi K, Tsuzuki Y, Ichikawa Y, Shiomi R, Ohgo H, Nakamoto H, Imaeda H. Positive zinc intake and a Japanese diet rich in n-3 fatty acids induces clinical remission in patients with mild active ulcerative colitis: a randomized interventional pilot study. J Clin Biochem Nutr 2023;72:82-8. [PMID: 36777083 DOI: 10.3164/jcbn.22-72] [Reference Citation Analysis]
|
| 5 |
Tomita T, Fukui H, Morishita D, Mori S, Oshima T, Shinzaki S, Miwa H. Efficacy of Serotonin Type 3 Receptor Antagonist Ramosetron on Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)-Like Symptoms in Patients with Quiescent Inflammatory Bowel Disease: A Randomized, Double-Blind, Placebo-Controlled Trial. J Clin Med 2022;11. [PMID: 36498457 DOI: 10.3390/jcm11236882] [Reference Citation Analysis]
|
| 6 |
Miyazu T, Ishida N, Asai Y, Tamura S, Tani S, Yamade M, Hamaya Y, Iwaizumi M, Osawa S, Furuta T, Baba S, Sugimoto K. Importance of eosinophilic infiltration of the colonic mucosa in ulcerative colitis patients who are refractory to maintenance therapy: A prospective, single-center study. Medicine (Baltimore) 2022;101:e31017. [PMID: 36221337 DOI: 10.1097/MD.0000000000031017] [Reference Citation Analysis]
|
| 7 |
Ishida N, Kaneko M, Asai Y, Miyazu T, Tamura S, Tani S, Yamade M, Iwaizumi M, Hamaya Y, Osawa S, Furuta T, Sugimoto K. Effect of disease duration on fecal biomarkers in ulcerative colitis: a prospective cohort study. BMC Gastroenterol 2022;22. [DOI: 10.1186/s12876-022-02502-8] [Reference Citation Analysis]
|
| 8 |
Fujii R, Awaga Y, Nozawa K, Matsushita M, Hama A, Natsume T, Takamatsu H. Regional brain activation during rectal distention and attenuation with alosetron in a nonhuman primate model of irritable bowel syndrome. FASEB BioAdvances 2022. [DOI: 10.1096/fba.2022-00048] [Reference Citation Analysis]
|
| 9 |
Nagasaka M, Nakagawa Y, Kamano T, Omori T, Nakaoka K, Funasaka K, Miyahara R, Hashimoto S, Shibata T, Hirooka Y. Endoscopic imaging in inflammatory bowel disease. J Med Ultrason (2001) 2022. [PMID: 36036332 DOI: 10.1007/s10396-022-01250-2] [Reference Citation Analysis]
|
| 10 |
Ishida N, Tani S, Asai Y, Miyazu T, Tamura S, Yamade M, Iwaizumi M, Hamaya Y, Osawa S, Furuta T, Sugimoto K. Lymphocyte to monocyte ratio and serum albumin changes predict tacrolimus therapy outcomes in patients with ulcerative colitis. Sci Rep 2022;12:13572. [PMID: 35945329 DOI: 10.1038/s41598-022-17763-2] [Reference Citation Analysis]
|
| 11 |
Sood A, Singh A, Mahajan R, Midha V, Bernstein CN, Rubin DT. (Re)Appraising Remission in Ulcerative Colitis. Inflamm Bowel Dis 2022:izac170. [PMID: 35917172 DOI: 10.1093/ibd/izac170] [Reference Citation Analysis]
|
| 12 |
Petersen AM. Gastrointestinal dysbiosis and Escherichia coli pathobionts in inflammatory bowel diseases. APMIS 2022;130 Suppl 144:1-38. [PMID: 35899316 DOI: 10.1111/apm.13256] [Reference Citation Analysis]
|
| 13 |
Stremmel W, Vural H, Evliyaoglu O, Weiskirchen R. Wirksamkeit von darmlöslichem Lecithin (Phosphatidylcholin) zur Behandlung der Colitis ulcerosa. MMW - Fortschritte der Medizin 2022;164:3-11. [DOI: 10.1007/s15006-022-0832-0] [Reference Citation Analysis]
|
| 14 |
Kurumi H, Takata T, Kanda T, Sugihara T, Kakugawa T, Yokota SI, Morisaki T, Akashi T, Isomoto H. Investigating the role of heat shock protein 47 in fibrosis in Crohn's disease. Sci Rep 2022;12:10966. [PMID: 35768471 DOI: 10.1038/s41598-022-15153-2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 15 |
Higuchi N, Hiraga H, Sasaki Y, Hiraga N, Igarashi S, Hasui K, Ogasawara K, Maeda T, Murai Y, Tatsuta T, Kikuchi H, Chinda D, Mikami T, Matsuzaka M, Sakuraba H, Fukuda S. Automated evaluation of colon capsule endoscopic severity of ulcerative colitis using ResNet50. PLoS One 2022;17:e0269728. [PMID: 35687553 DOI: 10.1371/journal.pone.0269728] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 16 |
Ishida N, Asai Y, Miyazu T, Tamura S, Tani S, Yamade M, Iwaizumi M, Hamaya Y, Osawa S, Furuta T, Sugimoto K. Lymphocyte-to-monocyte ratio is a short-term predictive marker of ulcerative colitis after induction of advanced therapy. Gastroenterol Rep (Oxf) 2022;10:goac025. [PMID: 35692303 DOI: 10.1093/gastro/goac025] [Reference Citation Analysis]
|
| 17 |
Ge C, Lu Y, Shen H, Zhu L. Monitoring of intestinal inflammation and prediction of recurrence in ulcerative colitis. Scandinavian Journal of Gastroenterology 2022;57:513-524. [DOI: 10.1080/00365521.2021.2022193] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 18 |
Stallhofer J, Veith L, Diegelmann J, Probst P, Brand S, Schnitzler F, Olszak T, Török H, Mayerle J, Stallmach A, Beigel F. Iron Deficiency in Inflammatory Bowel Disease Is Associated With Low Levels of Vitamin D Modulating Serum Hepcidin and Intestinal Ceruloplasmin Expression. Clin Transl Gastroenterol 2022. [PMID: 35029158 DOI: 10.14309/ctg.0000000000000450] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 19 |
Gulumsek E, Sumbul HE, Yesildal F, Kizildag C, Ozturk DD, Avci BS, Aktas B, Avci A, Bayrak E, Tas A, Kara B. Serum Elabela level is related to endoscopic activity index in patients with active ulcerative colitis. Ir J Med Sci 2022. [PMID: 35000117 DOI: 10.1007/s11845-021-02914-7] [Reference Citation Analysis]
|
| 20 |
Ishida N, Miyazu T, Tamura S, Tani S, Yamade M, Iwaizumi M, Hamaya Y, Osawa S, Furuta T, Sugimoto K. Real-World Efficacy and Safety Monitoring for Predicting Continuation of Tofacitinib Therapy in Patients with Ulcerative Colitis. Dig Dis Sci 2022;67:3984-92. [PMID: 34460029 DOI: 10.1007/s10620-021-07233-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 21 |
Kishi M, Hirai F, Takatsu N, Hisabe T, Takada Y, Beppu T, Takeuchi K, Naganuma M, Ohtsuka K, Watanabe K, Matsumoto T, Esaki M, Koganei K, Sugita A, Hata K, Futami K, Ajioka Y, Tanabe H, Iwashita A, Shimizu H, Arai K, Suzuki Y, Hisamatsu T. A review on the current status and definitions of activity indices in inflammatory bowel disease: how to use indices for precise evaluation. J Gastroenterol 2022;57:246-66. [PMID: 35235037 DOI: 10.1007/s00535-022-01862-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 22 |
Marsh A, Rindfleish S, Bennett K, Croft A, Chachay V. Outcomes of dietary management approaches in active ulcerative colitis: A systematic review. Clin Nutr 2021;41:298-306. [PMID: 34999323 DOI: 10.1016/j.clnu.2021.12.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 23 |
Garrido I, Santos AL, Lopes J, Lopes S, Macedo G. "Hepatotoxicity in inflammatory bowel disease: mesalazine, the forgotten drug". Eur J Gastroenterol Hepatol 2021;33:e1067-70. [PMID: 35048663 DOI: 10.1097/MEG.0000000000002306] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 24 |
Cifci S, Ekmen N. Prediction of Mucosal Health by NLR, CRP x NLR and MPV in Ulcerative Colitis: Can Their Availability Change According to Treatment Options? Cureus 2021. [DOI: 10.7759/cureus.19942] [Reference Citation Analysis]
|
| 25 |
Öhlmann H, Koenen LR, Labrenz F, Engler H, Theysohn N, Langhorst J, Elsenbruch S. Altered Brain Structure in Chronic Visceral Pain: Specific Differences in Gray Matter Volume and Associations With Visceral Symptoms and Chronic Stress. Front Neurol 2021;12:733035. [PMID: 34744973 DOI: 10.3389/fneur.2021.733035] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 26 |
Moriichi K, Fujiya M, Okumura T. The endoscopic diagnosis of mucosal healing and deep remission in inflammatory bowel disease. Digestive Endoscopy 2021;33:1008-1023. [DOI: 10.1111/den.13863] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 27 |
Kanazawa M, Tominaga K, Yamamiya A, Tanaka T, Watanabe S, Sugaya T, Abe K, Kanamori A, Arisaka T, Hoshi K, Iijima M, Goda K, Haruyama Y, Irisawa A. Analysis of Endoscopic Evaluation Reliability for Ulcerative Colitis in Histological Remission. Healthcare (Basel) 2021;9:1405. [PMID: 34828451 DOI: 10.3390/healthcare9111405] [Reference Citation Analysis]
|
| 28 |
Lubrano E, Luchetti MM, Benfaremo D, Mauro D, Ciccia F, Perrotta FM. Inflammatory bowel disease manifestations in spondyloarthritis: considerations for the clinician. Expert Rev Clin Immunol 2021;17:1199-209. [PMID: 34622735 DOI: 10.1080/1744666X.2021.1991315] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 29 |
Ishida N, Takahashi S, Asai Y, Miyazu T, Tamura S, Tani S, Yamade M, Iwaizumi M, Hamaya Y, Osawa S, Furuta T, Sugimoto K. Lymphocyte-to-Monocyte Ratio as a Marker for Endoscopic Activity in Ulcerative Colitis. Immuno 2021;1:360-8. [DOI: 10.3390/immuno1040024] [Reference Citation Analysis]
|
| 30 |
Peters V, Dijkstra G, Campmans-Kuijpers MJE. Are all dietary fibers equal for patients with inflammatory bowel disease? A systematic review of randomized controlled trials. Nutr Rev 2021:nuab062. [PMID: 34486663 DOI: 10.1093/nutrit/nuab062] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 31 |
Nakase H, Hirano T, Wagatsuma K, Ichimiya T, Yamakawa T, Yokoyama Y, Hayashi Y, Hirayama D, Kazama T, Yoshii S, Yamano HO. Artificial intelligence-assisted endoscopy changes the definition of mucosal healing in ulcerative colitis. Dig Endosc 2021;33:903-11. [PMID: 32909283 DOI: 10.1111/den.13825] [Cited by in Crossref: 11] [Cited by in F6Publishing: 18] [Article Influence: 5.5] [Reference Citation Analysis]
|
| 32 |
Defendenti C, Tarkowski M, Borille S, Cassinotti A, Massari A, Birindelli S, Riva A, Ardizzone S, Panteghini M. Anti-tumour necrosis factor α antibodies and circulating lymphocyte phenotypes in inflammatory bowel disease. Int Immunopharmacol 2021;100:108081. [PMID: 34461492 DOI: 10.1016/j.intimp.2021.108081] [Reference Citation Analysis]
|
| 33 |
Ishida N, Tamura S, Miyazu T, Tani S, Yamade M, Iwaizumi M, Hamaya Y, Osawa S, Furuta T, Sugimoto K. Comparison between Prostaglandin E-major urinary metabolite and C-reactive protein levels to reflect endoscopic scores in patients with ulcerative colitis. Sci Rep 2021;11:16205. [PMID: 34376764 DOI: 10.1038/s41598-021-95761-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 34 |
Schmidt C, Bachmann O, Baumgart DC, Goetz M, Drvarov O, Kucharzik TF, Kühbacher T, Langhorst J, Maul J, Mohl W, Mudter J, Repp M, Sturm A, Witzemann D, Atreya R. [Position paper on endoscopic reporting in IBD]. Z Gastroenterol 2021. [PMID: 34284522 DOI: 10.1055/a-1504-9782] [Reference Citation Analysis]
|
| 35 |
Holubar SD, Lightner AL, Poylin V, Vogel JD, Gaertner W, Davis B, Davis KG, Mahadevan U, Shah SA, Kane SV, Steele SR, Paquette IM, Feingold DL; Prepared on behalf of the Clinical Practice Guidelines Committee of the American Society of Colon and Rectal Surgeons. The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Surgical Management of Ulcerative Colitis. Dis Colon Rectum 2021;64:783-804. [PMID: 33853087 DOI: 10.1097/DCR.0000000000002037] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 36 |
Ishida N, Miyazu T, Tamura S, Tani S, Yamade M, Iwaizumi M, Hamaya Y, Osawa S, Furuta T, Sugimoto K. Early serum albumin changes in patients with ulcerative colitis treated with tacrolimus will predict clinical outcome. World J Gastroenterol 2021; 27(22): 3109-3120 [PMID: 34168412 DOI: 10.3748/wjg.v27.i22.3109] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 37 |
Chen H, Wu L, Wang M, Shao B, Ye L, Zhang Y, Cao Q. Use of the ulcerative colitis endoscopic index of severity and Mayo endoscopic score for predicting the therapeutic effect of mesalazine in patients with ulcerative colitis. Laparoscopic, Endoscopic and Robotic Surgery 2021;4:33-9. [DOI: 10.1016/j.lers.2021.04.003] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 38 |
Kobayashi T, Motoya S, Nakamura S, Yamamoto T, Nagahori M, Tanaka S, Hisamatsu T, Hirai F, Nakase H, Watanabe K, Matsumoto T, Tanaka M, Abe T, Suzuki Y, Watanabe M, Hibi T; HAYABUSA Study Group. Discontinuation of infliximab in patients with ulcerative colitis in remission (HAYABUSA): a multicentre, open-label, randomised controlled trial. Lancet Gastroenterol Hepatol 2021;6:429-37. [PMID: 33887262 DOI: 10.1016/S2468-1253(21)00062-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 39 |
Hagan M, Hayee BH, Rodriguez-Mateos A. (Poly)phenols in Inflammatory Bowel Disease and Irritable Bowel Syndrome: A Review. Molecules 2021;26:1843. [PMID: 33805938 DOI: 10.3390/molecules26071843] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 40 |
Gutierrez Becker B, Arcadu F, Thalhammer A, Gamez Serna C, Feehan O, Drawnel F, Oh YS, Prunotto M. Training and deploying a deep learning model for endoscopic severity grading in ulcerative colitis using multicenter clinical trial data. Ther Adv Gastrointest Endosc. 2021;14:2631774521990623. [PMID: 33718871 DOI: 10.1177/2631774521990623] [Cited by in Crossref: 9] [Cited by in F6Publishing: 16] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 41 |
Okuno H, Ogino H, Ihara E, Nishioka K, Tanaka Y, Chinen T, Kohjima M, Oono T, Tanaka M, Goya T, Fujimori N, Iboshi Y, Gotoda T, Ogawa Y. Discriminant equation using mucosally expressed cytokines and transcription factor for making definite diagnosis of inflammatory bowel disease unclassified. BMC Gastroenterol 2021;21:73. [PMID: 33593285 DOI: 10.1186/s12876-021-01656-1] [Reference Citation Analysis]
|
| 42 |
Nakayama T, Honda R. Electrochemical and Mechanistic Study of Superoxide Elimination by Mesalazine through Proton-Coupled Electron Transfer. Pharmaceuticals (Basel) 2021;14:120. [PMID: 33557324 DOI: 10.3390/ph14020120] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 43 |
Cushman GK, Shih S, Stolz MG, Hinrichs RC, Jovanovic T, Lee JL, Kugathasan S, Reed B. Stressful life events, depression, and the moderating role of psychophysiological reactivity in patients with pediatric inflammatory bowel disease. J Psychosom Res 2021;141:110323. [PMID: 33321262 DOI: 10.1016/j.jpsychores.2020.110323] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 44 |
Bitton S, Markowitz JF. Ulcerative Colitis in Children and Adolescents. Pediatric Gastrointestinal and Liver Disease 2021. [DOI: 10.1016/b978-0-323-67293-1.00043-8] [Reference Citation Analysis]
|
| 45 |
Ishida N, Onoue S, Miyazu T, Tamura S, Tani S, Yamade M, Iwaizumi M, Hamaya Y, Osawa S, Furuta T, Sugimoto K. Further research on the clinical relevance of the ulcerative colitis colonoscopic index of severity for predicting 5-year relapse. Int J Colorectal Dis 2021;36:2661-70. [PMID: 34409500 DOI: 10.1007/s00384-021-04009-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 46 |
Rodrigues BL, Mazzaro MC, Nagasako CK, Ayrizono MLS, Fagundes JJ, Leal RF. Assessment of disease activity in inflammatory bowel diseases: Non-invasive biomarkers and endoscopic scores. World J Gastrointest Endosc 2020; 12(12): 504-520 [PMID: 33362904 DOI: 10.4253/wjge.v12.i12.504] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
|
| 47 |
König P, Jimenez K, Saletu-zyhlarz G, Mittlböck M, Gasche C. Iron deficiency, depression, and fatigue in inflammatory bowel diseases. Z Gastroenterol 2020;58:1191-200. [DOI: 10.1055/a-1283-6832] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 48 |
Iwatani S, Shinzaki S, Amano T, Otake Y, Tani M, Yoshihara T, Tsujii Y, Hayashi Y, Inoue T, Okuzaki D, Mizushima T, Miyoshi E, Iijima H, Takehara T. Oligosaccharide-dependent anti-inflammatory role of galectin-1 for macrophages in ulcerative colitis. J Gastroenterol Hepatol 2020;35:2158-69. [PMID: 32424849 DOI: 10.1111/jgh.15097] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 49 |
Chibbar R, Moss AC. Mesalamine in the Initial Therapy of Ulcerative Colitis. Gastroenterol Clin North Am 2020;49:689-704. [PMID: 33121689 DOI: 10.1016/j.gtc.2020.07.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 50 |
Pabla BS, Schwartz DA. Assessing Severity of Disease in Patients with Ulcerative Colitis. Gastroenterol Clin North Am 2020;49:671-88. [PMID: 33121688 DOI: 10.1016/j.gtc.2020.08.003] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 8.3] [Reference Citation Analysis]
|
| 51 |
Hayashi R, Ueno Y, Tanaka S, Onishi K, Takasago T, Wakai M, Naito T, Sasaki K, Doi S, Masaki T, Chayama K. Clinical characteristics of inflammatory bowel disease patients with immunoglobulin A nephropathy. Intest Res 2021;19:430-7. [PMID: 33153254 DOI: 10.5217/ir.2020.00067] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 52 |
Fellermann K, Schiefke I, Rácz I, Derova J, Jonaitis L, Wehrum S, Nacak T, Greinwald R. Efficacy and safety of prolonged release budesonide granules in mesalazine-refractory ulcerative colitis: A multi-centre Phase IIa study (TOPICAL-1). United European Gastroenterol J 2020;8:1186-95. [PMID: 33028169 DOI: 10.1177/2050640620962632] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 53 |
Langhorst J, Schöls M, Cinar Z, Eilert R, Kofink K, Paul A, Zempel C, Elsenbruch S, Lauche R, Ahmed M, Haller D, Cramer H, Dobos G, Koch AK. Comprehensive Lifestyle-Modification in Patients with Ulcerative Colitis-A Randomized Controlled Trial. J Clin Med 2020;9:E3087. [PMID: 32987894 DOI: 10.3390/jcm9103087] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 54 |
Tkachev AV, Mazovka KE, Mkrtchyan LS, Makarenko AS, Takidze LT. Optimization of prediction of UC relapse and adjustment of adequate therapy in patient with ulcerative colitiss. jour 2020;1:65-71. [DOI: 10.21886/2712-8156-2020-1-2-65-71] [Reference Citation Analysis]
|
| 55 |
Iwańczak B, Ruczka M, Matusiewicz M, Pytrus T, Matusiewicz K, Krzesiek E. Correlation between biomarkers (calprotectin, seromucoid, metalloproteinase-3 and CRP) and clinical and endoscopic activity of ulcerative colitis in children. Adv Med Sci 2020;65:259-64. [PMID: 32361483 DOI: 10.1016/j.advms.2020.03.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 56 |
Murray A, Nguyen TM, Parker CE, Feagan BG, MacDonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2020;8:CD000543. [PMID: 32786164 DOI: 10.1002/14651858.CD000543.pub5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 57 |
Gökden Y, Hot S, Gönen C, Kalyon S, Akkan Çetinkaya Z. The value of adenosine deaminase level in assessing activation of inflammatory bowel disease. Journal of Surgery and Medicine 2020;4:654-659. [DOI: 10.28982/josam.769877] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 58 |
Iwatani S, Iijima H, Otake Y, Amano T, Tani M, Yoshihara T, Tashiro T, Tsujii Y, Inoue T, Hayashi Y, Takeda K, Hayashi A, Fujita S, Shinzaki S, Takehara T. Novel mass spectrometry-based comprehensive lipidomic analysis of plasma from patients with inflammatory bowel disease. J Gastroenterol Hepatol 2020;35:1355-64. [PMID: 32285970 DOI: 10.1111/jgh.15067] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 59 |
Hiyama S, Iijima H, Sakakibara Y, Yamada T, Mukai A, Otake Y, Yamaguchi T, Araki M, Kawai S, Tsujii Y, Inoue T, Hayashi Y, Shinzaki S, Takehara T. Endoscopic alterations in Peyer's patches in patients with ulcerative colitis: A prospective, multicenter study. J Gastroenterol Hepatol 2020;35:1143-9. [PMID: 31734952 DOI: 10.1111/jgh.14933] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 60 |
Li Y, Khamou M, Schaarschmidt BM, Umutlu L, Forsting M, Demircioglu A, Haubold J, Koch AK, Bruckmann NM, Sawicki LM, Herrmann K, Boone JH, Langhorst J. Comparison of 18F-FDG PET-MR and fecal biomarkers in the assessment of disease activity in patients with ulcerative colitis. Br J Radiol 2020;93:20200167. [PMID: 32579403 DOI: 10.1259/bjr.20200167] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 61 |
Li N, Mao J, Tang H, Zhu L, Tan X, Bi J, Wu H, Chen X, Wang Y. Efficacy and safety of adsorptive granulomonocytapheresis in Chinese patients with ulcerative colitis: A retrospective analysis of 50 cases with focus on factors impacting clinical efficacy. J Clin Apher 2020;35:271-80. [PMID: 32378240 DOI: 10.1002/jca.21787] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 62 |
Kotani S, Fukuba N, Kawashima K, Mishima Y, Sonoyama H, Okimoto E, Tada Y, Oka A, Tamagawa Y, Oshima N, Mishiro T, Tobita H, Shibagaki K, Moriyama I, Ishimura N, Kushiyama Y, Fujishiro H, Ishihara S. Prevalence of functional dyspepsia-like symptoms in ulcerative colitis patients in clinical remission and overlap with irritable bowel syndrome-like symptoms. Scand J Gastroenterol 2020;55:560-4. [PMID: 32412797 DOI: 10.1080/00365521.2020.1761998] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 63 |
Yarlas A, Maher S, Bayliss M, Lovley A, Cappelleri JC, Bushmakin AG, DiBonaventura MD. The Inflammatory Bowel Disease Questionnaire in Randomized Controlled Trials of Treatment for Ulcerative Colitis: Systematic Review and Meta-Analysis. J Patient Cent Res Rev 2020;7:189-205. [PMID: 32377552 DOI: 10.17294/2330-0698.1722] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 64 |
Wakai M, Hayashi R, Tanaka S, Naito T, Kumada J, Nomura M, Takigawa H, Oka S, Ueno Y, Ito M, Chayama K. Serum amyloid A is a better predictive biomarker of mucosal healing than C-reactive protein in ulcerative colitis in clinical remission. BMC Gastroenterol. 2020;20:85. [PMID: 32245401 DOI: 10.1186/s12876-020-01229-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 65 |
Limdi JK, Picco M, Farraye FA. A review of endoscopic scoring systems and their importance in a treat-to-target approach in inflammatory bowel disease (with videos). Gastrointest Endosc 2020;91:733-45. [PMID: 31786161 DOI: 10.1016/j.gie.2019.11.032] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 66 |
Sugitani Y, Nishida A, Inatomi O, Ohno M, Imai T, Kawahara M, Kitamura K, Andoh A. Sodium absorption stimulator prostasin (PRSS8) has an anti-inflammatory effect via downregulation of TLR4 signaling in inflammatory bowel disease. J Gastroenterol 2020;55:408-17. [PMID: 31916038 DOI: 10.1007/s00535-019-01660-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 67 |
Koch AK, Schöls M, Langhorst J, Dobos G, Cramer H. Perceived stress mediates the effect of yoga on quality of life and disease activity in ulcerative colitis. Secondary analysis of a randomized controlled trial. J Psychosom Res 2020;130:109917. [PMID: 31927346 DOI: 10.1016/j.jpsychores.2019.109917] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 68 |
Matsuno Y, Hirano A, Torisu T, Okamoto Y, Fuyuno Y, Fujioka S, Umeno J, Moriyama T, Nagai S, Hori Y, Fujiwara M, Kitazono T, Esaki M. Short-term and long-term outcomes of indigo naturalis treatment for inflammatory bowel disease. J Gastroenterol Hepatol 2020;35:412-7. [PMID: 31389626 DOI: 10.1111/jgh.14823] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 69 |
Langhorst J, Koch AK, Voiss P, Dobos GJ, Rueffer A. Distinct patterns of short-chain fatty acids during flare in patients with ulcerative colitis under treatment with mesalamine or a herbal combination of myrrh, chamomile flowers, and coffee charcoal: secondary analysis of a randomized controlled trial. Eur J Gastroenterol Hepatol 2020;32:175-80. [PMID: 31688306 DOI: 10.1097/MEG.0000000000001582] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 70 |
Takahashi N, Kitazawa C, Itani Y, Awaga Y, Hama A, Hayashi I, Takamatsu H. Exploratory clinical characterization of experimentally-induced ulcerative colitis nonhuman primates. Heliyon 2020;6:e03178. [PMID: 31938753 DOI: 10.1016/j.heliyon.2020.e03178] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 71 |
Rogler G, Biedermann L. Klassifikationen, Indizes, Aktivitätsbeurteilung. Chronisch-entzündliche Darmerkrankungen 2020. [DOI: 10.1007/978-3-662-59104-8_8] [Reference Citation Analysis]
|
| 72 |
Melendez-rosado J, Shen B. Endoscopic scores in inflammatory bowel disease. Atlas of Endoscopy Imaging in Inflammatory Bowel Disease 2020. [DOI: 10.1016/b978-0-12-814811-2.00014-1] [Reference Citation Analysis]
|
| 73 |
Yasutomi E, Hiraoka S, Yamamoto S, Oka S, Hirai M, Yamasaki Y, Inokuchi T, Kinugasa H, Takahara M, Harada K, Kato J, Okada H. Switching between Three Types of Mesalazine Formulation and Sulfasalazine in Patients with Active Ulcerative Colitis Who Have Already Received High-Dose Treatment with These Agents. J Clin Med 2019;8:E2109. [PMID: 31810227 DOI: 10.3390/jcm8122109] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 74 |
Chandan S, Mohan BP, Chandan OC, Ahmad R, Challa A, Tummala H, Singh S, Dhawan P, Ponnada S, Singh AB, Adler DG. Curcumin use in ulcerative colitis: is it ready for prime time? A systematic review and meta-analysis of clinical trials. Ann Gastroenterol 2020;33:53-8. [PMID: 31892798 DOI: 10.20524/aog.2019.0439] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 75 |
Takenaka K, Tominaga K, Kanazawa M, Fukushi K, Tanaka T, Kanamori A, Sugaya T, Tsuchida K, Iijima M, Goda K, Irisawa A. Endoscopic score vs blood cell indices for determining timing of immunomodulator withdrawal in quiescent ulcerative colitis. Sci Rep 2019;9:17751. [PMID: 31780764 DOI: 10.1038/s41598-019-54369-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 76 |
Rowan CR, Cullen G, Mulcahy HE, Sheridan J, Moss AC, Ryan EJ, Doherty GA. DUBLIN [Degree of Ulcerative colitis Burden of Luminal Inflammation] Score, a Simple Method to Quantify Inflammatory Burden in Ulcerative Colitis. J Crohns Colitis 2019;13:1365-71. [PMID: 30911757 DOI: 10.1093/ecco-jcc/jjz067] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 77 |
Tajiri H, Arai K, Kagimoto S, Kunisaki R, Hida N, Sato N, Yamada H, Nagano M, Susuta Y, Ozaki K, Kondo K, Hibi T. Infliximab for pediatric patients with ulcerative colitis: a phase 3, open-label, uncontrolled, multicenter trial in Japan. BMC Pediatr 2019;19:351. [PMID: 31607268 DOI: 10.1186/s12887-019-1739-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 78 |
Yamada T, Hino S, Iijima H, Genda T, Aoki R, Nagata R, Han KH, Hirota M, Kinashi Y, Oguchi H, Suda W, Furusawa Y, Fujimura Y, Kunisawa J, Hattori M, Fukushima M, Morita T, Hase K. Mucin O-glycans facilitate symbiosynthesis to maintain gut immune homeostasis. EBioMedicine 2019;48:513-25. [PMID: 31521614 DOI: 10.1016/j.ebiom.2019.09.008] [Cited by in Crossref: 40] [Cited by in F6Publishing: 43] [Article Influence: 10.0] [Reference Citation Analysis]
|
| 79 |
Johnson E, Therkelsen SP, Nentwich I, Nissen-Meyer LSH, Hetland G. IgE-sensitization to food and inhalant allergens in IBD patients compared with normal blood donors at Oslo University Hospital, Norway. Scand J Gastroenterol 2019;54:1107-10. [PMID: 31524013 DOI: 10.1080/00365521.2019.1663445] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 80 |
Maeda T, Sakai H, Ozawa N, Sugiyama T, Takada J, Kubota M, Ibuka T, Shirakami Y, Araki H, Shimizu M. Acute cytomegalovirus infection in an immunocompetent patient with ulcerative colitis: A case report. Exp Ther Med 2019;18:2271-7. [PMID: 31452714 DOI: 10.3892/etm.2019.7823] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 81 |
Yamamoto-furusho J, Bozada-gutiérrez K, Sánchez-rodríguez A, Bojalil-romano F, Barreto-zuñiga R, Martínez-benitez B. Validation of a novel integral disease index for evaluating the grade of activity in Mexican patients with ulcerative colitis: A prospective cohort study. Revista de Gastroenterología de México (English Edition) 2019;84:317-25. [DOI: 10.1016/j.rgmxen.2019.02.006] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 82 |
Yamamoto-furusho J, Bozada-gutiérrez K, Sánchez-rodríguez A, Bojalil-romano F, Barreto-zuñiga R, Martínez-benitez B. Validación de un nuevo índice integral de enfermedad para evaluar el grado de actividad en pacientes mexicanos con colitis ulcerosa: un estudio de cohorte prospectivo. Revista de Gastroenterología de México 2019;84:317-25. [DOI: 10.1016/j.rgmx.2018.07.006] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 83 |
Gheorghe C, Svoboda P, Mateescu B. Effectiveness and safety of biosimilar infliximab (CT-P13) in a real-life setting in patients with Crohn's disease or ulcerative colitis. J Drug Assess 2019;8:129-34. [PMID: 31259042 DOI: 10.1080/21556660.2019.1626735] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 84 |
Giuffrida P, Aronico N, Rosselli M, Lenti MV, Cococcia S, Roccarina D, Saffioti F, Delliponti M, Thorburn D, Miceli E, Corazza GR, Pinzani M, Di Sabatino A. Defective spleen function in autoimmune gastrointestinal disorders. Intern Emerg Med 2020;15:225-9. [PMID: 31214883 DOI: 10.1007/s11739-019-02129-w] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 85 |
Ciccocioppo R, Baumgart DC, Dos Santos CC, Galipeau J, Klersy C, Orlando G. Perspectives of the International Society for Cell & Gene Therapy Gastrointestinal Scientific Committee on the Intravenous Use of Mesenchymal Stromal Cells in Inflammatory Bowel Disease (PeMeGi). Cytotherapy 2019;21:824-39. [PMID: 31201092 DOI: 10.1016/j.jcyt.2019.05.003] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 86 |
Ciccocioppo R, Bozzini S, Betti E, Imbesi V, Klersy C, Lakyova LS, Sukovsky L, Benacka J, Kruzliak P, Corazza GR, Di Sabatino A, Falcone C. Functional polymorphisms of the receptor for the advanced glycation end product promoter gene in inflammatory bowel disease: a case–control study. Clin Exp Med 2019;19:367-75. [DOI: 10.1007/s10238-019-00562-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 87 |
Kinoshita K, Katsurada T, Nishida M, Omotehara S, Onishi R, Mabe K, Onodera A, Sato M, Eto K, Suya M, Maemoto A, Hasegawa T, Yamamoto J, Mitsumori D, Yoshii S, Ono K, Sakamoto N. Usefulness of transabdominal ultrasonography for assessing ulcerative colitis: a prospective, multicenter study. J Gastroenterol 2019;54:521-9. [PMID: 30519747 DOI: 10.1007/s00535-018-01534-w] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 5.3] [Reference Citation Analysis]
|
| 88 |
Restellini S, Chao CY, Martel M, Barkun A, Kherad O, Seidman E, Wild G, Bitton A, Afif W, Bessissow T, Lakatos PL. Clinical Parameters Correlate With Endoscopic Activity of Ulcerative Colitis: A Systematic Review. Clin Gastroenterol Hepatol 2019;17:1265-1275.e8. [PMID: 30583048 DOI: 10.1016/j.cgh.2018.12.021] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 6.3] [Reference Citation Analysis]
|
| 89 |
Yamada T, Hino S, Iijima H, Genda T, Aoki R, Nagata R, Han H, Hirota M, Kinashi Y, Oguchi H, Suda W, Furusawa Y, Fujimura Y, Kunisawa J, Hattori M, Fukushima M, Morita T, Hase K. Mucin O-glycans facilitate symbiosynthesis to maintain gut immune homeostasis.. [DOI: 10.1101/655597] [Reference Citation Analysis]
|
| 90 |
Chen X, Yang K, Xu Y, Li K. Top-100 highest-cited original articles in inflammatory bowel disease: A bibliometric analysis. Medicine (Baltimore) 2019;98:e15718. [PMID: 31096525 DOI: 10.1097/MD.0000000000015718] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 91 |
Nishio M, Ishii Y, Hashimoto Y, Otake H, Ogashiwa T, Tsuda S, Yasuhara H, Saigusa Y, Kimura H, Maeda S, Kunisaki R. Short- and long-term efficacy of adalimumab salvage therapy after failure of calcineurin inhibitors in steroid-refractory ulcerative colitis. Scand J Gastroenterol 2018;53:1236-44. [PMID: 30353757 DOI: 10.1080/00365521.2018.1511825] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 92 |
Arisaka T, Kanazawa M, Tominaga K, Takahashi F, Takenaka K, Sugaya T, Arisaka O, Irisawa A, Hiraishi H. Hematemesis due to Drug Allergy to Oral Prednisolone in a Patient with Ulcerative Colitis. Intern Med 2019;58:1093-1096. [DOI: 10.2169/internalmedicine.1639-18] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 93 |
Omotehara S, Nishida M, Kinoshita K, Onishi R, Onodera A, Suya M, Hasegawa T, Mitsumori D, Katsurada T, Teshima T. Validation of US evaluation of ulcerative colitis activity. Ultrasound Med Biol 2019;45:1537-44. [PMID: 30987912 DOI: 10.1016/j.ultrasmedbio.2019.02.018] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 94 |
Kanazawa M, Takahashi F, Tominaga K, Abe K, Izawa N, Fukushi K, Nagashima K, Kanamori A, Takenaka K, Sugaya T, Iijima M, Takada A, Imai Y, Hiraishi H, Irisawa A. Relationship between endoscopic mucosal healing and histologic inflammation during remission maintenance phase in ulcerative colitis: a retrospective study. Endosc Int Open 2019;7:E568-75. [PMID: 30957007 DOI: 10.1055/a-0869-7619] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 95 |
Mitsuishi T. Correlation between histological findings and endoscopic findings in patients with ulcerative colitis: Basal plasmacytosis is an important finding suggesting active inflammation. JGH Open 2019;3:100-4. [PMID: 31061883 DOI: 10.1002/jgh3.12111] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 96 |
Sturm A, Maaser C, Calabrese E, Annese V, Fiorino G, Kucharzik T, Vavricka SR, Verstockt B, van Rheenen P, Tolan D, Taylor SA, Rimola J, Rieder F, Limdi JK, Laghi A, Krustiņš E, Kotze PG, Kopylov U, Katsanos K, Halligan S, Gordon H, González Lama Y, Ellul P, Eliakim R, Castiglione F, Burisch J, Borralho Nunes P, Bettenworth D, Baumgart DC, Stoker J; European Crohn’s and Colitis Organisation [ECCO] and the European Society of Gastrointestinal and Abdominal Radiology [ESGAR]. ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 2: IBD scores and general principles and technical aspects. J Crohns Colitis 2019;13:273-84. [PMID: 30137278 DOI: 10.1093/ecco-jcc/jjy114] [Cited by in Crossref: 166] [Cited by in F6Publishing: 172] [Article Influence: 41.5] [Reference Citation Analysis]
|
| 97 |
Rubin DT, Ananthakrishnan AN, Siegel CA, Sauer BG, Long MD. ACG Clinical Guideline: Ulcerative Colitis in Adults. Am J Gastroenterol 2019;114:384-413. [PMID: 30840605 DOI: 10.14309/ajg.0000000000000152] [Cited by in Crossref: 612] [Cited by in F6Publishing: 559] [Article Influence: 153.0] [Reference Citation Analysis]
|
| 98 |
Singh S, Feuerstein JD, Binion DG, Tremaine WJ. AGA Technical Review on the Management of Mild-to-Moderate Ulcerative Colitis. Gastroenterology 2019;156:769-808.e29. [PMID: 30576642 DOI: 10.1053/j.gastro.2018.12.008] [Cited by in Crossref: 66] [Cited by in F6Publishing: 70] [Article Influence: 16.5] [Reference Citation Analysis]
|
| 99 |
Galeev AR, Dmitriev MV, Mokrushin IG, Mashevskaya IV, Maslivets AN, Rubin M. Synthesis of meta -substituted anilines via a three-component reaction of acetone, amines, and 1,3-diketones. Org Biomol Chem 2019;17:10030-44. [DOI: 10.1039/c9ob02120e] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 100 |
Kruis W, Neshta V, Pesegova M, Alekseeva O, Andreev P, Datsenko O, Levchenko O, Abdulkhakov S, Lozynskyy Y, Mostovoy Y, Soloviev K, Dorofeyev AE, Vieth M, Stiess M, Greinwald R, Mohrbacher R, Siegmund B. Budesonide Suppositories Are Effective and Safe for Treating Acute Ulcerative Proctitis. Clin Gastroenterol Hepatol 2019;17:98-106.e4. [PMID: 29702300 DOI: 10.1016/j.cgh.2018.04.027] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 101 |
Takano R, Osawa S, Uotani T, Tani S, Ishida N, Tamura S, Yamade M, Iwaizumi M, Hamaya Y, Furuta T, Miyajima H, Sugimoto K. Evaluating mucosal healing using colon capsule endoscopy predicts outcome in patients with ulcerative colitis in clinical remission. World J Clin Cases 2018; 6(15): 952-960 [PMID: 30568951 DOI: 10.12998/wjcc.v6.i15.952] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 102 |
Engler H, Elsenbruch S, Rebernik L, Köcke J, Cramer H, Schöls M, Langhorst J. Stress burden and neuroendocrine regulation of cytokine production in patients with ulcerative colitis in remission. Psychoneuroendocrinology 2018;98:101-7. [PMID: 30125791 DOI: 10.1016/j.psyneuen.2018.08.009] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.6] [Reference Citation Analysis]
|
| 103 |
Abbati G, Incerti F, Boarini C, Pileri F, Bocchi D, Ventura P, Buzzetti E, Pietrangelo A. Safety and efficacy of sucrosomial iron in inflammatory bowel disease patients with iron deficiency anemia. Intern Emerg Med 2019;14:423-31. [PMID: 30499070 DOI: 10.1007/s11739-018-1993-9] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 104 |
Bevivino G, Sedda S, Marafini I, Monteleone G. Oligonucleotide-Based Therapies for Inflammatory Bowel Disease. BioDrugs 2018;32:331-8. [PMID: 29948918 DOI: 10.1007/s40259-018-0286-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 105 |
Grammatikopoulou MG, Gkiouras K, Theodoridis X, Asteriou E, Forbes A, Bogdanos DP. Oral Adjuvant Curcumin Therapy for Attaining Clinical Remission in Ulcerative Colitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Nutrients 2018;10:E1737. [PMID: 30424514 DOI: 10.3390/nu10111737] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 6.4] [Reference Citation Analysis]
|
| 106 |
Jaeger SU, Klag T, Hoeger K, Klumpp S, Escher M, Malek N, Stange E, Wehkamp J. Tacrolimus Suppositories in Therapy-Resistant Ulcerative Proctitis. Inflamm Intest Dis 2019;3:116-24. [PMID: 30820433 DOI: 10.1159/000493979] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 107 |
Saniabadi AR, Tanaka T, Yamamoto T, Kruis W, Sacco R. Granulomonocytapheresis as a cell-dependent treatment option for patients with inflammatory bowel disease: Concepts and clinical features for better therapeutic outcomes. J Clin Apher. 2019;34:51-60. [PMID: 30407662 DOI: 10.1002/jca.21670] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 108 |
Suzuki H, Mizokami Y, Gosho M, Kaneko T, Matsui H, Yanaka A. Long-Term Maintenance Effect of Qing Dai for Ulcerative Colitis. The Journal of Alternative and Complementary Medicine 2018;24:1130-1. [DOI: 10.1089/acm.2018.0057] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 109 |
Urushikubo J, Yanai S, Nakamura S, Kawasaki K, Akasaka R, Sato K, Toya Y, Asakura K, Gonai T, Sugai T, Matsumoto T. Practical fecal calprotectin cut-off value for Japanese patients with ulcerative colitis. World J Gastroenterol 2018; 24(38): 4384-4392 [PMID: 30344422 DOI: 10.3748/wjg.v24.i38.4384] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 110 |
Tsuda S, Kunisaki R, Kato J, Murakami M, Nishio M, Ogashiwa T, Yoshida T, Kimura H, Kitano M. Patient self-reported symptoms using visual analog scales are useful to estimate endoscopic activity in ulcerative colitis. Intest Res 2018;16:579-87. [PMID: 30301332 DOI: 10.5217/ir.2018.00021] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 111 |
Shinzaki S, Fujii T, Bamba S, Ogawa M, Kobayashi T, Oshita M, Tanaka H, Ozeki K, Takahashi S, Kitamoto H, Kani K, Nanjo S, Sugaya T, Sakakibara Y, Inokuchi T, Kakimoto K, Yamada A, Yasuhara H, Yokoyama Y, Yoshino T, Matsui A, Nakamura M, Tomizawa T, Sakemi R, Kamata N, Hibi T. Seven days triple therapy for eradication of Helicobacter pylori does not alter the disease activity of patients with inflammatory bowel disease. Intest Res 2018;16:609-18. [PMID: 30301329 DOI: 10.5217/ir.2018.00044] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 112 |
Atreya R, Reinisch W, Peyrin-Biroulet L, Scaldaferri F, Admyre C, Knittel T, Kowalski J, Neurath MF, Hawkey C. Clinical efficacy of the Toll-like receptor 9 agonist cobitolimod using patient-reported-outcomes defined clinical endpoints in patients with ulcerative colitis. Dig Liver Dis 2018;50:1019-29. [PMID: 30120066 DOI: 10.1016/j.dld.2018.06.010] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
|
| 113 |
Oltulu P, Oltulu R, Asil M, Satirtav G, Mirza E. Conjunctival Impression Cytology and Dry Eye in Patients With Ulcerative Colitis: A Pilot Study. Eye & Contact Lens: Science & Clinical Practice 2018;44:S190-3. [DOI: 10.1097/icl.0000000000000380] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 114 |
Lee JS, Kim ES, Moon W. Chronological Review of Endoscopic Indices in Inflammatory Bowel Disease. Clin Endosc. 2018;. [PMID: 30130840 DOI: 10.5946/ce.2018.042] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 115 |
Nguyen NH, Fumery M, Dulai PS, Prokop LJ, Sandborn WJ, Murad MH, Singh S. Comparative efficacy and tolerability of pharmacological agents for management of mild to moderate ulcerative colitis: a systematic review and network meta-analyses. Lancet Gastroenterol Hepatol 2018;3:742-53. [PMID: 30122356 DOI: 10.1016/S2468-1253(18)30231-0] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 4.2] [Reference Citation Analysis]
|
| 116 |
James SL, van Langenberg DR, Taylor KM, Gibson PR. Characterization of ulcerative colitis-associated constipation syndrome (proximal constipation). JGH Open 2018;2:217-22. [PMID: 30483593 DOI: 10.1002/jgh3.12076] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 117 |
Sahin A, Artas H, Eroglu Y, Tunc N, Oguz G, Demirel U, Poyrazoglu OK, Yalniz M, Bahcecioglu IH. A Neglected Issue in Ulcerative Colitis: Mesenteric Lymph Nodes. J Clin Med 2018;7:E142. [PMID: 29890635 DOI: 10.3390/jcm7060142] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 118 |
Akar M, Aydin F, Yurci MA, Abay S, Ateş İ, Deniz K. The possible relationship between Campylobacter spp./Arcobacter spp. and patients with ulcerative colitis. Eur J Gastroenterol Hepatol 2018;30:531-8. [PMID: 29432367 DOI: 10.1097/MEG.0000000000001095] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 119 |
Yarlas A, Rubin DT, Panés J, Lindsay JO, Vermeire S, Bayliss M, Cappelleri JC, Maher S, Bushmakin AG, Chen LA, DiBonaventura M. Burden of Ulcerative Colitis on Functioning and Well-being: A Systematic Literature Review of the SF-36® Health Survey. J Crohns Colitis 2018;12:600-9. [PMID: 29718244 DOI: 10.1093/ecco-jcc/jjy024] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 6.8] [Reference Citation Analysis]
|
| 120 |
Nath A, Haktanirlar G, Varga Á, Molnár MA, Albert K, Galambos I, Koris A, Vatai G. Biological Activities of Lactose-Derived Prebiotics and Symbiotic with Probiotics on Gastrointestinal System. Medicina (Kaunas) 2018;54:E18. [PMID: 30344249 DOI: 10.3390/medicina54020018] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 121 |
Dignass A, Akbar A, Baumgart DC, Bommelaer G, Bouguen G, Cadiot G, Gillessen A, Grimaud JC, Hart A, Hoque S, Makins R, Michiels C, Moreau J, Premchand P, Ramlow W, Schanz S, Subramanian S, von Tirpitz C, Bonaz B. Granulocyte/monocyte adsorptive apheresis for the treatment of therapy-refractory chronic active ulcerative colitis. Scand J Gastroenterol 2018;53:442-8. [PMID: 29513111 DOI: 10.1080/00365521.2018.1447598] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 122 |
Mohammadi E, Qujeq D, Taheri H, Hajian-tilaki K. Inappropriate Total Oxidant/Antioxidant Status, Nitric Oxide Oxidation End Products and Trace Element Levels in Patients with Inflammatory Bowel Disease. Ann Colorectal Res 2018;6. [DOI: 10.5812/acr.64029] [Reference Citation Analysis]
|
| 123 |
Kawalec P, Stawowczyk E. Relationship between physician-based assessment of disease activity, quality of life, and costs of ulcerative colitis in Poland. Prz Gastroenterol 2018;13:61-8. [PMID: 29657613 DOI: 10.5114/pg.2018.74568] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
|
| 124 |
Dignass A, Schnabel R, Romatowski J, Pavlenko V, Dorofeyev A, Derova J, Jonaitis L, Dilger K, Nacak T, Greinwald R; International SAT-25 Study Group. Efficacy and safety of a novel high-dose mesalazine tablet in mild to moderate active ulcerative colitis: a double-blind, multicentre, randomised trial. United European Gastroenterol J. 2018;6:138-147. [PMID: 29435324 DOI: 10.1177/2050640617703842,] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 125 |
Mohammed Vashist N, Samaan M, Mosli MH, Parker CE, MacDonald JK, Nelson SA, Zou GY, Feagan BG, Khanna R, Jairath V. Endoscopic scoring indices for evaluation of disease activity in ulcerative colitis. Cochrane Database Syst Rev 2018;1:CD011450. [PMID: 29338066 DOI: 10.1002/14651858.CD011450.pub2] [Cited by in Crossref: 31] [Cited by in F6Publishing: 53] [Article Influence: 6.2] [Reference Citation Analysis]
|
| 126 |
Kobayashi T. Endoscopic Indices for Ulcerative Colitis. Advances in Endoscopy in Inflammatory Bowel Disease 2018. [DOI: 10.1007/978-4-431-56018-0_16] [Reference Citation Analysis]
|
| 127 |
Matsuoka K, Kobayashi T, Ueno F, Matsui T, Hirai F, Inoue N, Kato J, Kobayashi K, Kobayashi K, Koganei K, Kunisaki R, Motoya S, Nagahori M, Nakase H, Omata F, Saruta M, Watanabe T, Tanaka T, Kanai T, Noguchi Y, Takahashi KI, Watanabe K, Hibi T, Suzuki Y, Watanabe M, Sugano K, Shimosegawa T. Evidence-based clinical practice guidelines for inflammatory bowel disease. J Gastroenterol 2018;53:305-53. [PMID: 29429045 DOI: 10.1007/s00535-018-1439-1] [Cited by in Crossref: 281] [Cited by in F6Publishing: 281] [Article Influence: 56.2] [Reference Citation Analysis]
|
| 128 |
Nikolaus S, Waetzig GH, Butzin S, Ziolkiewicz M, Al-Massad N, Thieme F, Lövgren U, Rasmussen BB, Reinheimer TM, Seegert D, Rosenstiel P, Szymczak S, Schreiber S. Evaluation of interleukin-6 and its soluble receptor components sIL-6R and sgp130 as markers of inflammation in inflammatory bowel diseases. Int J Colorectal Dis 2018;33:927-36. [PMID: 29748708 DOI: 10.1007/s00384-018-3069-8] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 129 |
Nakase H, Iida T, Kawakami K, Hirayama D. Mucosal Healing in Ulcerative Colitis. Advances in Endoscopy in Inflammatory Bowel Disease 2018. [DOI: 10.1007/978-4-431-56018-0_18] [Reference Citation Analysis]
|
| 130 |
Chen JM, Liu T, Gao S, Tong XD, Deng FH, Nie B. Efficacy of noninvasive evaluations in monitoring inflammatory bowel disease activity: A prospective study in China. World J Gastroenterol 2017; 23(46): 8235-8247 [PMID: 29290660 DOI: 10.3748/wjg.v23.i46.8235] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 24] [Article Influence: 4.2] [Reference Citation Analysis]
|
| 131 |
Hood MM, Jedel S. Mindfulness-Based Interventions in Inflammatory Bowel Disease. Gastroenterol Clin North Am 2017;46:859-74. [PMID: 29173527 DOI: 10.1016/j.gtc.2017.08.008] [Cited by in Crossref: 35] [Cited by in F6Publishing: 87] [Article Influence: 5.8] [Reference Citation Analysis]
|
| 132 |
Defendenti C, Atzeni F, Malandrin S, Ardizzone S, Almasio PL, Saibeni S, Bezzio C, Bollani S, Salerno R, Declich P, Sarno Z, Bruno S, Talotta R, Sarzi-Puttini P. Anti-tumour necrosis factor-α antibodies and B cell homeostasis in human inflammatory bowel diseases. Int Immunopharmacol 2018;54:329-35. [PMID: 29197269 DOI: 10.1016/j.intimp.2017.11.016] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 133 |
Fukuba N, Ishihara S, Kawashima K, Mishima Y, Oshima N, Kinoshita Y. Irritable bowel syndrome-like symptoms associated with endoscopic activity predict ulcerative colitis relapse in patients with clinical remission. Intest Res 2017;15:543-5. [PMID: 29142525 DOI: 10.5217/ir.2017.15.4.543] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 134 |
Fukunaga S, Kuwaki K, Mitsuyama K, Takedatsu H, Yoshioka S, Yamasaki H, Yamauchi R, Mori A, Kakuma T, Tsuruta O, Torimura T. Detection of calprotectin in inflammatory bowel disease: Fecal and serum levels and immunohistochemical localization. Int J Mol Med 2018;41:107-18. [PMID: 29115397 DOI: 10.3892/ijmm.2017.3244] [Cited by in Crossref: 20] [Cited by in F6Publishing: 26] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 135 |
Yuksel M, Ates I, Kaplan M, Arikan MF, Ozin YO, Kilic ZMY, Topcuoglu C, Kayacetin E. Is Oxidative Stress Associated with Activation and Pathogenesis of Inflammatory Bowel Disease? J Med Biochem 2017;36:341-8. [PMID: 30581331 DOI: 10.1515/jomb-2017-0013] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 136 |
Sawada K. Cytapheresis (CAP) with leukocyte removal filter/bead column as one therapeutic option for inflammatory bowel disease. Transfus Apher Sci 2017;56:689-97. [PMID: 28986009 DOI: 10.1016/j.transci.2017.08.016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 137 |
Kusaka S, Nishida A, Takahashi K, Bamba S, Yasui H, Kawahara M, Inatomi O, Sugimoto M, Andoh A. Expression of human cathelicidin peptide LL-37 in inflammatory bowel disease. Clin Exp Immunol 2018;191:96-106. [PMID: 28872665 DOI: 10.1111/cei.13047] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 138 |
Langbrandtner J, Hüppe A, Jessen P, Büning J, Nikolaus S, Raspe H, Bokemeyer B. Quality of care in inflammatory bowel disease: results of a prospective controlled cohort study in Germany (NETIBD). Clin Exp Gastroenterol 2017;10:215-27. [PMID: 28919797 DOI: 10.2147/CEG.S135346] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 139 |
Nikolaus S, Schreiber S, Siegmund B, Bokemeyer B, Bästlein E, Bachmann O, Görlich D, Hofmann U, Schwab M, Kruis W. Patient Education in a 14-month Randomised Trial Fails to Improve Adherence in Ulcerative Colitis: Influence of Demographic and Clinical Parameters on Non-adherence. J Crohns Colitis 2017;11:1052-62. [PMID: 28486634 DOI: 10.1093/ecco-jcc/jjx062] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 140 |
Yarlas A, Bayliss M, Cappelleri JC, Maher S, Bushmakin AG, Chen LA, Manuchehri A, Healey P. Psychometric validation of the SF-36® Health Survey in ulcerative colitis: results from a systematic literature review. Qual Life Res 2018;27:273-90. [DOI: 10.1007/s11136-017-1690-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 141 |
Jitsumura M, Kokelaar RF, Harris DA. Remission endpoints in ulcerative colitis: A systematic review. World J Meta-Anal 2017; 5(4): 85-102 [DOI: 10.13105/wjma.v5.i4.85] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 142 |
Fujii M, Nishida A, Imaeda H, Ohno M, Nishino K, Sakai S, Inatomi O, Bamba S, Kawahara M, Shimizu T, Andoh A. Expression of Interleukin-26 is upregulated in inflammatory bowel disease. World J Gastroenterol 2017; 23(30): 5519-5529 [PMID: 28852311 DOI: 10.3748/wjg.v23.i30.5519] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 24] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 143 |
Ruiz PA, Morón B, Becker HM, Lang S, Atrott K, Spalinger MR, Scharl M, Wojtal KA, Fischbeck-Terhalle A, Frey-Wagner I, Hausmann M, Kraemer T, Rogler G. Titanium dioxide nanoparticles exacerbate DSS-induced colitis: role of the NLRP3 inflammasome. Gut 2017;66:1216-24. [PMID: 26848183 DOI: 10.1136/gutjnl-2015-310297] [Cited by in Crossref: 174] [Cited by in F6Publishing: 178] [Article Influence: 29.0] [Reference Citation Analysis]
|
| 144 |
Cramer H, Dobos G, Langhorst J. Editorial: yoga for QoL in ulcerative colitis-any better than other supportive activities? Authors' reply. Aliment Pharmacol Ther 2017;46:202-3. [PMID: 28621065 DOI: 10.1111/apt.14141] [Reference Citation Analysis]
|
| 145 |
Cramer H, Schäfer M, Schöls M, Köcke J, Elsenbruch S, Lauche R, Engler H, Dobos G, Langhorst J. Randomised clinical trial: yoga vs written self-care advice for ulcerative colitis. Aliment Pharmacol Ther 2017;45:1379-89. [PMID: 28378342 DOI: 10.1111/apt.14062] [Cited by in Crossref: 35] [Cited by in F6Publishing: 86] [Article Influence: 5.8] [Reference Citation Analysis]
|
| 146 |
Suluvoy JK, Sakthivel KM, Guruvayoorappan C, Berlin Grace VM. Protective effect of Averrhoa bilimbi L. fruit extract on ulcerative colitis in wistar rats via regulation of inflammatory mediators and cytokines. Biomed Pharmacother. 2017;91:1113-1121. [PMID: 28531922 DOI: 10.1016/j.biopha.2017.05.057] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 147 |
Dubinsky MC. Reviewing treatments and outcomes in the evolving landscape of ulcerative colitis. Postgraduate Medicine 2017;129:538-53. [DOI: 10.1080/00325481.2017.1319730] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 148 |
Turner D, Yerushalmi B, Kori M, Broide E, Mozer-Glassberg Y, Shaoul R, Kolho KL, Shteyer E, Shamaly H, Ledder O, Cohen S, Peleg S, On A, Levine A. Once- Versus Twice-daily Mesalazine to Induce Remission in Paediatric Ulcerative Colitis: A Randomised Controlled Trial. J Crohns Colitis 2017;11:527-33. [PMID: 28453754 DOI: 10.1093/ecco-jcc/jjw180] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 149 |
Boal Carvalho P, Cotter J. Mucosal Healing in Ulcerative Colitis: A Comprehensive Review. Drugs. 2017;77:159-173. [PMID: 28078646 DOI: 10.1007/s40265-016-0676-y] [Cited by in Crossref: 58] [Cited by in F6Publishing: 56] [Article Influence: 9.7] [Reference Citation Analysis]
|
| 150 |
Berding A, Witte C, Gottschald M, Kaltz B, Weiland R, Gerlich C, Reusch A, Kruis W, Faller H. Beneficial Effects of Education on Emotional Distress, Self-Management, and Coping in Patients with Inflammatory Bowel Disease: A Prospective Randomized Controlled Study. Inflamm Intest Dis 2017;1:182-90. [PMID: 29922675 DOI: 10.1159/000452989] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 151 |
Dignass A, Schnabel R, Romatowski J, Pavlenko V, Dorofeyev A, Derova J, Jonaitis L, Dilger K, Nacak T, Greinwald R; International SAT-25 Study Group. Efficacy and safety of a novel high-dose mesalazine tablet in mild to moderate active ulcerative colitis: a double-blind, multicentre, randomised trial. United European Gastroenterol J 2018;6:138-47. [PMID: 29435324 DOI: 10.1177/2050640617703842] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 152 |
Therkelsen SP, Hetland G, Lyberg T, Lygren I, Johnson E. Cytokine Levels After Consumption of a Medicinal Agaricus blazei Murill-Based Mushroom Extract, AndoSan™ , in Patients with Crohn's Disease and Ulcerative Colitis in a Randomized Single-Blinded Placebo-Controlled Study. Scand J Immunol 2016;84:323-31. [PMID: 27588816 DOI: 10.1111/sji.12476] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 153 |
Iboshi Y, Nakamura K, Fukaura K, Iwasa T, Ogino H, Sumida Y, Ihara E, Akiho H, Harada N, Nakamuta M. Increased IL-17A/IL-17F expression ratio represents the key mucosal T helper/regulatory cell-related gene signature paralleling disease activity in ulcerative colitis. J Gastroenterol 2017;52:315-26. [PMID: 27178567 DOI: 10.1007/s00535-016-1221-1] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 154 |
Vuitton L, Peyrin-Biroulet L, Colombel JF, Pariente B, Pineton de Chambrun G, Walsh AJ, Panes J, Travis SP, Mary JY, Marteau P. Defining endoscopic response and remission in ulcerative colitis clinical trials: an international consensus. Aliment Pharmacol Ther 2017;45:801-13. [PMID: 28112419 DOI: 10.1111/apt.13948] [Cited by in Crossref: 76] [Cited by in F6Publishing: 55] [Article Influence: 12.7] [Reference Citation Analysis]
|
| 155 |
Kucharzik T, Lemmnitz G, Abels C, Maaser C. Tripeptide K(D)PT Is Well Tolerated in Mild-to-moderate Ulcerative Colitis: Results from a Randomized Multicenter Study. Inflamm Bowel Dis 2017;23:261-71. [PMID: 28092306 DOI: 10.1097/MIB.0000000000001000] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 156 |
Manolakis AC, Christodoulidis G, Kapsoritakis AN, Georgoulias P, Tiaka EK, Oikonomou K, Valotassiou VJ, Potamianos SP. α2-Heremans-schmid glycoprotein (fetuin A) downregulation and its utility in inflammatory bowel disease. World J Gastroenterol 2017; 23(3): 437-446 [PMID: 28210079 DOI: 10.3748/wjg.v23.i3.437] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 157 |
Takenaka K, Hoshino A, Takahashi F, Sugaya T, Nakano M, Tominaga K, Hiraishi H. Tacrolimus-Induced Paralytic Ileus in a Patient with Ulcerative Colitis. Journal of Japan Society of Coloproctology 2017;70:243-247. [DOI: 10.3862/jcoloproctology.70.243] [Reference Citation Analysis]
|
| 158 |
Yamamoto-furusho J, Bosques-padilla F, de-Paula J, Galiano M, Ibañez P, Juliao F, Kotze P, Rocha J, Steinwurz F, Veitia G, Zaltman C. Diagnosis and treatment of inflammatory bowel disease: First Latin American Consensus of the Pan American Crohn's and Colitis Organisation. Revista de Gastroenterología de México (English Edition) 2017;82:46-84. [DOI: 10.1016/j.rgmxen.2016.07.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 159 |
Christensen B, Rubin DT. Objective Assessment of Endoscopic Disease Activity and Mucosal Healing. Crohn's Disease and Ulcerative Colitis 2017. [DOI: 10.1007/978-3-319-33703-6_24] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 160 |
Louis E, Van Kemseke C, Reenaers C. Objective Assessment of Clinical Disease Activity. Crohn's Disease and Ulcerative Colitis 2017. [DOI: 10.1007/978-3-319-33703-6_23] [Reference Citation Analysis]
|
| 161 |
Hou JK, Gasche C, Drazin NZ, Weaver SA, Ehrlich OG, Oberai R, Zapala S, Siegel CA, Melmed G. Assessment of Gaps in Care and the Development of a Care Pathway for Anemia in Patients with Inflammatory Bowel Diseases. Inflamm Bowel Dis 2017;23:35-43. [PMID: 27749376 DOI: 10.1097/MIB.0000000000000953] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 4.2] [Reference Citation Analysis]
|
| 162 |
Shinzaki S, Matsuoka K, Iijima H, Mizuno S, Serada S, Fujimoto M, Arai N, Koyama N, Morii E, Watanabe M, Hibi T, Kanai T, Takehara T, Naka T. Leucine-rich Alpha-2 Glycoprotein is a Serum Biomarker of Mucosal Healing in Ulcerative Colitis. J Crohns Colitis 2017;11:84-91. [PMID: 27466171 DOI: 10.1093/ecco-jcc/jjw132] [Cited by in Crossref: 69] [Cited by in F6Publishing: 70] [Article Influence: 11.5] [Reference Citation Analysis]
|
| 163 |
Yamamoto-furusho J, Bosques-padilla F, de-Paula J, Galiano M, Ibañez P, Juliao F, Kotze P, Rocha J, Steinwurz F, Veitia G, Zaltman C. Diagnóstico y tratamiento de la enfermedad inflamatoria intestinal: Primer Consenso Latinoamericano de la Pan American Crohn's and Colitis Organisation. Revista de Gastroenterología de México 2017;82:46-84. [DOI: 10.1016/j.rgmx.2016.07.003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 164 |
Turner D, Ledder O. Clinical Indices for Pediatric Inflammatory Bowel Disease Research. Pediatric Inflammatory Bowel Disease 2017. [DOI: 10.1007/978-3-319-49215-5_46] [Reference Citation Analysis]
|
| 165 |
Di Girolamo M, Sartini A, Critelli R, Bertani A, Merighi A, Villa E. Efficacy of a Novel Granulocyte Monocyte Apheresis Adsorber Device in the Treatment of Inflammatory Bowel Diseases: A Pilot Study. Ther Apher Dial 2016;20:668-76. [PMID: 27921374 DOI: 10.1111/1744-9987.12453] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 166 |
Park S, Abdi T, Gentry M, Laine L. Histological Disease Activity as a Predictor of Clinical Relapse Among Patients With Ulcerative Colitis: Systematic Review and Meta-Analysis. Am J Gastroenterol 2016;111:1692-701. [PMID: 27725645 DOI: 10.1038/ajg.2016.418] [Cited by in Crossref: 110] [Cited by in F6Publishing: 90] [Article Influence: 15.7] [Reference Citation Analysis]
|
| 167 |
Mohammadi E, Qujeq D, Taheri H, Hajian-Tilaki K. Evaluation of Serum Trace Element Levels and Superoxide Dismutase Activity in Patients with Inflammatory Bowel Disease: Translating Basic Research into Clinical Application. Biol Trace Elem Res 2017;177:235-40. [PMID: 27864666 DOI: 10.1007/s12011-016-0891-0] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 4.7] [Reference Citation Analysis]
|
| 168 |
Manguso F, Bennato R, Lombardi G, Riccio E, Costantino G, Fries W. Efficacy and Safety of Oral Beclomethasone Dipropionate in Ulcerative Colitis: A Systematic Review and Meta-Analysis. PLoS One 2016;11:e0166455. [PMID: 27846307 DOI: 10.1371/journal.pone.0166455] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 169 |
Mohammed N, Subramanian V. Clinical relevance of endoscopic assessment of inflammation in ulcerative colitis: Can endoscopic evaluation predict outcomes? World J Gastroenterol 2016; 22(42): 9324-9332 [PMID: 27895420 DOI: 10.3748/wjg.v22.i42.9324] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 170 |
Atreya R, Bloom S, Scaldaferri F, Gerardi V, Admyre C, Karlsson Å, Knittel T, Kowalski J, Lukas M, Löfberg R, Nancey S, Petryka R, Rydzewska G, Schnabel R, Seidler U, Neurath MF, Hawkey C. Clinical Effects of a Topically Applied Toll-like Receptor 9 Agonist in Active Moderate-to-Severe Ulcerative Colitis. J Crohns Colitis 2016;10:1294-302. [PMID: 27208386 DOI: 10.1093/ecco-jcc/jjw103] [Cited by in Crossref: 47] [Cited by in F6Publishing: 47] [Article Influence: 6.7] [Reference Citation Analysis]
|
| 171 |
Meijer B, Mulder CJ, Peters GJ, van Bodegraven AA, de Boer NK. Efficacy of thioguanine treatment in inflammatory bowel disease: A systematic review. World J Gastroenterol 2016; 22(40): 9012-9021 [PMID: 27833392 DOI: 10.3748/wjg.v22.i40.9012] [Cited by in CrossRef: 45] [Cited by in F6Publishing: 44] [Article Influence: 6.4] [Reference Citation Analysis]
|
| 172 |
Connelly TM, Devane L, Kelly JC, Wrafter P, Messaris E. The 100 classic papers in ulcerative colitis: a bibliometric analysis. Expert Rev Gastroenterol Hepatol 2016;10:1187-95. [PMID: 27531253 DOI: 10.1080/17474124.2016.1216786] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 173 |
Kolho KL. Assessment of disease activity in pediatric ulcerative colitis. Expert Rev Gastroenterol Hepatol 2016;10:1127-34. [PMID: 27145213 DOI: 10.1080/17474124.2016.1185364] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 174 |
Mirsepasi-Lauridsen HC, Halkjaer SI, Mortensen EM, Lydolph MC, Nordgaard-Lassen I, Krogfelt KA, Petersen AM. Extraintestinal pathogenic Escherichia coli are associated with intestinal inflammation in patients with ulcerative colitis. Sci Rep 2016;6:31152. [PMID: 27686530 DOI: 10.1038/srep31152] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 175 |
Saigusa K, Matsuoka K, Sugimoto S, Arai M, Kiyohara H, Takeshita K, Mizuno S, Mori K, Nanki K, Takeshita T, Nakazato Y, Yajima T, Naganuma M, Hisamatsu T, Ogata H, Iwao Y, Kanai T. Ulcerative colitis endoscopic index of severity is associated with long-term prognosis in ulcerative colitis patients treated with infliximab. Dig Endosc 2016;28:665-70. [PMID: 26997640 DOI: 10.1111/den.12655] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 176 |
Takahashi F, Tominaga K, Kanamori A, Takenaka K, Hoshino A, Sugaya T, Nakano M, Hiraishi H. Timing for dose-down of 5-ASA depends on mucosal status with ulcerative colitis. Scand J Gastroenterol 2016;51:827-34. [PMID: 26853910 DOI: 10.3109/00365521.2016.1141315] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 177 |
Sagawa T, Kakizaki S, Tomizawa T, Nakayama T, Tanaka H, Tojima H, Sato K, Kusano M, Okamura S, Yamada M. Faecal lactoferrin is a useful biomarker for mucosal healing in patients with ulcerative colitis during granulocyte and monocyte adsorptive apheresis therapy. Colorectal Dis 2016;18:696-702. [PMID: 26748553 DOI: 10.1111/codi.13258] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 178 |
Langhorst J, Boone J, Lauche R, Rueffer A, Dobos G. Faecal Lactoferrin, Calprotectin, PMN-elastase, CRP, and White Blood Cell Count as Indicators for Mucosal Healing and Clinical Course of Disease in Patients with Mild to Moderate Ulcerative Colitis: Post Hoc Analysis of a Prospective Clinical Trial. J Crohns Colitis 2016;10:786-94. [PMID: 26874351 DOI: 10.1093/ecco-jcc/jjw044] [Cited by in Crossref: 52] [Cited by in F6Publishing: 52] [Article Influence: 7.4] [Reference Citation Analysis]
|
| 179 |
Dignass A, Akbar A, Hart A, Subramanian S, Bommelaer G, Baumgart DC, Grimaud JC, Cadiot G, Makins R, Hoque S, Bouguen G, Bonaz B. Safety and Efficacy of Granulocyte/Monocyte Apheresis in Steroid-Dependent Active Ulcerative Colitis with Insufficient Response or Intolerance to Immunosuppressants and/or Biologics [the ART Trial]: 12-week Interim Results. J Crohns Colitis 2016;10:812-20. [PMID: 26818659 DOI: 10.1093/ecco-jcc/jjw032] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 4.3] [Reference Citation Analysis]
|
| 180 |
Di Sabatino A, Santilli F, Guerci M, Simeone P, Ardizzone S, Massari A, Giuffrida P, Tripaldi R, Malara A, Liani R, Gurini E, Aronico N, Balduini A, Corazza GR, Davì G. Oxidative stress and thromboxane-dependent platelet activation in inflammatory bowel disease: effects of anti-TNF-α treatment. Thromb Haemost 2016;116:486-95. [PMID: 27305860 DOI: 10.1160/TH16-02-0167] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 181 |
Kaplan M, Yuksel M, Ates I, Kilic ZM, Kilic H, Kuzu UB, Kayacetin E. Is ischemia modified albumin a disease activity marker for inflammatory bowel diseases? J Gastroenterol Hepatol 2016;31:1120-5. [PMID: 26642816 DOI: 10.1111/jgh.13254] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 182 |
Kucharski M, Karczewski J, Mańkowska-Wierzbicka D, Karmelita-Katulska K, Grzymisławski M, Kaczmarek E, Iwanik K, Rzymski P, Swora-Cwynar E, Linke K, Dobrowolska A. Applicability of endoscopic indices in the determination of disease activity in patients with ulcerative colitis. Eur J Gastroenterol Hepatol 2016;28:722-30. [PMID: 26894632 DOI: 10.1097/MEG.0000000000000601] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 183 |
Wang Y, Parker CE, Bhanji T, Feagan BG, MacDonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2016;4:CD000543. [PMID: 27101467 DOI: 10.1002/14651858.cd000543.pub4] [Cited by in Crossref: 38] [Cited by in F6Publishing: 52] [Article Influence: 5.4] [Reference Citation Analysis]
|
| 184 |
Kawashima K, Ishihara S, Yuki T, Fukuba N, Oshima N, Kazumori H, Sonoyama H, Yamashita N, Tada Y, Kusunoki R, Oka A, Mishima Y, Moriyama I, Kinoshita Y. Fecal calprotectin level correlated with both endoscopic severity and disease extent in ulcerative colitis. BMC Gastroenterol 2016;16:47. [PMID: 27071448 DOI: 10.1186/s12876-016-0462-z] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 4.4] [Reference Citation Analysis]
|
| 185 |
Boga S, Alkim H, Koksal AR, Ozagari AA, Bayram M, Tekin Neijmann S, Sen I, Alkim C. Serum ST2 in inflammatory bowel disease: a potential biomarker for disease activity. J Investig Med 2016;64:1016-24. [PMID: 27001944 DOI: 10.1136/jim-2016-000062] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 186 |
Simsek HD, Basyigit S, Aktas B, Simsek GG, Vargol E, Kucukazman M, Nazlıgul Y. Assessment of the Correlation between Endoscopic Activity and Histological Activity in Ulcerative Colitis Patients. Med Princ Pract 2016;25:378-84. [PMID: 26985865 DOI: 10.1159/000445502] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 187 |
Therkelsen SP, Hetland G, Lyberg T, Lygren I, Johnson E. Effect of a Medicinal Agaricus blazei Murill-Based Mushroom Extract, AndoSan™, on Symptoms, Fatigue and Quality of Life in Patients with Ulcerative Colitis in a Randomized Single-Blinded Placebo Controlled Study. PLoS One 2016;11:e0150191. [PMID: 26933886 DOI: 10.1371/journal.pone.0150191] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 188 |
Kaplan M, Yuksel M, Ates I, Yaln Kilic ZM, Kilic H, Ates H, Kayacetin E. Are sTWEAK and IL-17A Levels in Inflammatory Bowel Disease Associated with Disease Activity and Etiopathogenesis? Inflamm Bowel Dis 2016;22:615-22. [PMID: 26650150 DOI: 10.1097/MIB.0000000000000632] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 189 |
Peyrin-Biroulet L, Panés J, Sandborn WJ, Vermeire S, Danese S, Feagan BG, Colombel JF, Hanauer SB, Rycroft B. Defining Disease Severity in Inflammatory Bowel Diseases: Current and Future Directions. Clin Gastroenterol Hepatol 2016;14:348-354.e17. [PMID: 26071941 DOI: 10.1016/j.cgh.2015.06.001] [Cited by in Crossref: 239] [Cited by in F6Publishing: 241] [Article Influence: 34.1] [Reference Citation Analysis]
|
| 190 |
Ikeya K, Hanai H, Sugimoto K, Osawa S, Kawasaki S, Iida T, Maruyama Y, Watanabe F. The Ulcerative Colitis Endoscopic Index of Severity More Accurately Reflects Clinical Outcomes and Long-term Prognosis than the Mayo Endoscopic Score. J Crohns Colitis 2016;10:286-95. [PMID: 26581895 DOI: 10.1093/ecco-jcc/jjv210] [Cited by in Crossref: 88] [Cited by in F6Publishing: 87] [Article Influence: 12.6] [Reference Citation Analysis]
|
| 191 |
Cintolo M, Costantino G, Pallio S, Fries W. Mucosal healing in inflammatory bowel disease: Maintain or de-escalate therapy. World J Gastrointest Pathophysiol 2016; 7(1): 1-16 [PMID: 26909224 DOI: 10.4291/wjgp.v7.i1.1] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
|
| 192 |
Nishida A, Hidaka K, Kanda T, Imaeda H, Shioya M, Inatomi O, Bamba S, Kitoh K, Sugimoto M, Andoh A. Increased Expression of Interleukin-36, a Member of the Interleukin-1 Cytokine Family, in Inflammatory Bowel Disease. Inflamm Bowel Dis 2016;22:303-14. [PMID: 26752465 DOI: 10.1097/MIB.0000000000000654] [Cited by in Crossref: 90] [Cited by in F6Publishing: 89] [Article Influence: 12.9] [Reference Citation Analysis]
|
| 193 |
Endo K, Onodera M, Shiga H, Kuroha M, Kimura T, Hiramoto K, Kakuta Y, Kinouchi Y, Shimosegawa T. A Comparison of Short- and Long-Term Therapeutic Outcomes of Infliximab- versus Tacrolimus-Based Strategies for Steroid-Refractory Ulcerative Colitis. Gastroenterol Res Pract. 2016;2016:3162595. [PMID: 26904108 DOI: 10.1155/2016/3162595] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 194 |
Christensen B, Rubin DT. Understanding Endoscopic Disease Activity in IBD: How to Incorporate It into Practice. Curr Gastroenterol Rep 2016;18. [DOI: 10.1007/s11894-015-0477-6] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 195 |
Tamaki H, Nakase H, Inoue S, Kawanami C, Itani T, Ohana M, Kusaka T, Uose S, Hisatsune H, Tojo M, Noda T, Arasawa S, Izuta M, Kubo A, Ogawa C, Matsunaka T, Shibatouge M. Efficacy of probiotic treatment with Bifidobacterium longum 536 for induction of remission in active ulcerative colitis: A randomized, double-blinded, placebo-controlled multicenter trial. Dig Endosc 2016;28:67-74. [PMID: 26418574 DOI: 10.1111/den.12553] [Cited by in Crossref: 111] [Cited by in F6Publishing: 110] [Article Influence: 15.9] [Reference Citation Analysis]
|
| 196 |
Klare P, Nigg J, Nold J, Haller B, Krug AB, Mair S, Thoeringer CK, Christle JW, Schmid RM, Halle M, Huber W. The impact of a ten-week physical exercise program on health-related quality of life in patients with inflammatory bowel disease: a prospective randomized controlled trial. Digestion 2015;91:239-47. [PMID: 25823689 DOI: 10.1159/000371795] [Cited by in Crossref: 69] [Cited by in F6Publishing: 120] [Article Influence: 8.6] [Reference Citation Analysis]
|
| 197 |
Keller J, Binnewies U, Rösch M, Juul Holst J, Beglinger C, Andresen V, Layer P. Gastric emptying and disease activity in inflammatory bowel disease. Eur J Clin Invest 2015;45:1234-42. [PMID: 26426315 DOI: 10.1111/eci.12542] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 4.1] [Reference Citation Analysis]
|
| 198 |
Hirten R, Sultan K, Thomas A, Bernstein DE. Hepatic manifestations of non-steroidal inflammatory bowel disease therapy. World J Hepatol 2015;7:2716-28. [PMID: 26644815 DOI: 10.4254/wjh.v7.i27.2716] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 199 |
Wang WQ, Dong K, Zhou L, Jiao GH, Zhu CZ, Li WW, Yu G, Wu WT, Chen S, Sun ZN, Wang YM, Liu WT, Zhang J, Wang BM, Feng XM. IL-37b gene transfer enhances the therapeutic efficacy of mesenchumal stromal cells in DSS-induced colitis mice. Acta Pharmacol Sin 2015;36:1377-87. [PMID: 26190499 DOI: 10.1038/aps.2015.51] [Cited by in Crossref: 35] [Cited by in F6Publishing: 38] [Article Influence: 4.4] [Reference Citation Analysis]
|
| 200 |
Boon GJ, Day AS, Mulder CJ, Gearry RB. Are faecal markers good indicators of mucosal healing in inflammatory bowel disease? World J Gastroenterol 2015; 21(40): 11469-11480 [PMID: 26523111 DOI: 10.3748/wjg.v21.i40.11469] [Cited by in CrossRef: 39] [Cited by in F6Publishing: 40] [Article Influence: 4.9] [Reference Citation Analysis]
|
| 201 |
Sherlock ME, MacDonald JK, Griffiths AM, Steinhart AH, Seow CH. Oral budesonide for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2015;26:CD007698. [PMID: 26497719 DOI: 10.1002/14651858.cd007698.pub3] [Cited by in Crossref: 30] [Cited by in F6Publishing: 38] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 202 |
Lobatón T, Bessissow T, De Hertogh G, Lemmens B, Maedler C, Van Assche G, Vermeire S, Bisschops R, Rutgeerts P, Bitton A, Afif W, Marcus V, Ferrante M. The Modified Mayo Endoscopic Score (MMES): A New Index for the Assessment of Extension and Severity of Endoscopic Activity in Ulcerative Colitis Patients. J Crohns Colitis 2015;9:846-52. [PMID: 26116558 DOI: 10.1093/ecco-jcc/jjv111] [Cited by in Crossref: 77] [Cited by in F6Publishing: 78] [Article Influence: 9.6] [Reference Citation Analysis]
|
| 203 |
Alrubaiy L, Rikaby I, Sageer M, Hutchings HA, Williams JG. Systematic Review of the Clinical Disease Severity Indices for Inflammatory Bowel Disease. Inflamm Bowel Dis 2015;21:2460-6. [PMID: 25966838 DOI: 10.1097/MIB.0000000000000438] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 204 |
Stallhofer J, Friedrich M, Konrad-Zerna A, Wetzke M, Lohse P, Glas J, Tillack-Schreiber C, Schnitzler F, Beigel F, Brand S. Lipocalin-2 Is a Disease Activity Marker in Inflammatory Bowel Disease Regulated by IL-17A, IL-22, and TNF-α and Modulated by IL23R Genotype Status. Inflamm Bowel Dis 2015;21:2327-40. [PMID: 26263469 DOI: 10.1097/MIB.0000000000000515] [Cited by in Crossref: 29] [Cited by in F6Publishing: 45] [Article Influence: 3.6] [Reference Citation Analysis]
|
| 205 |
Defendenti C, Sarzi-Puttini P, Saibeni S, Bollani S, Bruno S, Almasio PL, Declich P, Atzeni F. Significance of serum Il-9 levels in inflammatory bowel disease. Int J Immunopathol Pharmacol. 2015;28:569-575. [PMID: 26377844 DOI: 10.1177/0394632015600535] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 206 |
Wang Y, MacDonald JK, Benchimol EI, Griffiths AM, Steinhart AH, Panaccione R, Seow CH. Type I interferons for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2015;CD006790. [PMID: 26368001 DOI: 10.1002/14651858.cd006790.pub3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 207 |
Matsumoto S, Yoshida Y. Efficacy of a pH-dependent controlled-release mesalazine based on clinical and endoscopic assessment for ulcerative colitis: a retrospective cohort study. Clin Exp Gastroenterol 2015;8:225-30. [PMID: 26347309 DOI: 10.2147/CEG.S86528] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 208 |
Peyrin-Biroulet L, Sandborn W, Sands BE, Reinisch W, Bemelman W, Bryant RV, D'Haens G, Dotan I, Dubinsky M, Feagan B, Fiorino G, Gearry R, Krishnareddy S, Lakatos PL, Loftus EV Jr, Marteau P, Munkholm P, Murdoch TB, Ordás I, Panaccione R, Riddell RH, Ruel J, Rubin DT, Samaan M, Siegel CA, Silverberg MS, Stoker J, Schreiber S, Travis S, Van Assche G, Danese S, Panes J, Bouguen G, O'Donnell S, Pariente B, Winer S, Hanauer S, Colombel JF. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target. Am J Gastroenterol 2015;110:1324-38. [PMID: 26303131 DOI: 10.1038/ajg.2015.233] [Cited by in Crossref: 1160] [Cited by in F6Publishing: 1034] [Article Influence: 145.0] [Reference Citation Analysis]
|
| 209 |
Cohen LJ, Kang HS, Chu J, Huang YH, Gordon EA, Reddy BV, Ternei MA, Craig JW, Brady SF. Functional metagenomic discovery of bacterial effectors in the human microbiome and isolation of commendamide, a GPCR G2A/132 agonist. Proc Natl Acad Sci U S A 2015;112:E4825-34. [PMID: 26283367 DOI: 10.1073/pnas.1508737112] [Cited by in Crossref: 108] [Cited by in F6Publishing: 107] [Article Influence: 13.5] [Reference Citation Analysis]
|
| 210 |
Rutka M, Milassin Á, Szepes Z, SzŰcs M, Nyári T, Bálint A, Bor R, Molnár T, Farkas K. Is mucosal healing more common than clinical remission in ulcerative colitis? - Is it the truth or only a myth coming from the studies? Scand J Gastroenterol 2015;50:985-90. [PMID: 25733077 DOI: 10.3109/00365521.2015.1018313] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 211 |
Alrubaiy L, Dodds P, Hutchings HA, Russell IT, Watkins A, Williams JG. Development and validation of a new disease severity index: the Inflammatory Bowel Disease Index (IBDEX). Frontline Gastroenterol 2015;6:161-8. [PMID: 28839806 DOI: 10.1136/flgastro-2014-100530] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 212 |
Hiejima E, Kawai T, Nakase H, Tsuruyama T, Morimoto T, Yasumi T, Taga T, Kanegane H, Hori M, Ohmori K, Higuchi T, Matsuura M, Yoshino T, Ikeuchi H, Kawada K, Sakai Y, Kitazume MT, Hisamatsu T, Chiba T, Nishikomori R, Heike T. Reduced Numbers and Proapoptotic Features of Mucosal-associated Invariant T Cells as a Characteristic Finding in Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis 2015;21:1529-40. [PMID: 25946569 DOI: 10.1097/MIB.0000000000000397] [Cited by in Crossref: 68] [Cited by in F6Publishing: 66] [Article Influence: 8.5] [Reference Citation Analysis]
|
| 213 |
Takayama T, Okamoto S, Hisamatsu T, Naganuma M, Matsuoka K, Mizuno S, Bessho R, Hibi T, Kanai T. Computer-Aided Prediction of Long-Term Prognosis of Patients with Ulcerative Colitis after Cytoapheresis Therapy. PLoS One 2015;10:e0131197. [PMID: 26111148 DOI: 10.1371/journal.pone.0131197] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 214 |
Vatn MH, Sandvik AK. Inflammatory bowel disease. Scand J Gastroenterol 2015;50:748-62. [PMID: 25855003 DOI: 10.3109/00365521.2015.1033000] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 215 |
Ikeya K, Sugimoto K, Kawasaki S, Iida T, Maruyama Y, Watanabe F, Hanai H. Tacrolimus for remission induction in ulcerative colitis: Mayo endoscopic subscore 0 and 1 predict long-term prognosis. Dig Liver Dis 2015;47:365-71. [PMID: 25682993 DOI: 10.1016/j.dld.2015.01.149] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 216 |
Van Assche G, Manguso F, Zibellini M, Cabriada Nuño JL, Goldis A, Tkachenko E, Varoli G, Kleczkowski D, Annese V, D'Heygere F, Balzano A; BETA study participating centers. Oral prolonged release beclomethasone dipropionate and prednisone in the treatment of active ulcerative colitis: results from a double-blind, randomized, parallel group study. Am J Gastroenterol 2015;110:708-15. [PMID: 25869389 DOI: 10.1038/ajg.2015.114] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 5.4] [Reference Citation Analysis]
|
| 217 |
Ueki T, Kawamoto K, Otsuka Y, Minoda R, Maruo T, Matsumura K, Noma E, Mitsuyasu T, Otani K, Aomi Y, Yano Y, Hisabe T, Matsui T, Ota A, Iwashita A. Prevalence and clinicopathological features of autoimmune pancreatitis in Japanese patients with inflammatory bowel disease. Pancreas 2015;44:434-40. [PMID: 25469544 DOI: 10.1097/MPA.0000000000000261] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 3.9] [Reference Citation Analysis]
|
| 218 |
Sacco R, Tanaka T, Yamamoto T, Bresci G, Saniabadi AR. Adacolumn leucocytapheresis for ulcerative colitis: clinical and endoscopic features of responders and unresponders. Expert Rev Gastroenterol Hepatol 2015;9:327-33. [PMID: 25160857 DOI: 10.1586/17474124.2014.953060] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 219 |
Schmid J, Langhorst J, Gaß F, Theysohn N, Benson S, Engler H, Gizewski ER, Forsting M, Elsenbruch S. Placebo analgesia in patients with functional and organic abdominal pain: a fMRI study in IBS, UC and healthy volunteers. Gut 2015;64:418-27. [PMID: 24833636 DOI: 10.1136/gutjnl-2013-306648] [Cited by in Crossref: 68] [Cited by in F6Publishing: 70] [Article Influence: 8.5] [Reference Citation Analysis]
|
| 220 |
Ruemmele FM, Hyams JS, Otley A, Griffiths A, Kolho KL, Dias JA, Levine A, Escher JC, Taminiau J, Veres G, Colombel JF, Vermeire S, Wilson DC, Turner D. Outcome measures for clinical trials in paediatric IBD: an evidence-based, expert-driven practical statement paper of the paediatric ECCO committee. Gut 2015;64:438-46. [PMID: 24821616 DOI: 10.1136/gutjnl-2014-307008] [Cited by in Crossref: 60] [Cited by in F6Publishing: 58] [Article Influence: 7.5] [Reference Citation Analysis]
|
| 221 |
Ciccocioppo R, Racca F, Paolucci S, Campanini G, Pozzi L, Betti E, Riboni R, Vanoli A, Baldanti F, Corazza GR. Human cytomegalovirus and Epstein-Barr virus infection in inflammatory bowel disease: Need for mucosal viral load measurement. World J Gastroenterol 2015; 21(6): 1915-1926 [PMID: 25684960 DOI: 10.3748/wjg.v21.i6.1915] [Cited by in CrossRef: 54] [Cited by in F6Publishing: 82] [Article Influence: 6.8] [Reference Citation Analysis]
|
| 222 |
Burri E, Beglinger C, von Felten S, Lehmann FS. Fecal calprotectin and the clinical activity index are both useful to monitor medical treatment in patients with ulcerative colitis. Dig Dis Sci 2015;60:485-91. [PMID: 25344905 DOI: 10.1007/s10620-014-3383-0] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 223 |
Mosli M, Samaan M, Nelson SA, Feagan BG, Travis S, D'haens G, Sandborn WJ, Zou G, Macdonald JK, Levesque BG. Endoscopic scoring indices for evaluation of disease activity in ulcerative colitis. Cochrane Database of Systematic Reviews 2015. [DOI: 10.1002/14651858.cd011450] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 224 |
Scott FI, Lichtenstein GR. The Evaluation, Diagnosis, and Treatment of Inflammatory Bowel Diseases over the Past 100 Years: A Brief Review. Endoscopy in Inflammatory Bowel Disease 2015. [DOI: 10.1007/978-3-319-11077-6_1] [Reference Citation Analysis]
|
| 225 |
Kawaguchi T, Mori M, Saito K, Suga Y, Hashimoto M, Sako M, Yoshimura N, Uo M, Danjo K, Ikenoue Y, Oomura K, Shinozaki J, Mitsui A, Kajiura T, Suzuki M, Takazoe M. Food antigen-induced immune responses in Crohn's disease patients and experimental colitis mice. J Gastroenterol 2015;50:394-405. [PMID: 25099432 DOI: 10.1007/s00535-014-0981-8] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 3.6] [Reference Citation Analysis]
|
| 226 |
Lasson A, Stotzer PO, Öhman L, Isaksson S, Sapnara M, Strid H. The intra-individual variability of faecal calprotectin: a prospective study in patients with active ulcerative colitis. J Crohns Colitis 2015;9:26-32. [PMID: 25008478 DOI: 10.1016/j.crohns.2014.06.002] [Cited by in Crossref: 37] [Cited by in F6Publishing: 57] [Article Influence: 4.6] [Reference Citation Analysis]
|
| 227 |
Taghvaei T, Maleki I, Nagshvar F, Fakheri H, Hosseini V, Valizadeh SM, Neishaboori H. Fecal calprotectin and ulcerative colitis endoscopic activity index as indicators of mucosal healing in ulcerative colitis. Intern Emerg Med 2015;10:321-8. [DOI: 10.1007/s11739-014-1144-x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 228 |
Guidi L, Marzo M, Andrisani G, Felice C, Pugliese D, Mocci G, Nardone O, De Vitis I, Papa A, Rapaccini G, Forni F, Armuzzi A. Faecal calprotectin assay after induction with anti-Tumour Necrosis Factor α agents in inflammatory bowel disease: Prediction of clinical response and mucosal healing at one year. Dig Liver Dis 2014;46:974-9. [PMID: 25096964 DOI: 10.1016/j.dld.2014.07.013] [Cited by in Crossref: 51] [Cited by in F6Publishing: 51] [Article Influence: 5.7] [Reference Citation Analysis]
|
| 229 |
Kobayashi K, Hirai F, Naganuma M, Watanabe K, Ando T, Nakase H, Matsuoka K, Watanabe M. A randomized clinical trial of mesalazine suppository: the usefulness and problems of central review of evaluations of colonic mucosal findings. J Crohns Colitis 2014;8:1444-53. [PMID: 24923656 DOI: 10.1016/j.crohns.2014.05.005] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 230 |
Tang R, Yang G, Zhang S, Wu C, Chen M. Opposite effects of interferon regulatory factor 1 and osteopontin on the apoptosis of epithelial cells induced by TNF-α in inflammatory bowel disease. Inflamm Bowel Dis 2014;20:1950-61. [PMID: 25208103 DOI: 10.1097/MIB.0000000000000192] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 2.9] [Reference Citation Analysis]
|
| 231 |
Petersen AM, Mirsepasi H, Halkjær SI, Mortensen EM, Nordgaard-Lassen I, Krogfelt KA. Ciprofloxacin and probiotic Escherichia coli Nissle add-on treatment in active ulcerative colitis: a double-blind randomized placebo controlled clinical trial. J Crohns Colitis 2014;8:1498-505. [PMID: 24972748 DOI: 10.1016/j.crohns.2014.06.001] [Cited by in Crossref: 83] [Cited by in F6Publishing: 84] [Article Influence: 9.2] [Reference Citation Analysis]
|
| 232 |
Saito E, Nagahori M, Fujii T, Ohtsuka K, Watanabe M. Efficacy of salvage therapy and its effect on operative outcomes in patients with ulcerative colitis. Digestion 2014;89:55-60. [PMID: 24458114 DOI: 10.1159/000356221] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 233 |
Frehn L, Jansen A, Bennek E, Mandic AD, Temizel I, Tischendorf S, Verdier J, Tacke F, Streetz K, Trautwein C. Distinct patterns of IgG and IgA against food and microbial antigens in serum and feces of patients with inflammatory bowel diseases. PLoS One. 2014;9:e106750. [PMID: 25215528 DOI: 10.1371/journal.pone.0106750] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 234 |
Kohashi M, Nishiumi S, Ooi M, Yoshie T, Matsubara A, Suzuki M, Hoshi N, Kamikozuru K, Yokoyama Y, Fukunaga K, Nakamura S, Azuma T, Yoshida M. A novel gas chromatography mass spectrometry-based serum diagnostic and assessment approach to ulcerative colitis. J Crohns Colitis 2014;8:1010-21. [PMID: 24582087 DOI: 10.1016/j.crohns.2014.01.024] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 235 |
Langhorst J, Frede A, Knott M, Pastille E, Buer J, Dobos GJ, Westendorf AM. Distinct Kinetics in the Frequency of Peripheral CD4+ T Cells in Patients with Ulcerative Colitis Experiencing a Flare during Treatment with Mesalazine or with a Herbal Preparation of Myrrh, Chamomile, and Coffee Charcoal. PLoS One. 2014;9:e104257. [PMID: 25144293 DOI: 10.1371/journal.pone.0104257] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 236 |
Saniabadi AR, Tanaka T, Ohmori T, Sawada K, Yamamoto T, Hanai H. Treating inflammatory bowel disease by adsorptive leucocytapheresis: A desire to treat without drugs. World J Gastroenterol 2014; 20(29): 9699-9715 [PMID: 25110409 DOI: 10.3748/wjg.v20.i29.9699] [Cited by in CrossRef: 54] [Cited by in F6Publishing: 57] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 237 |
Korkmaz H, Sahin F, Ipekci SH, Temel T, Kebapcilar L. Increased pulse wave velocity and relationship with inflammation, insulin, and insulin resistance in inflammatory bowel disease. Eur J Gastroenterol Hepatol 2014;26:725-32. [PMID: 24901818 DOI: 10.1097/MEG.0000000000000104] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 238 |
Tontini GE, Bisschops R, Neumann H. Endoscopic scoring systems for inflammatory bowel disease: pros and cons. Expert Rev Gastroenterol Hepatol 2014;8:543-54. [PMID: 24650249 DOI: 10.1586/17474124.2014.899899] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 239 |
Carter D, Eliakim R. Current role of endoscopy in inflammatory bowel disease diagnosis and management. Curr Opin Gastroenterol 2014;30:370-7. [PMID: 24837226 DOI: 10.1097/MOG.0000000000000074] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 240 |
Walsh A, Palmer R, Travis S. Mucosal healing as a target of therapy for colonic inflammatory bowel disease and methods to score disease activity. Gastrointest Endosc Clin N Am 2014;24:367-78. [PMID: 24975528 DOI: 10.1016/j.giec.2014.03.005] [Cited by in Crossref: 77] [Cited by in F6Publishing: 79] [Article Influence: 8.6] [Reference Citation Analysis]
|
| 241 |
Schultheiß C, Weischenberg R, Herrmann A, Haller B, Schmid RM, Reindl W, Huber W. Dose-intensified granulocyte-monocyte apheresis in therapy refractory ulcerative colitis. Artif Organs 2015;39:187-92. [PMID: 24981894 DOI: 10.1111/aor.12329] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 242 |
Nagayama K, Takedatsu H, Mitsuyama K, Yamasaki H, Kuwaki K, Yoshioka S, Kobayashi T, Yamauchi R, Kakuma T, Sata M. Univariate analysis to examine predictors of response to leukocytapheresis in ulcerative colitis patients. Ther Apher Dial 2014;18:244-51. [PMID: 24965290 DOI: 10.1111/1744-9987.12211] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 243 |
Sturm EM, Radnai B, Jandl K, Stančić A, Parzmair GP, Högenauer C, Kump P, Wenzl H, Petritsch W, Pieber TR, Schuligoi R, Marsche G, Ferreirós N, Heinemann A, Schicho R. Opposing roles of prostaglandin D2 receptors in ulcerative colitis. J Immunol 2014;193:827-39. [PMID: 24929001 DOI: 10.4049/jimmunol.1303484] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 2.9] [Reference Citation Analysis]
|
| 244 |
Fukuba N, Ishihara S, Tada Y, Oshima N, Moriyama I, Yuki T, Kawashima K, Kushiyama Y, Fujishiro H, Kinoshita Y. Prevalence of irritable bowel syndrome-like symptoms in ulcerative colitis patients with clinical and endoscopic evidence of remission: prospective multicenter study. Scand J Gastroenterol 2014;49:674-80. [PMID: 24646420 DOI: 10.3109/00365521.2014.898084] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 3.4] [Reference Citation Analysis]
|
| 245 |
Hueppe A, Langbrandtner J, Raspe H. Inviting patients with inflammatory bowel disease to active involvement in their own care: a randomized controlled trial. Inflamm Bowel Dis 2014;20:1057-69. [PMID: 24788217 DOI: 10.1097/MIB.0000000000000044] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 246 |
Brahmania M, Bernstein CN. Physician global assessments or blood tests do not predict mucosal healing in ulcerative colitis. Can J Gastroenterol Hepatol 2014;28:325-9. [PMID: 24945187 DOI: 10.1155/2014/737349] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 247 |
Iboshi Y, Nakamura K, Ihara E, Iwasa T, Akiho H, Harada N, Nakamuta M, Takayanagi R. Multigene analysis unveils distinctive expression profiles of helper T-cell-related genes in the intestinal mucosa that discriminate between ulcerative colitis and Crohn's disease. Inflamm Bowel Dis 2014;20:967-77. [PMID: 24739631 DOI: 10.1097/MIB.0000000000000028] [Cited by in Crossref: 5] [Cited by in F6Publishing: 14] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 248 |
Meijer B, Hoskin T, Ashcroft A, Burgess L, Keenan JI, Falvey J, Gearry RB, Day AS. Total soluble and endogenous secretory receptor for advanced glycation endproducts (RAGE) in IBD. J Crohns Colitis 2014;8:513-20. [PMID: 24291021 DOI: 10.1016/j.crohns.2013.11.004] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 249 |
Paine ER. Colonoscopic evaluation in ulcerative colitis. Gastroenterol Rep (Oxf). 2014;2:161-168. [PMID: 24879406 DOI: 10.1093/gastro/gou028] [Cited by in Crossref: 44] [Cited by in F6Publishing: 48] [Article Influence: 4.9] [Reference Citation Analysis]
|
| 250 |
Pagnini C, Menasci F, Festa S, Rizzatti G, Fave GD. “Mucosal healing” in ulcerative colitis: Between clinical evidence and market suggestion. World J Gastrointest Pathophysiol 2014; 5(2): 54-62 [PMID: 24891976 DOI: 10.4291/wjgp.v5.i2.54] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 251 |
Kuznetsov NV, Zargari A, Gielen AW, von Stein OD, Musch E, Befrits R, Lofberg R, von Stein P. Biomarkers can predict potential clinical responders to DIMS0150 a toll-like receptor 9 agonist in ulcerative colitis patients. BMC Gastroenterol 2014;14:79. [PMID: 24758565 DOI: 10.1186/1471-230X-14-79] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
|
| 252 |
Vlachos II, Barbatis C, Tsopanomichalou M, Abou-Assabeh L, Goumas K, Ginieri-Coccossis M, Economou M, Papadimitriou GN, Patsouris E, Nicolopoulou-Stamati P. Correlation between depression, anxiety, and polymorphonuclear cells' resilience in ulcerative colitis: the mediating role of heat shock protein 70. BMC Gastroenterol 2014;14:77. [PMID: 24742079 DOI: 10.1186/1471-230X-14-77] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 253 |
Meister T, Heinzow H, Domagk D, Dortgolz A, Lenze F, Ross M, Domschke W, Lügering A. Kapselendoskopie des Kolons versus Standardkoloskopie zur Ermittlung der Krankheitsaktivität bei Colitis ulcerosa: eine prospektive Studie. coloproctology 2014;36:86-91. [DOI: 10.1007/s00053-014-0431-3] [Reference Citation Analysis]
|
| 254 |
Yoon JY, Park SJ, Hong SP, Kim TI, Kim WH, Cheon JH. Correlations of C-reactive protein levels and erythrocyte sedimentation rates with endoscopic activity indices in patients with ulcerative colitis. Dig Dis Sci 2014;59:829-37. [PMID: 24352705 DOI: 10.1007/s10620-013-2907-3] [Cited by in Crossref: 49] [Cited by in F6Publishing: 46] [Article Influence: 5.4] [Reference Citation Analysis]
|
| 255 |
Walsh AJ, Ghosh A, Brain AO, Buchel O, Burger D, Thomas S, White L, Collins GS, Keshav S, Travis SP. Comparing disease activity indices in ulcerative colitis. J Crohns Colitis 2014;8:318-25. [PMID: 24120021 DOI: 10.1016/j.crohns.2013.09.010] [Cited by in Crossref: 74] [Cited by in F6Publishing: 74] [Article Influence: 8.2] [Reference Citation Analysis]
|
| 256 |
Matusiewicz M, Neubauer K, Mierzchala-Pasierb M, Gamian A, Krzystek-Korpacka M. Matrix metalloproteinase-9: its interplay with angiogenic factors in inflammatory bowel diseases. Dis Markers. 2014;2014:643645. [PMID: 24803722 DOI: 10.1155/2014/643645] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 257 |
Guslandi M, Giollo P, Testoni PA. Corticosteroid-sparing effect of rifaximin, a nonabsorbable oral antibiotic, in active ulcerative colitis: Preliminary clinical experience. Curr Ther Res Clin Exp 2004;65:292-6. [PMID: 24672084 DOI: 10.1016/S0011-393X(04)80097-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 258 |
Schreiber S, Bachmann O. Neue Biologika für die Behandlung chronisch-entzündlicher Darmerkrankungen. Internist 2014;55:367-76. [DOI: 10.1007/s00108-013-3415-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 259 |
Hiyama S, Iijima H, Shinzaki S, Mukai A, Inoue T, Shiraishi E, Kawai S, Yamada T, Nishida T, Tsujii M, Takehara T. Narrow band imaging with magnifying endoscopy for Peyer's patches in patients with inflammatory bowel disease. Digestion 2013;87:269-80. [PMID: 23774764 DOI: 10.1159/000349953] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 260 |
Gionchetti P, Praticò C, Rizzello F, Calafiore A, Capozzi N, Campieri M, Calabrese C. The role of Budesonide-MMX in active ulcerative colitis. Expert Rev Gastroenterol Hepatol 2014;8:215-22. [PMID: 24502535 DOI: 10.1586/17474124.2014.887437] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 261 |
Hagihara Y, Ohfuji S, Watanabe K, Yamagami H, Fukushima W, Maeda K, Kamata N, Sogawa M, Shiba M, Tanigawa T, Tominaga K, Watanabe T, Fujiwara Y, Hirota Y, Arakawa T. Infliximab and/or immunomodulators inhibit immune responses to trivalent influenza vaccination in adults with inflammatory bowel disease. J Crohns Colitis 2014;8:223-33. [PMID: 24011513 DOI: 10.1016/j.crohns.2013.08.008] [Cited by in Crossref: 61] [Cited by in F6Publishing: 62] [Article Influence: 6.8] [Reference Citation Analysis]
|
| 262 |
Travis SP, Danese S, Kupcinskas L, Alexeeva O, D'Haens G, Gibson PR, Moro L, Jones R, Ballard ED, Masure J, Rossini M, Sandborn WJ. Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study. Gut 2014;63:433-41. [PMID: 23436336 DOI: 10.1136/gutjnl-2012-304258] [Cited by in Crossref: 175] [Cited by in F6Publishing: 183] [Article Influence: 19.4] [Reference Citation Analysis]
|
| 263 |
Vavricka SR, Rogler G, Maetzler S, Misselwitz B, Safroneeva E, Frei P, Manser CN, Biedermann L, Fried M, Higgins P, Wojtal KA, Schoepfer AM. High altitude journeys and flights are associated with an increased risk of flares in inflammatory bowel disease patients. J Crohns Colitis 2014;8:191-9. [PMID: 23953239 DOI: 10.1016/j.crohns.2013.07.011] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 3.2] [Reference Citation Analysis]
|
| 264 |
Stewart MJ, Kutcher M, Storr M, Seow CH. Interventions for induction of mucosal healing in ulcerative colitis. Cochrane Database of Systematic Reviews 2014. [DOI: 10.1002/14651858.cd010997] [Reference Citation Analysis]
|
| 265 |
Stewart MJ, Kutcher M, Storr M, Seow CH. Interventions for maintenance of mucosal healing in ulcerative colitis. Cochrane Database of Systematic Reviews 2014. [DOI: 10.1002/14651858.cd010998] [Reference Citation Analysis]
|
| 266 |
Biancheri P, Di Sabatino A, Ammoscato F, Facciotti F, Caprioli F, Curciarello R, Hoque SS, Ghanbari A, Joe‐njoku I, Giuffrida P, Rovedatti L, Geginat J, Corazza GR, Macdonald TT. Absence of a role for interleukin‐13 in inflammatory bowel disease. Eur J Immunol 2013;44:370-85. [DOI: 10.1002/eji.201343524] [Cited by in Crossref: 64] [Cited by in F6Publishing: 64] [Article Influence: 7.1] [Reference Citation Analysis]
|
| 267 |
Song M, Park HJ. Anti-inflammatory effect of Phellinus linteus grown on germinated brown rice on dextran sodium sulfate-induced acute colitis in mice and LPS-activated macrophages. J Ethnopharmacol 2014;154:311-8. [PMID: 24495471 DOI: 10.1016/j.jep.2013.12.059] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 268 |
Bunchorntavakul C, Reddy KR. Medical Therapy of Hepatobiliary Diseases Associated with Ulcerative Colitis. Medical Therapy of Ulcerative Colitis 2014. [DOI: 10.1007/978-1-4939-1677-1_41] [Reference Citation Analysis]
|
| 269 |
Mudireddy PR, Blonski W, Lichtenstein GR. Contrast and Comparison of Mesalamine Derivatives in the Treatment of Ulcerative Colitis. Medical Therapy of Ulcerative Colitis 2014. [DOI: 10.1007/978-1-4939-1677-1_7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 270 |
Palmer R, Walsh A, Travis S. Assessment of Disease Activity in Ulcerative Colitis. Medical Therapy of Ulcerative Colitis 2014. [DOI: 10.1007/978-1-4939-1677-1_32] [Reference Citation Analysis]
|
| 271 |
Malayandi R, Kondamudi PK, Ruby PK, Aggarwal D. Biopharmaceutical considerations and characterizations in development of colon targeted dosage forms for inflammatory bowel disease. Drug Deliv and Transl Res 2014;4:187-202. [DOI: 10.1007/s13346-013-0185-4] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 272 |
Annese V, Daperno M, Rutter MD, Amiot A, Bossuyt P, East J, Ferrante M, Götz M, Katsanos KH, Kießlich R, Ordás I, Repici A, Rosa B, Sebastian S, Kucharzik T, Eliakim R; European Crohn's and Colitis Organisation. European evidence based consensus for endoscopy in inflammatory bowel disease. J Crohns Colitis 2013;7:982-1018. [PMID: 24184171 DOI: 10.1016/j.crohns.2013.09.016] [Cited by in Crossref: 558] [Cited by in F6Publishing: 598] [Article Influence: 55.8] [Reference Citation Analysis]
|
| 273 |
Mazzuoli S, Guglielmi FW, Antonelli E, Salemme M, Bassotti G, Villanacci V. Definition and evaluation of mucosal healing in clinical practice. Dig Liver Dis 2013;45:969-77. [PMID: 23932331 DOI: 10.1016/j.dld.2013.06.010] [Cited by in Crossref: 91] [Cited by in F6Publishing: 91] [Article Influence: 9.1] [Reference Citation Analysis]
|
| 274 |
Däbritz J, Bonkowski E, Chalk C, Trapnell BC, Langhorst J, Denson LA, Foell D. Granulocyte macrophage colony-stimulating factor auto-antibodies and disease relapse in inflammatory bowel disease. Am J Gastroenterol 2013;108:1901-10. [PMID: 24145675 DOI: 10.1038/ajg.2013.360] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 275 |
Sacco R, Romano A, Mazzoni A, Bertini M, Federici G, Metrangolo S, Parisi G, Nencini C, Giampietro C, Bertoni M, Tumino E, Scatena F, Bresci G. Granulocytapheresis in steroid-dependent and steroid-resistant patients with inflammatory bowel disease: a prospective observational study. J Crohns Colitis 2013;7:e692-7. [PMID: 23870727 DOI: 10.1016/j.crohns.2013.06.012] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 3.6] [Reference Citation Analysis]
|
| 276 |
Wolff S, Terheggen G, Mueller R, Greinwald R, Franklin J, Kruis W. Are endoscopic endpoints reliable in therapeutic trials of ulcerative colitis? Inflamm Bowel Dis 2013;19:2611-5. [PMID: 24108110 DOI: 10.1097/01.MIB.0000437044.43961.00] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 277 |
Miyahara K, Nouso K, Saito S, Hiraoka S, Harada K, Takahashi S, Morimoto Y, Kobayashi S, Ikeda F, Miyake Y, Shiraha H, Takaki A, Okada H, Amano M, Hirose K, Nishimura S, Yamamoto K. Serum glycan markers for evaluation of disease activity and prediction of clinical course in patients with ulcerative colitis. PLoS One 2013;8:e74861. [PMID: 24116015 DOI: 10.1371/journal.pone.0074861] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 278 |
Langhorst J, Hofstetter A, Wolfe F, Häuser W. Short-term stress, but not mucosal healing nor depression was predictive for the risk of relapse in patients with ulcerative colitis: a prospective 12-month follow-up study. Inflamm Bowel Dis 2013;19:2380-6. [PMID: 23942564 DOI: 10.1097/MIB.0b013e3182a192ba] [Cited by in Crossref: 62] [Cited by in F6Publishing: 55] [Article Influence: 6.2] [Reference Citation Analysis]
|
| 279 |
Miheller P, Mandel MD, Mullner K, Lakatos PL. Clinical aspects of mucosal healing in inflammatory bowel diseases: what is it and what is the real value for the everyday practice? Expert Rev Clin Immunol 2013;9:871-82. [PMID: 24070050 DOI: 10.1586/1744666X.2013.824675] [Reference Citation Analysis]
|
| 280 |
Bamba T, Yamamoto T, Umegae S, Matsumoto K. Effects of preoperative leukocytapheresis on inflammatory cytokines following surgery for ulcerative colitis: a prospective randomized study. J Clin Apher. 2014;29:107-112. [PMID: 24000140 DOI: 10.1002/jca.21299] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 281 |
Saibeni S, Etchevers MJ, Tassies D, Panés J, Reverter JC, Danese S, Piqué JM, Bruno S, Vecchi M, Gasbarrini A, Sans M. Assessment of anti-prothrombin antibodies in thrombosis complicating inflammatory bowel diseases. Int J Colorectal Dis 2013;28:1281-6. [PMID: 23588875 DOI: 10.1007/s00384-013-1696-7] [Reference Citation Analysis]
|
| 282 |
Langhorst J, Varnhagen I, Schneider SB, Albrecht U, Rueffer A, Stange R, Michalsen A, Dobos GJ. Randomised clinical trial: a herbal preparation of myrrh, chamomile and coffee charcoal compared with mesalazine in maintaining remission in ulcerative colitis--a double-blind, double-dummy study. Aliment Pharmacol Ther 2013;38:490-500. [PMID: 23826890 DOI: 10.1111/apt.12397] [Cited by in Crossref: 56] [Cited by in F6Publishing: 53] [Article Influence: 5.6] [Reference Citation Analysis]
|
| 283 |
Bergamaschi G, Di Sabatino A, Albertini R, Costanzo F, Guerci M, Masotti M, Pasini A, Massari A, Campostrini N, Corbella M, Girelli D, Corazza GR. Serum hepcidin in inflammatory bowel diseases: biological and clinical significance. Inflamm Bowel Dis 2013;19:2166-72. [PMID: 23867871 DOI: 10.1097/MIB.0b013e31829a6e43] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 284 |
Yeşil A, Gönen C, Senateş E, Paker N, Gökden Y, Koçhan K, Erdem ED, Gündüz F. Relationship between neutrophil gelatinase-associated lipocalin (NGAL) levels and inflammatory bowel disease type and activity. Dig Dis Sci 2013;58:2587-93. [PMID: 23633156 DOI: 10.1007/s10620-013-2676-z] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 285 |
Guidi L, Felice C, Procoli A, Bonanno G, Martinelli E, Marzo M, Mocci G, Pugliese D, Andrisani G, Danese S, De Vitis I, Papa A, Armuzzi A, Rutella S. FOXP3⁺ T regulatory cell modifications in inflammatory bowel disease patients treated with anti-TNFα agents. Biomed Res Int 2013;2013:286368. [PMID: 24063002 DOI: 10.1155/2013/286368] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 286 |
Tanaka T, Sugiyama S, Goishi H, Kajihara T, Akagi M, Miura T. Treatment of children and adolescents with ulcerative colitis by adsorptive depletion of myeloid lineage leucocytes as monotherapy or in combination with low dose prednisolone after failure of first-line medications. BMC Gastroenterol. 2013;13:130. [PMID: 23961883 DOI: 10.1186/1471-230x-13-130] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 287 |
Tanaka T, Sugiyama S, Goishi H, Kajihara T, Akagi M, Miura T. Treatment of children and adolescents with ulcerative colitis by adsorptive depletion of myeloid lineage leucocytes as monotherapy or in combination with low dose prednisolone after failure of first-line medications. BMC Gastroenterol. 2013;13:130. [PMID: 23961883 DOI: 10.1016/s1873-9946(13)60351-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 288 |
Zallot C, Peyrin-Biroulet L. Deep remission in inflammatory bowel disease: looking beyond symptoms. Curr Gastroenterol Rep. 2013;15:315. [PMID: 23354742 DOI: 10.1007/s11894-013-0315-7] [Cited by in Crossref: 86] [Cited by in F6Publishing: 97] [Article Influence: 8.6] [Reference Citation Analysis]
|
| 289 |
Alrubaiy L, Hutchings HA, Williams JG. Protocol for a prospective multicentre cohort study to develop and validate two new outcome measures for patients with inflammatory bowel disease. BMJ Open 2013;3:e003192. [PMID: 23842503 DOI: 10.1136/bmjopen-2013-003192] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 290 |
Varela E, Manichanh C, Gallart M, Torrejón A, Borruel N, Casellas F, Guarner F, Antolin M. Colonisation by Faecalibacterium prausnitzii and maintenance of clinical remission in patients with ulcerative colitis. Aliment Pharmacol Ther 2013;38:151-61. [PMID: 23725320 DOI: 10.1111/apt.12365] [Cited by in Crossref: 146] [Cited by in F6Publishing: 141] [Article Influence: 14.6] [Reference Citation Analysis]
|
| 291 |
Zielińska-duda H, Szaflarska-popławska A, Olejarz P, Ryżko J, Czerwionka-szaflarska M. Wrzodziejące zapalenie jelita grubego u 2-letniego dziecka. Pediatria Polska 2013;88:357-361. [DOI: 10.1016/j.pepo.2013.03.007] [Reference Citation Analysis]
|
| 292 |
Imaeda H, Takahashi K, Fujimoto T, Kasumi E, Ban H, Bamba S, Sonoda H, Shimizu T, Fujiyama Y, Andoh A. Epithelial expression of interleukin-37b in inflammatory bowel disease. Clin Exp Immunol. 2013;172:410-416. [PMID: 23600829 DOI: 10.1111/cei.12061] [Cited by in Crossref: 91] [Cited by in F6Publishing: 91] [Article Influence: 9.1] [Reference Citation Analysis]
|
| 293 |
Thin LW, Murray K, Lawrance IC. Oral tacrolimus for the treatment of refractory inflammatory bowel disease in the biologic era. Inflamm Bowel Dis 2013;19:1490-8. [PMID: 23615528 DOI: 10.1097/MIB.0b013e318281f362] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 294 |
Zhang X, Yu P, Wang Y, Jiang W, Shen F, Wang Y, Tu H, Yang X, Shi R, Zhang H. Genetic polymorphisms of interleukin 17A and interleukin 17F and their association with inflammatory bowel disease in a Chinese Han population. Inflamm Res. 2013;62:743-750. [PMID: 23652560 DOI: 10.1007/s00011-013-0629-9] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 295 |
Suzuki H, Kaneko T, Mizokami Y, Narasaka T, Endo S, Matsui H, Yanaka A, Hirayama A, Hyodo I. Therapeutic efficacy of the Qing Dai in patients with intractable ulcerative colitis. World J Gastroenterol 2013; 19(17): 2718-2722 [PMID: 23674882 DOI: 10.3748/wjg.v19.i17.2718] [Cited by in CrossRef: 47] [Cited by in F6Publishing: 48] [Article Influence: 4.7] [Reference Citation Analysis]
|
| 296 |
Iida T, Ikeya K, Watanabe F, Abe J, Maruyama Y, Ohata A, Teruyuki S, Sugimoto K, Hanai H. Looking for endoscopic features of cytomegalovirus colitis: a study of 187 patients with active ulcerative colitis, positive and negative for cytomegalovirus. Inflamm Bowel Dis 2013;19:1156-63. [PMID: 23619714 DOI: 10.1097/MIB.0b013e31828075ce] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 297 |
Däbritz J, Langhorst J, Lügering A, Heidemann J, Mohr M, Wittkowski H, Krummenerl T, Foell D. Improving relapse prediction in inflammatory bowel disease by neutrophil-derived S100A12. Inflamm Bowel Dis 2013;19:1130-8. [PMID: 23377171 DOI: 10.1097/MIB.0b013e318280b1cd] [Cited by in Crossref: 51] [Cited by in F6Publishing: 52] [Article Influence: 5.1] [Reference Citation Analysis]
|
| 298 |
Lin H, Dong Y, Fei ZY, Chen XT, Wang RW, Chen QF, Xu Y. Therapeutic effect of salvianolate against ulcerative colitis. Shijie Huaren Xiaohua Zazhi 2013; 21(10): 936-939 [DOI: 10.11569/wcjd.v21.i10.936] [Reference Citation Analysis]
|
| 299 |
Palkovits J, Novacek G, Kollars M, Hron G, Osterode W, Quehenberger P, Kyrle PA, Vogelsang H, Reinisch W, Papay P, Weltermann A. Tissue factor exposing microparticles in inflammatory bowel disease. J Crohns Colitis 2013;7:222-9. [PMID: 22705067 DOI: 10.1016/j.crohns.2012.05.016] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 300 |
Okuyama Y, Andoh A, Nishishita M, Fukunaga K, Kamikozuru K, Yokoyama Y, Ueno Y, Tanaka S, Kuge H, Yoshikawa S, Sugahara A, Anami E, Munetomo Y, Watanabe C, Fujiyama Y, Matsumoto T. Multicenter prospective study for clinical and endoscopic efficacies of leukocytapheresis therapy in patients with ulcerative colitis. Scand J Gastroenterol 2013;48:412-8. [PMID: 23356660 DOI: 10.3109/00365521.2012.763175] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 301 |
Nancey S, Boschetti G, Moussata D, Cotte E, Peyras J, Cuerq C, Haybrard J, Charlois AL, Mialon A, Chauvenet M, Stroeymeyt K, Kaiserlian D, Drai J, Flourié B. Neopterin is a novel reliable fecal marker as accurate as calprotectin for predicting endoscopic disease activity in patients with inflammatory bowel diseases. Inflamm Bowel Dis 2013;19:1043-52. [PMID: 23511035 DOI: 10.1097/MIB.0b013e3182807577] [Cited by in Crossref: 79] [Cited by in F6Publishing: 65] [Article Influence: 7.9] [Reference Citation Analysis]
|
| 302 |
Flourié B, Hagège H, Tucat G, Maetz D, Hébuterne X, Kuyvenhoven JP, Tan TG, Pierik MJ, Masclee AA, Dewit O, Probert CS, Aoucheta D; MOTUS study investigators. Randomised clinical trial: once- vs. twice-daily prolonged-release mesalazine for active ulcerative colitis. Aliment Pharmacol Ther 2013;37:767-75. [PMID: 23451806 DOI: 10.1111/apt.12266] [Cited by in Crossref: 47] [Cited by in F6Publishing: 40] [Article Influence: 4.7] [Reference Citation Analysis]
|
| 303 |
Takayama T, Kanai T, Matsuoka K, Okamoto S, Sujino T, Mikami Y, Hisamatsu T, Yajima T, Iwao Y, Ogata H, Hibi T. Long-term prognosis of patients with ulcerative colitis treated with cytapheresis therapy. J Crohns Colitis 2013;7:e49-54. [PMID: 22633997 DOI: 10.1016/j.crohns.2012.05.005] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 304 |
Tominaga K, Nakano M, Hoshino M, Kanke K, Hiraishi H. Efficacy, safety and cost analyses in ulcerative colitis patients undergoing granulocyte and monocyte adsorption or receiving prednisolone. BMC Gastroenterol. 2013;13:41. [PMID: 23452668 DOI: 10.1186/1471-230x-13-41] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 305 |
Ramlow W, Waitz G, Sparmann G, Prophet H, Bodammer P, Emmrich J. First Human Application of a Novel Adsorptive-Type Cytapheresis Module in Patients With Active Ulcerative Colitis: A Pilot Study: Novel Apheresis Device for UC. Therapeutic Apheresis and Dialysis 2013;17:339-47. [DOI: 10.1111/1744-9987.12007] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 306 |
Li FJ, Zou YY, Cui Y, Yin Y, Guo G, Lu FG. Calcitonin gene-related peptide is a promising marker in ulcerative colitis. Dig Dis Sci 2013;58:686-93. [PMID: 23010746 DOI: 10.1007/s10620-012-2406-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 307 |
Osterman MT. Mucosal healing in inflammatory bowel disease. J Clin Gastroenterol 2013;47:212-21. [PMID: 23340060 DOI: 10.1097/MCG.0b013e3182732ff5] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 4.1] [Reference Citation Analysis]
|
| 308 |
Yokoyama Y, Kawai M, Fukunaga K, Kamikozuru K, Nagase K, Nogami K, Kono T, Ohda Y, Iimuro M, Hida N, Nakamura S, Miwa H, Matsumoto T. Looking for predictive factors of clinical response to adsorptive granulocyte and monocyte apheresis in patients with ulcerative colitis: markers of response to GMA. BMC Gastroenterol. 2013;13:27. [PMID: 23399416 DOI: 10.1186/1471-230x-13-27] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 309 |
Manolakis AC, Kapsoritakis AN, Kapsoritaki A, Tiaka EK, Oikonomou KA, Lotis V, Vamvakopoulou D, Davidi I, Vamvakopoulos N, Potamianos SP. Readressing the role of Toll-like receptor-4 alleles in inflammatory bowel disease: colitis, smoking, and seroreactivity. Dig Dis Sci 2013;58:371-80. [PMID: 22918682 DOI: 10.1007/s10620-012-2348-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 310 |
Musch E, Lutfi T, von Stein P, Zargari A, Admyre C, Malek M, Löfberg R, von Stein OD. Topical treatment with the Toll-like receptor agonist DIMS0150 has potential for lasting relief of symptoms in patients with chronic active ulcerative colitis by restoring glucocorticoid sensitivity. Inflamm Bowel Dis 2013;19:283-92. [PMID: 22605641 DOI: 10.1002/ibd.23019] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 3.1] [Reference Citation Analysis]
|
| 311 |
Nakano R, Iwakiri R, Ikeda Y, Kishi T, Tsuruoka N, Shimoda R, Sakata Y, Yamaguchi K, Fujimoto K. Factors affecting short- and long-term effects of leukocyte removal therapy in active ulcerative colitis. J Gastroenterol Hepatol 2013;28:303-8. [PMID: 23339387 DOI: 10.1111/jgh.12049] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 312 |
Kato J, Hiraoka S, Nakarai A, Ichinose M. Noninvasive evaluation of mucosal healing in inflammatory bowel diseases. Clin J Gastroenterol 2013;6:1-7. [DOI: 10.1007/s12328-012-0346-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 313 |
Shinzaki S, Kuroki E, Iijima H, Tatsunaka N, Ishii M, Fujii H, Kamada Y, Kobayashi T, Shibukawa N, Inoue T, Tsujii M, Takeishi S, Mizushima T, Ogata A, Naka T, Plevy SE, Takehara T, Miyoshi E. Lectin-based immunoassay for aberrant IgG glycosylation as the biomarker for Crohn's disease. Inflamm Bowel Dis 2013;19:321-31. [PMID: 23287897 DOI: 10.1097/MIB.0b013e318280eade] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 314 |
Meister T, Heinzow HS, Domagk D, Dortgolz A, Lenze F, Ross M, Domschke W, Lügering A. Colon capsule endoscopy versus standard colonoscopy in assessing disease activity of ulcerative colitis: a prospective trial. Tech Coloproctol 2013;17:641-6. [DOI: 10.1007/s10151-012-0965-8] [Cited by in Crossref: 35] [Cited by in F6Publishing: 42] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 315 |
Awaad AS, El-meligy RM, Soliman GA. Natural products in treatment of ulcerative colitis and peptic ulcer. Journal of Saudi Chemical Society 2013;17:101-24. [DOI: 10.1016/j.jscs.2012.03.002] [Cited by in Crossref: 88] [Cited by in F6Publishing: 88] [Article Influence: 8.8] [Reference Citation Analysis]
|
| 316 |
Samuel S, Bruining DH, Loftus EV Jr, Thia KT, Schroeder KW, Tremaine WJ, Faubion WA, Kane SV, Pardi DS, de Groen PC, Harmsen WS, Zinsmeister AR, Sandborn WJ. Validation of the ulcerative colitis colonoscopic index of severity and its correlation with disease activity measures. Clin Gastroenterol Hepatol 2013;11:49-54.e1. [PMID: 22902762 DOI: 10.1016/j.cgh.2012.08.003] [Cited by in Crossref: 97] [Cited by in F6Publishing: 102] [Article Influence: 9.7] [Reference Citation Analysis]
|
| 317 |
Cucchiara S, Di Nardo G, Aloi M. Clinical Trials (Clinician Perspective). Pediatric Inflammatory Bowel Disease 2013. [DOI: 10.1007/978-1-4614-5061-0_42] [Reference Citation Analysis]
|
| 318 |
Noble A, Turner D. Clinical Indices for Pediatric Inflammatory Bowel Disease Research. Pediatric Inflammatory Bowel Disease 2013. [DOI: 10.1007/978-1-4614-5061-0_41] [Reference Citation Analysis]
|
| 319 |
Hanai H, Iida T, Ikeya K, Abe J, Maruyama Y, Shimura T, Sugimoto K, Watanabe F. A new paradigm in ulcerative colitis: regulatory T cells are key factor which induces/exacerbates UC through an immune imbalance. Mol Immunol. 2013;54:173-180. [PMID: 23280396 DOI: 10.1016/j.molimm.2012.11.015] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 320 |
Smith LA, Gaya DR. Utility of faecal calprotectin analysis in adult inflammatory bowel disease. World J Gastroenterol 2012; 18(46): 6782-6789 [PMID: 23239916 DOI: 10.3748/wjg.v18.i46.6782] [Cited by in CrossRef: 43] [Cited by in F6Publishing: 45] [Article Influence: 3.9] [Reference Citation Analysis]
|
| 321 |
Fukunaga K, Ohda Y, Hida N, Iimuro M, Yokoyama Y, Kamikozuru K, Nagase K, Nakamura S, Miwa H, Matsumoto T. Placebo controlled evaluation of Xilei San, a herbal preparation in patients with intractable ulcerative proctitis. J Gastroenterol Hepatol 2012;27:1808-15. [PMID: 22775479 DOI: 10.1111/j.1440-1746.2012.07215.x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 322 |
Serada S, Fujimoto M, Terabe F, Iijima H, Shinzaki S, Matsuzaki S, Ohkawara T, Nezu R, Nakajima S, Kobayashi T, Plevy SE, Takehara T, Naka T. Serum leucine-rich alpha-2 glycoprotein is a disease activity biomarker in ulcerative colitis. Inflamm Bowel Dis 2012;18:2169-79. [PMID: 22374925 DOI: 10.1002/ibd.22936] [Cited by in Crossref: 111] [Cited by in F6Publishing: 105] [Article Influence: 10.1] [Reference Citation Analysis]
|
| 323 |
Sandborn WJ, Travis S, Moro L, Jones R, Gautille T, Bagin R, Huang M, Yeung P, Ballard ED 2nd. Once-daily budesonide MMX® extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study. Gastroenterology 2012;143:1218-1226.e2. [PMID: 22892337 DOI: 10.1053/j.gastro.2012.08.003] [Cited by in Crossref: 167] [Cited by in F6Publishing: 176] [Article Influence: 15.2] [Reference Citation Analysis]
|
| 324 |
Love BL, Miller AD. Extended-release mesalamine granules for ulcerative colitis. Ann Pharmacother 2012;46:1529-36. [PMID: 23115226 DOI: 10.1345/aph.1R171] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 325 |
Feagan BG, Macdonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2012;10:CD000543. [PMID: 23076889 DOI: 10.1002/14651858.cd000543.pub3] [Cited by in Crossref: 31] [Cited by in F6Publishing: 61] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 326 |
Buisson A, Bommelaer G, Peyrin-biroulet L. Rectocolite hémorragique : épidémiologie, physiopathologie, diagnostic, histoire naturelle et stratégie thérapeutique. EMC - Gastro-entérologie 2012;7:1-19. [DOI: 10.1016/s1155-1968(12)43559-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 327 |
Katsurada T, Kobayashi W, Tomaru U, Baba T, Furukawa S, Ishizu A, Takeda K, Sakamoto N, Asaka M, Takeda H, Kasahara M. Decrease of peripheral and intestinal NKG2A-positive T cells in patients with ulcerative colitis. PLoS One 2012;7:e44113. [PMID: 22970169 DOI: 10.1371/journal.pone.0044113] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 328 |
Inoue T, Iijima H, Tajiri M, Shinzaki S, Shiraishi E, Hiyama S, Mukai A, Nakajima S, Iwatani H, Nishida T, Mizushima T, Yasui T, Isaka Y, Kanto T, Tsujii M, Miyoshi E, Wada Y, Takehara T. Deficiency of N-acetylgalactosamine in O-linked oligosaccharides of IgA is a novel biologic marker for Crohn's disease. Inflamm Bowel Dis 2012;18:1723-34. [PMID: 22241690 DOI: 10.1002/ibd.22876] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 329 |
Somada S, Muta H, Nakamura K, Sun X, Honda K, Ihara E, Akiho H, Takayanagi R, Yoshikai Y, Podack ER, Tani K. CD30 ligand/CD30 interaction is involved in pathogenesis of inflammatory bowel disease. Dig Dis Sci 2012;57:2031-7. [PMID: 22451116 DOI: 10.1007/s10620-012-2129-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 330 |
Chan G, Fefferman DS, Farrell RJ. Endoscopic assessment of inflammatory bowel disease: colonoscopy/esophagogastroduodenoscopy. Gastroenterol Clin North Am 2012;41:271-90. [PMID: 22500517 DOI: 10.1016/j.gtc.2012.01.014] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 331 |
Oikonomou KA, Kapsoritakis AN, Theodoridou C, Karangelis D, Germenis A, Stefanidis I, Potamianos SP. Neutrophil gelatinase-associated lipocalin (NGAL) in inflammatory bowel disease: association with pathophysiology of inflammation, established markers, and disease activity. J Gastroenterol 2012;47:519-30. [PMID: 22200942 DOI: 10.1007/s00535-011-0516-5] [Cited by in Crossref: 82] [Cited by in F6Publishing: 83] [Article Influence: 7.5] [Reference Citation Analysis]
|
| 332 |
Nowacki TM, Bettenworth D, Ross M, Heidemann J, Lehmann PV, Lügering A. Cytomegalovirus (CMV)-Specific Perforin and Granzyme B ELISPOT Assays Detect Reactivation of CMV Infection in Inflammatory Bowel Disease. Cells 2012;1:35-50. [PMID: 24710412 DOI: 10.3390/cells1020035] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 333 |
Vilela EG, Torres HODG, Martins FP, Ferrari MLA, Andrade MM, Cunha ASD. Evaluation of inflammatory activity in Crohn’s disease and ulcerative colitis. World J Gastroenterol 2012; 18(9): 872-881 [PMID: 22408345 DOI: 10.3748/wjg.v18.i9.872] [Cited by in CrossRef: 64] [Cited by in F6Publishing: 71] [Article Influence: 5.8] [Reference Citation Analysis]
|
| 334 |
Bermejo F, Guerra I, López-sanromán A. Colitis ulcerosa. Medicine - Programa de Formación Médica Continuada Acreditado 2012;11:266-274. [DOI: 10.1016/s0304-5412(12)70298-6] [Reference Citation Analysis]
|
| 335 |
Fusco V, Ebert B, Weber-Eibel J, Jost C, Fleige B, Stolte M, Oberhuber G, Rinneberg H, Lochs H, Ortner M. Cancer prevention in ulcerative colitis: long-term outcome following fluorescence-guided colonoscopy. Inflamm Bowel Dis 2012;18:489-95. [PMID: 21648021 DOI: 10.1002/ibd.21703] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 336 |
Uko V, Thangada S, Radhakrishnan K. Liver disorders in inflammatory bowel disease. Gastroenterol Res Pract. 2012;2012:642923. [PMID: 22474447 DOI: 10.1155/2012/642923] [Cited by in Crossref: 34] [Cited by in F6Publishing: 40] [Article Influence: 3.1] [Reference Citation Analysis]
|
| 337 |
Bitton A, Buie D, Enns R, Feagan BG, Jones JL, Marshall JK, Whittaker S, Griffiths AM, Panaccione R; Canadian Association of Gastroenterology Severe Ulcerative Colitis Consensus Group. Treatment of hospitalized adult patients with severe ulcerative colitis: Toronto consensus statements. Am J Gastroenterol 2012;107:179-94; author reply 195. [PMID: 22108451 DOI: 10.1038/ajg.2011.386] [Cited by in Crossref: 118] [Cited by in F6Publishing: 111] [Article Influence: 10.7] [Reference Citation Analysis]
|
| 338 |
Beyazit Y, Koklu S, Tas A, Purnak T, Sayilir A, Kurt M, Turhan T, Celik T, Suvak B, Torun S, Akbal E. Serum adenosine deaminase activity as a predictor of disease severity in ulcerative colitis. J Crohns Colitis 2012;6:102-7. [PMID: 22261534 DOI: 10.1016/j.crohns.2011.07.010] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 339 |
Louis E, van Kemseke C, Reenaers C. Activity Indices-Based Assessment of Disease Activity in Inflammatory Bowel Disease. Crohn's Disease and Ulcerative Colitis 2012. [DOI: 10.1007/978-1-4614-0998-4_23] [Reference Citation Analysis]
|
| 340 |
Rembacken B, Thoufeeq M. The Role of Ileoscopy in Inflammatory Bowel Disease. Ileoscopy 2012. [DOI: 10.1007/978-88-470-2345-1_6] [Reference Citation Analysis]
|
| 341 |
Ogata H, Hibi T. Endoscopic Assessment of Disease Activity and Mucosal Healing in Inflammatory Bowel Disease. Crohn's Disease and Ulcerative Colitis 2012. [DOI: 10.1007/978-1-4614-0998-4_24] [Reference Citation Analysis]
|
| 342 |
Yoshimura N, Tadami T, Kawaguchi T, Sako M, Yoshimoto H, Yamaka T, Takazoe M. Processed blood volume impacts clinical efficacy in patients with ulcerative colitis undergoing adsorptive depletion of myeloid lineage leucocytes. J Gastroenterol 2012;47:49-55. [PMID: 21915624 DOI: 10.1007/s00535-011-0464-0] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 343 |
Shibukawa N, Nishida T, Yamada T, Shinzaki S, Iijima H, Tsutsui S, Tsujii M. Improvement of Peripheral Arthritis by Infliximab in a Patient with Refractory Ulcerative Colitis: a Case Report. Journal of Japan Society of Coloproctology 2012;65:277-282. [DOI: 10.3862/jcoloproctology.65.277] [Reference Citation Analysis]
|
| 344 |
Osada T, Arakawa A, Sakamoto N, Ueyama H, Shibuya T, Ogihara T, Yao T, Watanabe S. Autofluorescence imaging endoscopy for identification and assessment of inflammatory ulcerative colitis. World J Gastroenterol 2011; 17(46): 5110-5116 [PMID: 22171146 DOI: 10.3748/wjg.v17.i46.5110] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 26] [Article Influence: 2.1] [Reference Citation Analysis]
|
| 345 |
Ford AC, Khan KJ, Sandborn WJ, Kane SV, Moayyedi P. Once-daily dosing vs. conventional dosing schedule of mesalamine and relapse of quiescent ulcerative colitis: systematic review and meta-analysis. Am J Gastroenterol 2011;106:2070-7; quiz 2078. [PMID: 21894226 DOI: 10.1038/ajg.2011.296] [Cited by in Crossref: 44] [Cited by in F6Publishing: 42] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 346 |
Fukunaga K, Kamikozuru K, Yokoyama Y, Hida N, Ohda Y, Takeda N, Yoshida K, Iimuro M, Kikuyama R, Kato K, Nagase K, Nakamura S, Miwa H, Matsumoto T. Optimal apheresis treatment volume for the efficacy and safety of leukocytapheresis with cellsorba in patients with active ulcerative colitis. J Clin Apheresis 2011;26:326-31. [DOI: 10.1002/jca.20314] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 347 |
Passalacqua S, Ferraro PM, Bresci G, D'Ovidio V, Astegiano M, Principi M, Testa R, D'Incà R, Valpiani D, Armuzzi A, Sablich R, Cavallaro F, Costa F, Di Leo V, Colombo E, Santini A, Aratari A, Lecis P, Saladino V, Riegler G, Marco M, Calella F, Ricci C, Guidi ML, Repaci G, Silla M. The Italian Registry of Therapeutic Apheresis: granulocyte-monocyte apheresis in the treatment of inflammatory bowel disease. A multicentric study. J Clin Apher 2011;26:332-7. [PMID: 22072543 DOI: 10.1002/jca.20315] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 348 |
Leifeld L, Pfützer R, Morgenstern J, Gibson PR, Marakhouski Y, Greinwald R, Mueller R, Kruis W. Mesalazine granules are superior to Eudragit-L-coated mesalazine tablets for induction of remission in distal ulcerative colitis - a pooled analysis. Aliment Pharmacol Ther 2011;34:1115-22. [PMID: 21923715 DOI: 10.1111/j.1365-2036.2011.04840.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 349 |
Leidl R, Reitmeir P, König HH, Stark R. The performance of a value set for the EQ-5D based on experienced health states in patients with inflammatory bowel disease. Value Health 2012;15:151-7. [PMID: 22264983 DOI: 10.1016/j.jval.2011.08.004] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 350 |
Daperno M, Castiglione F, de Ridder L, Dotan I, Färkkilä M, Florholmen J, Fraser G, Fries W, Hebuterne X, Lakatos PL, Panés J, Rimola J, Louis E; Scientific Committee of the European Crohn's and Colitis Organization. Results of the 2nd part Scientific Workshop of the ECCO. II: Measures and markers of prediction to achieve, detect, and monitor intestinal healing in inflammatory bowel disease. J Crohns Colitis 2011;5:484-98. [PMID: 21939926 DOI: 10.1016/j.crohns.2011.07.003] [Cited by in Crossref: 80] [Cited by in F6Publishing: 83] [Article Influence: 6.7] [Reference Citation Analysis]
|
| 351 |
Di Sabatino A, Battista N, Biancheri P, Rapino C, Rovedatti L, Astarita G, Vanoli A, Dainese E, Guerci M, Piomelli D, Pender SL, MacDonald TT, Maccarrone M, Corazza GR. The endogenous cannabinoid system in the gut of patients with inflammatory bowel disease. Mucosal Immunol 2011;4:574-83. [PMID: 21471961 DOI: 10.1038/mi.2011.18] [Cited by in Crossref: 61] [Cited by in F6Publishing: 64] [Article Influence: 5.1] [Reference Citation Analysis]
|
| 352 |
Chande N, MacDonald JK, Wang JJ, McDonald JW. Unfractionated or low molecular weight heparin for induction of remission in ulcerative colitis: a Cochrane inflammatory bowel disease and functional bowel disorders systematic review of randomized trials. Inflamm Bowel Dis 2011;17:1979-86. [PMID: 21618363 DOI: 10.1002/ibd.21776] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 353 |
Boye B, Lundin KE, Jantschek G, Leganger S, Mokleby K, Tangen T, Jantschek I, Pripp AH, Wojniusz S, Dahlstroem A, Rivenes AC, Benninghoven D, Hausken T, Roseth A, Kunzendorf S, Wilhelmsen I, Sharpe M, Blomhoff S, Malt UF, Jahnsen J. INSPIRE study: does stress management improve the course of inflammatory bowel disease and disease-specific quality of life in distressed patients with ulcerative colitis or Crohn's disease? A randomized controlled trial. Inflamm Bowel Dis 2011;17:1863-73. [PMID: 21287660 DOI: 10.1002/ibd.21575] [Cited by in Crossref: 73] [Cited by in F6Publishing: 72] [Article Influence: 6.1] [Reference Citation Analysis]
|
| 354 |
Mattioli G, Pini-Prato A, Barabino A, Gandullia P, Avanzini S, Guida E, Rossi V, Pio L, Disma N, Mameli L, Mirta DR, Montobbio G, Jasonni V. Laparoscopic approach for children with inflammatory bowel diseases. Pediatr Surg Int 2011;27:839-46. [PMID: 21442425 DOI: 10.1007/s00383-011-2885-5] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 355 |
Wang Y, Liu XP, Zhao ZB, Chen JH, Yu CG. Expression of CD4+ forkhead box P3 (FOXP3)+ regulatory T cells in inflammatory bowel disease. J Dig Dis 2011;12:286-94. [PMID: 21791023 DOI: 10.1111/j.1751-2980.2011.00505.x] [Cited by in Crossref: 67] [Cited by in F6Publishing: 69] [Article Influence: 5.6] [Reference Citation Analysis]
|
| 356 |
Ashida T, Kohgo Y, Munakata A, Noguchi M, Iizuka B, Endo Y, Hanai H, Yoshikawa T, Matsumoto T, Aoyama N. A multicenter study of the efficacy and safety of leukocytapheresis therapy without concomitant systemic steroid treatment in patients with active ulcerative colitis. Transfus Apher Sci. 2011;44:113-117. [PMID: 21402309 DOI: 10.1016/j.transci.2011.01.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 357 |
Travis SP, Higgins PD, Orchard T, Van Der Woude CJ, Panaccione R, Bitton A, O'Morain C, Panés J, Sturm A, Reinisch W, Kamm MA, D'Haens G. Review article: defining remission in ulcerative colitis. Aliment Pharmacol Ther 2011;34:113-24. [PMID: 21615435 DOI: 10.1111/j.1365-2036.2011.04701.x] [Cited by in Crossref: 124] [Cited by in F6Publishing: 125] [Article Influence: 10.3] [Reference Citation Analysis]
|
| 358 |
Tomomasa T, Tajiri H, Kagimoto S, Shimizu T, Yoden A, Ushijima K, Uchida K, Kaneko H, Abukawa D, Konno M, Maisawa S, Kohsaka T, Kobayashi A; Japanese Study Group for Pediatric Ulcerative Colitis. Leukocytapheresis in pediatric patients with ulcerative colitis. J Pediatr Gastroenterol Nutr 2011;53:34-9. [PMID: 21694533 DOI: 10.1097/MPG.0b013e31821058bc] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 359 |
Ciccocioppo R, Klersy C, Russo ML, Valli M, Boccaccio V, Imbesi V, Ardizzone S, Porro GB, Corazza GR. Validation of the Italian translation of the Inflammatory Bowel Disease Questionnaire. Dig Liver Dis 2011;43:535-41. [PMID: 21315666 DOI: 10.1016/j.dld.2010.12.014] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 360 |
Drastich P, Frolova-Brizova L, Zanvit P, Spicak J, Tlaskalova-Hogenova H. Spontaneous in vitro IL-6 production in various intestinal segments in patients with inflammatory bowel disease. Folia Microbiol (Praha). 2011;56:185-190. [PMID: 21681687 DOI: 10.1007/s12223-011-0018-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 361 |
Blumenstein I, Herrmann E, Filmann N, Zosel C, Tacke W, Bock H, Dignass A, Hartmann F, Zeuzem S, Stein J, Schröder O. Female patients suffering from inflammatory bowel diseases are treated less frequently with immunosuppressive medication and have a higher disease activity: a subgroup analysis of a large multi-centre, prospective, internet-based study. J Crohns Colitis 2011;5:203-10. [PMID: 21575882 DOI: 10.1016/j.crohns.2010.12.012] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 362 |
Karoui S, Laz S, Serghini M, Bibani N, Boubaker J, Filali A. Correlation of C-reactive protein with clinical and endoscopic activity in patients with ulcerative colitis. Dig Dis Sci 2011;56:1801-5. [PMID: 21127977 DOI: 10.1007/s10620-010-1496-7] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 3.1] [Reference Citation Analysis]
|
| 363 |
Raso T, Crivellaro S, Chirillo MG, Pais P, Gaia E, Savoia D. Analysis of Escherichia coli isolated from patients affected by Crohn's disease. Curr Microbiol. 2011;63:131-137. [PMID: 21626145 DOI: 10.1007/s00284-011-9947-8] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 2.1] [Reference Citation Analysis]
|
| 364 |
Alkim H, Ayaz S, Alkim C, Ulker A, Sahin B. Continuous active state of coagulation system in patients with nonthrombotic inflammatory bowel disease. Clin Appl Thromb Hemost. 2011;17:600-604. [PMID: 21593018 DOI: 10.1177/1076029611405034] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 365 |
Werkstetter KJ, Pozza SB, Filipiak-Pittroff B, Schatz SB, Prell C, Bufler P, Koletzko B, Koletzko S. Long-term development of bone geometry and muscle in pediatric inflammatory bowel disease. Am J Gastroenterol 2011;106:988-98. [PMID: 21224841 DOI: 10.1038/ajg.2010.495] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 366 |
Ooi M, Nishiumi S, Yoshie T, Shiomi Y, Kohashi M, Fukunaga K, Nakamura S, Matsumoto T, Hatano N, Shinohara M. GC/MS-based profiling of amino acids and TCA cycle-related molecules in ulcerative colitis. Inflamm Res. 2011;60:831-840. [PMID: 21523508 DOI: 10.1007/s00011-011-0340-7] [Cited by in Crossref: 88] [Cited by in F6Publishing: 80] [Article Influence: 7.3] [Reference Citation Analysis]
|
| 367 |
Ooi M, Nishiumi S, Yoshie T, Shiomi Y, Kohashi M, Fukunaga K, Nakamura S, Matsumoto T, Hatano N, Shinohara M. GC/MS-based profiling of amino acids and TCA cycle-related molecules in ulcerative colitis. Inflamm Res. 2011;60:831-840. [PMID: 21523508 DOI: 10.1007/s00011-011-0340- 7] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 368 |
D'Ovidio V, Meo D, Viscido A, Bresci G, Vernia P, Caprilli R. Predictive factors of clinical response in steroid-refractory ulcerative colitis treated with granulocyte-monocyte apheresis. World J Gastroenterol 2011; 17(14): 1831-1835 [PMID: 21528055 DOI: 10.3748/wjg.v17.i14.1831] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 369 |
Gross V, Bunganic I, Belousova EA, Mikhailova TL, Kupcinskas L, Kiudelis G, Tulassay Z, Gabalec L, Dorofeyev AE, Derova J, Dilger K, Greinwald R, Mueller R; International BUC-57 Study Group. 3g mesalazine granules are superior to 9mg budesonide for achieving remission in active ulcerative colitis: a double-blind, double-dummy, randomised trial. J Crohns Colitis 2011;5:129-38. [PMID: 21453882 DOI: 10.1016/j.crohns.2010.11.006] [Cited by in Crossref: 49] [Cited by in F6Publishing: 49] [Article Influence: 4.1] [Reference Citation Analysis]
|
| 370 |
Regueiro M, Rodemann J, Kip KE, Saul M, Swoger J, Baidoo L, Schwartz M, Barrie A, Binion D. Physician assessment of ulcerative colitis activity correlates poorly with endoscopic disease activity. Inflamm Bowel Dis 2011;17:1008-14. [PMID: 20812333 DOI: 10.1002/ibd.21445] [Cited by in Crossref: 30] [Cited by in F6Publishing: 23] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 371 |
Nakajima S, Iijima H, Shinzaki S, Egawa S, Inoue T, Mukai A, Hayashi Y, Kondo J, Akasaka T, Nishida T, Kanto T, Morii E, Mizushima T, Miyoshi E, Tsujii M, Hayashi N. Functional analysis of agalactosyl IgG in inflammatory bowel disease patients. Inflamm Bowel Dis 2011;17:927-36. [PMID: 20824817 DOI: 10.1002/ibd.21459] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 1.9] [Reference Citation Analysis]
|
| 372 |
Andoh A, Imaeda H, Aomatsu T, Inatomi O, Bamba S, Sasaki M, Saito Y, Tsujikawa T, Fujiyama Y. Comparison of the fecal microbiota profiles between ulcerative colitis and Crohn's disease using terminal restriction fragment length polymorphism analysis. J Gastroenterol 2011;46:479-86. [PMID: 21253779 DOI: 10.1007/s00535-010-0368-4] [Cited by in Crossref: 148] [Cited by in F6Publishing: 153] [Article Influence: 12.3] [Reference Citation Analysis]
|
| 373 |
Oikonomou KA, Kapsoritakis AN, Kapsoritaki AI, Manolakis AC, Tiaka EK, Tsiopoulos FD, Tsiompanidis IA, Potamianos SP. Angiogenin, angiopoietin-1, angiopoietin-2, and endostatin serum levels in inflammatory bowel disease. Inflamm Bowel Dis 2011;17:963-70. [PMID: 20629092 DOI: 10.1002/ibd.21410] [Cited by in Crossref: 39] [Cited by in F6Publishing: 41] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 374 |
Mannon PJ, Hornung RL, Yang Z, Yi C, Groden C, Friend J, Yao M, Strober W, Fuss IJ. Suppression of inflammation in ulcerative colitis by interferon-β-1a is accompanied by inhibition of IL-13 production. Gut 2011;60:449-55. [PMID: 20971977 DOI: 10.1136/gut.2010.226860] [Cited by in Crossref: 75] [Cited by in F6Publishing: 81] [Article Influence: 6.3] [Reference Citation Analysis]
|
| 375 |
Ha C, Kornbluth A. Mucosal healing in inflammatory bowel disease: where do we stand? Curr Gastroenterol Rep. 2010;12:471-478. [PMID: 20886319 DOI: 10.1007/s11894-010-0146-8] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 376 |
Häuser W, Janke KH, Klump B, Hinz A. Anxiety and depression in patients with inflammatory bowel disease: comparisons with chronic liver disease patients and the general population. Inflamm Bowel Dis 2011;17:621-32. [PMID: 20848528 DOI: 10.1002/ibd.21346] [Cited by in Crossref: 103] [Cited by in F6Publishing: 97] [Article Influence: 8.6] [Reference Citation Analysis]
|
| 377 |
Kruis W, Jonaitis L, Pokrotnieks J, Mikhailova TL, Horynski M, Bátovský M, Lozynsky YS, Zakharash Y, Rácz I, Kull K, Vcev A, Faszczyk M, Dilger K, Greinwald R, Mueller R; International Salofalk OD Study Group. Randomised clinical trial: a comparative dose-finding study of three arms of dual release mesalazine for maintaining remission in ulcerative colitis. Aliment Pharmacol Ther 2011;33:313-22. [PMID: 21138455 DOI: 10.1111/j.1365-2036.2010.04537.x] [Cited by in Crossref: 57] [Cited by in F6Publishing: 43] [Article Influence: 4.8] [Reference Citation Analysis]
|
| 378 |
Yilmaz A, Yilmaz Demirci N, Hoşgün D, Uner E, Erdoğan Y, Gökçek A, Cağlar A. Pulmonary involvement in inflammatory bowel disease. World J Gastroenterol. 2010;16:4952-4957. [PMID: 20954282 DOI: 10.3748/wjp.v16.i39.4952] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 379 |
Oh YS, Chung WC, Hwang SS, Lee KM, Paik CN, Cho YS, Lee BI, Choi GY. [The usefulness of Doppler sonography in the assessment of disease activity of ulcerative colitis]. Korean J Gastroenterol 2010;56:346-52. [PMID: 21173557 DOI: 10.4166/kjg.2010.56.6.346] [Reference Citation Analysis]
|
| 380 |
Oikonomou KA, Kapsoritakis AN, Kapsoritaki AI, Manolakis AC, Tsiopoulos FD, Germenis AE, Potamianos SP. Downregulation of serum epidermal growth factor in patients with inflammatory bowel disease. Is there a link with mucosal damage? Growth Factors 2010;28:461-6. [PMID: 20969541 DOI: 10.3109/08977194.2010.527967] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 381 |
Andus T, Kocjan A, Müser M, Baranovsky A, Mikhailova TL, Zvyagintseva TD, Dorofeyev AE, Lozynskyy YS, Cascorbi I, Stolte M, Vieth M, Dilger K, Mohrbacher R, Greinwald R; International Salofalk Suppository OD Study Group. Clinical trial: a novel high-dose 1 g mesalamine suppository (Salofalk) once daily is as efficacious as a 500-mg suppository thrice daily in active ulcerative proctitis. Inflamm Bowel Dis 2010;16:1947-56. [PMID: 20310020 DOI: 10.1002/ibd.21258] [Cited by in Crossref: 45] [Cited by in F6Publishing: 37] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 382 |
Prenzler A, Bokemeyer B, von der Schulenburg J, Mittendorf T. Health care costs and their predictors of inflammatory bowel diseases in Germany. Eur J Health Econ 2011;12:273-83. [DOI: 10.1007/s10198-010-0281-z] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 383 |
Yılmaz A, Demirci NY, Hoşgün D, Üner E, Erdoğan Y, Gökçek A, Çağlar A. Pulmonary involvement in inflammatory bowel disease. World J Gastroenterol 2010; 16(39): 4952-4957 [PMID: 20954282 DOI: 10.3748/wjg.v16.i39.4952] [Cited by in CrossRef: 40] [Cited by in F6Publishing: 47] [Article Influence: 3.1] [Reference Citation Analysis]
|
| 384 |
Manolakis AC, Kapsoritakis AN, Georgoulias P, Tzavara C, Valotassiou V, Kapsoritaki A, Potamianos SP. Moderate performance of serum S100A12, in distinguishing inflammatory bowel disease from irritable bowel syndrome. BMC Gastroenterol. 2010;10:118. [PMID: 20946669 DOI: 10.1186/1471-230x-10-118] [Cited by in Crossref: 27] [Cited by in F6Publishing: 32] [Article Influence: 2.1] [Reference Citation Analysis]
|
| 385 |
Tanaka T, Okanobu H, Kuga Y, Yoshifuku Y, Fujino H, Miwata T, Moriya T, Nishida T, Oya T. Clinical and endoscopic features of responders and non-responders to adsorptive leucocytapheresis: a report based on 120 patients with active ulcerative colitis. Gastroenterol Clin Biol. 2010;34:687-695. [PMID: 20934287 DOI: 10.1016/j.gcb.2010.08.007] [Cited by in Crossref: 21] [Cited by in F6Publishing: 25] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 386 |
Chande N, McDonald JW, Macdonald JK, Wang JJ. Unfractionated or low-molecular weight heparin for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2010;CD006774. [PMID: 20927749 DOI: 10.1002/14651858.CD006774.pub4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 387 |
Sherlock ME, Seow CH, Steinhart AH, Griffiths AM. Oral budesonide for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2010;:CD007698. [PMID: 20927762 DOI: 10.1002/14651858.CD007698.pub2] [Cited by in Crossref: 21] [Cited by in F6Publishing: 31] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 388 |
Chande N, Mcdonald JW, Macdonald JK, Wang JJ, Chande N. Unfractionated or low-molecular weight heparin for induction of remission in ulcerative colitis. Cochrane Database of Systematic Reviews. Chichester: John Wiley & Sons, Ltd; 1996. [DOI: 10.1002/14651858.cd006774.pub3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 19] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 389 |
Kobori A, Yagi Y, Imaeda H, Ban H, Bamba S, Tsujikawa T, Saito Y, Fujiyama Y, Andoh A. Interleukin-33 expression is specifically enhanced in inflamed mucosa of ulcerative colitis. J Gastroenterol 2010;45:999-1007. [PMID: 20405148 DOI: 10.1007/s00535-010-0245-1] [Cited by in Crossref: 183] [Cited by in F6Publishing: 193] [Article Influence: 14.1] [Reference Citation Analysis]
|
| 390 |
Naganuma M, Ichikawa H, Inoue N, Kobayashi T, Okamoto S, Hisamatsu T, Kanai T, Ogata H, Iwao Y, Hibi T. Novel endoscopic activity index is useful for choosing treatment in severe active ulcerative colitis patients. J Gastroenterol 2010;45:936-43. [PMID: 20401498 DOI: 10.1007/s00535-010-0244-2] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 391 |
Navaneethan U, Shen B. Hepatopancreatobiliary manifestations and complications associated with inflammatory bowel disease. Inflammatory Bowel Diseases 2010;16:1598-1619. [DOI: 10.1002/ibd.21219] [Cited by in Crossref: 148] [Cited by in F6Publishing: 124] [Article Influence: 11.4] [Reference Citation Analysis]
|
| 392 |
Sonu I, Lin MV, Blonski W, Lichtenstein GR. Clinical pharmacology of 5-ASA compounds in inflammatory bowel disease. Gastroenterol Clin North Am 2010;39:559-99. [PMID: 20951918 DOI: 10.1016/j.gtc.2010.08.011] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 393 |
Docena G, Rovedatti L, Kruidenier L, Fanning A, Leakey NA, Knowles CH, Lee K, Shanahan F, Nally K, McLean PG. Down-regulation of p38 mitogen-activated protein kinase activation and proinflammatory cytokine production by mitogen-activated protein kinase inhibitors in inflammatory bowel disease. Clin Exp Immunol. 2010;162:108-115. [PMID: 20731675 DOI: 10.1111/j.1365-2249.2010.04203.x] [Cited by in Crossref: 39] [Cited by in F6Publishing: 40] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 394 |
Hartmann F, Stein J; BudMesa-Study Group. Clinical trial: controlled, open, randomized multicentre study comparing the effects of treatment on quality of life, safety and efficacy of budesonide or mesalazine enemas in active left-sided ulcerative colitis. Aliment Pharmacol Ther 2010;32:368-76. [PMID: 20491741 DOI: 10.1111/j.1365-2036.2010.04354.x] [Cited by in Crossref: 50] [Cited by in F6Publishing: 45] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 395 |
Hanai H, Iida T, Takeuchi K, Arai O, Watanabe F, Abe J, Maruyama Y, Oohata A, Ikeya K, Kageoka M, Miwa I, Yoshirou S, Hosoda Y, Kubota T. Thiopurine maintenance therapy for ulcerative colitis: the clinical significance of monitoring 6-thioguanine nucleotide. Inflamm Bowel Dis 2010;16:1376-81. [PMID: 20049951 DOI: 10.1002/ibd.21190] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 396 |
Erbayrak M, Turkay C, Eraslan E, Cetinkaya H, Kasapoglu B, Bektas M. The role of fecal calprotectin in investigating inflammatory bowel diseases. Clinics (Sao Paulo) 2009;64:421-5. [PMID: 19488608 DOI: 10.1590/s1807-59322009000500009] [Cited by in Crossref: 24] [Cited by in F6Publishing: 31] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 397 |
Schirbel A, Reichert A, Roll S, Baumgart DC, Büning C, Wittig B, Wiedenmann B, Dignass A, Sturm A. Impact of pain on health-related quality of life in patients with inflammatory bowel disease. World J Gastroenterol 2010; 16(25): 3168-3177 [PMID: 20593502 DOI: 10.3748/wjg.v16.i25.3168] [Cited by in CrossRef: 97] [Cited by in F6Publishing: 103] [Article Influence: 7.5] [Reference Citation Analysis]
|
| 398 |
Papi C, Aratari A, Moretti A, Mangone M, Margagnoni G, Koch M, Capurso L. Oral beclomethasone dipropionate as an alternative to systemic steroids in mild to moderate ulcerative colitis not responding to aminosalicylates. Dig Dis Sci 2010;55:2002-7. [PMID: 19937467 DOI: 10.1007/s10620-009-0962-6] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 399 |
Dignass AU, Eriksson A, Kilander A, Pukitis A, Rhodes JM, Vavricka S. Clinical trial: five or ten cycles of granulocyte-monocyte apheresis show equivalent efficacy and safety in ulcerative colitis. Aliment Pharmacol Ther 2010;31:1286-95. [PMID: 20331579 DOI: 10.1111/j.1365-2036.2010.04295.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 400 |
Engel MA, Neurath MF. New pathophysiological insights and modern treatment of IBD. J Gastroenterol 2010;45:571-83. [PMID: 20213337 DOI: 10.1007/s00535-010-0219-3] [Cited by in Crossref: 130] [Cited by in F6Publishing: 143] [Article Influence: 10.0] [Reference Citation Analysis]
|
| 401 |
D'Haens GR, Kovács A, Vergauwe P, Nagy F, Molnár T, Bouhnik Y, Weiss W, Brunner H, Lavergne-Slove A, Binelli D, Di Stefano AF, Marteau P. Clinical trial: Preliminary efficacy and safety study of a new Budesonide-MMX® 9 mg extended-release tablets in patients with active left-sided ulcerative colitis. J Crohns Colitis 2010;4:153-60. [PMID: 21122499 DOI: 10.1016/j.crohns.2009.09.007] [Cited by in Crossref: 62] [Cited by in F6Publishing: 63] [Article Influence: 4.8] [Reference Citation Analysis]
|
| 402 |
Nylund K, Hausken T, Gilja OH. Ultrasound and inflammatory bowel disease. Ultrasound Q 2010;26:3-15. [PMID: 20216190 DOI: 10.1097/RUQ.0b013e3181ce0929] [Cited by in Crossref: 48] [Cited by in F6Publishing: 36] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 403 |
Akbulut S, Altiparmak E, Topal F, Ozaslan E, Kucukazman M, Yonem O. Increased levels of homocysteine in patients with ulcerative colitis. World J Gastroenterol 2010; 16(19): 2411-2416 [PMID: 20480528 DOI: 10.3748/wjg.v16.i19.2411] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 404 |
Stremmel W, Braun A, Hanemann A, Ehehalt R, Autschbach F, Karner M. Delayed release phosphatidylcholine in chronic-active ulcerative colitis: a randomized, double-blinded, dose finding study. J Clin Gastroenterol 2010;44:e101-7. [PMID: 20048683 DOI: 10.1097/MCG.0b013e3181c29860] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 405 |
Vertzoni M, Goumas K, Söderlind E, Abrahamsson B, Dressman JB, Poulou A, Reppas C. Characterization of the Ascending Colon Fluids in Ulcerative Colitis. Pharm Res 2010;27:1620-6. [DOI: 10.1007/s11095-010-0158-y] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 1.9] [Reference Citation Analysis]
|
| 406 |
Ooi CJ, Fock KM, Makharia GK, Goh KL, Ling KL, Hilmi I, Lim WC, Kelvin T, Gibson PR, Gearry RB, Ouyang Q, Sollano J, Manatsathit S, Rerknimitr R, Wei SC, Leung WK, de Silva HJ, Leong RW; Asia Pacific Association of Gastroenterology Working Group on Inflammatory Bowel Disease. The Asia-Pacific consensus on ulcerative colitis. J Gastroenterol Hepatol 2010;25:453-68. [PMID: 20370724 DOI: 10.1111/j.1440-1746.2010.06241.x] [Cited by in Crossref: 111] [Cited by in F6Publishing: 104] [Article Influence: 8.5] [Reference Citation Analysis]
|
| 407 |
Do VT, Baird BG, Kockler DR. Probiotics for maintaining remission of ulcerative colitis in adults. Ann Pharmacother. 2010;44:565-571. [PMID: 20124461 DOI: 10.1345/aph.1M498] [Cited by in Crossref: 18] [Cited by in F6Publishing: 22] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 408 |
Sibartie S, Scully P, Keohane J, O'Neill S, O'Mahony J, O'Hanlon D, Kirwan WO, O'Mahony L, Shanahan F. Mycobacterium avium subsp. Paratuberculosis (MAP) as a modifying factor in Crohn's disease. Inflamm Bowel Dis 2010;16:296-304. [PMID: 19824071 DOI: 10.1002/ibd.21052] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 409 |
Lichtenstein GR, Rutgeerts P. Importance of mucosal healing in ulcerative colitis. Inflammatory Bowel Diseases 2010;16:338-346. [DOI: 10.1002/ibd.20997] [Cited by in Crossref: 157] [Cited by in F6Publishing: 141] [Article Influence: 12.1] [Reference Citation Analysis]
|
| 410 |
Celasco G, Papa A, Jones R, Moro L, Bozzella R, Surace MM, Naccari GC, Gasbarrini G. Clinical trial: oral colon-release parnaparin sodium tablets (CB-01-05 MMX) for active left-sided ulcerative colitis. Aliment Pharmacol Ther 2010;31:375-86. [PMID: 19891665 DOI: 10.1111/j.1365-2036.2009.04194.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 411 |
Bechtold S, Alberer M, Arenz T, Putzker S, Filipiak-Pittroff B, Schwarz HP, Koletzko S. Reduced muscle mass and bone size in pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis 2010;16:216-25. [PMID: 19637389 DOI: 10.1002/ibd.21021] [Cited by in Crossref: 55] [Cited by in F6Publishing: 46] [Article Influence: 4.2] [Reference Citation Analysis]
|
| 412 |
Marshall JK, Thabane M, Steinhart AH, Newman JR, Anand A, Irvine EJ. Rectal 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2010;20:CD004115. [PMID: 20091560 DOI: 10.1002/14651858.cd004115.pub2] [Cited by in Crossref: 44] [Cited by in F6Publishing: 59] [Article Influence: 3.4] [Reference Citation Analysis]
|
| 413 |
Sugihara T, Kobori A, Imaeda H, Tsujikawa T, Amagase K, Takeuchi K, Fujiyama Y, Andoh A. The increased mucosal mRNA expressions of complement C3 and interleukin-17 in inflammatory bowel disease. Clin Exp Immunol. 2010;160:386-393. [PMID: 20089077 DOI: 10.1111/j.1365-2249.2010.04093.x] [Cited by in Crossref: 77] [Cited by in F6Publishing: 85] [Article Influence: 5.9] [Reference Citation Analysis]
|
| 414 |
Hirai F, Matsui T, Aoyagi K, Inoue N, Hibi T, Oshitani N, Fujii H, Kobayashi K, Suzuki Y, Tanaka S. Validity of activity indices in ulcerative colitis: comparison of clinical and endoscopic indices. Dig Endosc 2010;22:39-44. [PMID: 20078663 DOI: 10.1111/j.1443-1661.2009.00916.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 415 |
Stark RG, Reitmeir P, Leidl R, König HH. Validity, reliability, and responsiveness of the EQ-5D in inflammatory bowel disease in Germany. Inflamm Bowel Dis 2010;16:42-51. [PMID: 19475674 DOI: 10.1002/ibd.20989] [Cited by in Crossref: 63] [Cited by in F6Publishing: 62] [Article Influence: 4.8] [Reference Citation Analysis]
|
| 416 |
Treton X, Attar A, Bouhnik Y. La cicatrisation muqueuse endoscopique est-elle un nouvel objectif thérapeutique dans les MICI? Post’U FMC-HGE 2010. [DOI: 10.1007/978-2-8178-0097-4_26] [Reference Citation Analysis]
|
| 417 |
Pineton de Chambrun G, Peyrin-Biroulet L, Lémann M, Colombel JF. Clinical implications of mucosal healing for the management of IBD. Nat Rev Gastroenterol Hepatol 2010;7:15-29. [PMID: 19949430 DOI: 10.1038/nrgastro.2009.203] [Cited by in Crossref: 328] [Cited by in F6Publishing: 271] [Article Influence: 25.2] [Reference Citation Analysis]
|
| 418 |
Doherty GA, Peppercorn MA. Update on the role of modified release mesalamine in the management of ulcerative colitis and Crohn's disease. Clin Exp Gastroenterol 2009;2:139-47. [PMID: 21694838 DOI: 10.2147/ceg.s6145] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 419 |
Schoepfer AM, Beglinger C, Straumann A, Trummler M, Renzulli P, Seibold F. Ulcerative colitis: correlation of the Rachmilewitz endoscopic activity index with fecal calprotectin, clinical activity, C-reactive protein, and blood leukocytes. Inflamm Bowel Dis 2009;15:1851-8. [PMID: 19462421 DOI: 10.1002/ibd.20986] [Cited by in Crossref: 217] [Cited by in F6Publishing: 190] [Article Influence: 15.5] [Reference Citation Analysis]
|
| 420 |
Keller J, Beglinger C, Holst JJ, Andresen V, Layer P. Mechanisms of gastric emptying disturbances in chronic and acute inflammation of the distal gastrointestinal tract. Am J Physiol Gastrointest Liver Physiol 2009;297:G861-8. [PMID: 20501434 DOI: 10.1152/ajpgi.00145.2009] [Cited by in Crossref: 37] [Cited by in F6Publishing: 39] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 421 |
Braun A, Treede I, Gotthardt D, Tietje A, Zahn A, Ruhwald R, Schoenfeld U, Welsch T, Kienle P, Erben G, Lehmann WD, Fuellekrug J, Stremmel W, Ehehalt R. Alterations of phospholipid concentration and species composition of the intestinal mucus barrier in ulcerative colitis: a clue to pathogenesis. Inflamm Bowel Dis 2009;15:1705-20. [PMID: 19504612 DOI: 10.1002/ibd.20993] [Cited by in Crossref: 117] [Cited by in F6Publishing: 115] [Article Influence: 8.4] [Reference Citation Analysis]
|
| 422 |
Bergamaschi G, Di Sabatino A, Albertini R, Ardizzone S, Biancheri P, Bonetti E, Cassinotti A, Cazzola P, Markopoulos K, Massari A. Prevalence and pathogenesis of anemia in inflammatory bowel disease. Influence of anti-tumor necrosis factor-alpha treatment. Haematologica. 2010;95:199-205. [PMID: 19815838 DOI: 10.3324/haematol.2009.009985] [Cited by in Crossref: 110] [Cited by in F6Publishing: 119] [Article Influence: 7.9] [Reference Citation Analysis]
|
| 423 |
Turner D, Seow CH, Greenberg GR, Griffiths AM, Silverberg MS, Steinhart AH. A systematic prospective comparison of noninvasive disease activity indices in ulcerative colitis. Clin Gastroenterol Hepatol 2009;7:1081-8. [PMID: 19577010 DOI: 10.1016/j.cgh.2009.06.024] [Cited by in Crossref: 124] [Cited by in F6Publishing: 126] [Article Influence: 8.9] [Reference Citation Analysis]
|
| 424 |
Watanabe O, Ando T, El-Omar EM, Shimada M, Ina K, Ishiguro K, Hasegawa M, Miyake N, Nakamura M, Miyahara R, Ohmiya N, Niwa Y, Goto H. Role of endoscopic ultrasonography in predicting the response to cyclosporin A in ulcerative colitis refractory to steroids. Dig Liver Dis 2009;41:735-9. [PMID: 19403349 DOI: 10.1016/j.dld.2009.03.014] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 425 |
Yoshizaki A, Nakayama T, Naito S, Sekine I. Expression patterns of angiopoietin-1, -2, and tie-2 receptor in ulcerative colitis support involvement of the angiopoietin/tie pathway in the progression of ulcerative colitis. Dig Dis Sci 2009;54:2094-9. [PMID: 19051019 DOI: 10.1007/s10620-008-0593-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 426 |
Yüksel O, Helvaci K, Başar O, Köklü S, Caner S, Helvaci N, Abayli E, Altiparmak E. An overlooked indicator of disease activity in ulcerative colitis: mean platelet volume. Platelets 2009;20:277-81. [PMID: 19459134 DOI: 10.1080/09537100902856781] [Cited by in Crossref: 118] [Cited by in F6Publishing: 107] [Article Influence: 8.4] [Reference Citation Analysis]
|
| 427 |
Sato K, Shiota M, Fukuda S, Iwamoto E, Machida H, Inamine T, Kondo S, Yanagihara K, Isomoto H, Mizuta Y, Kohno S, Tsukamoto K. Strong evidence of a combination polymorphism of the tyrosine kinase 2 gene and the signal transducer and activator of transcription 3 gene as a DNA-based biomarker for susceptibility to Crohn's disease in the Japanese population. J Clin Immunol. 2009;29:815-825. [PMID: 19653082 DOI: 10.1007/s10875-009-9320-x] [Cited by in Crossref: 49] [Cited by in F6Publishing: 50] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 428 |
Hibi T, Sameshima Y, Sekiguchi Y, Hisatome Y, Maruyama F, Moriwaki K, Shima C, Saniabadi AR, Matsumoto T. Treating ulcerative colitis by Adacolumn therapeutic leucocytapheresis: clinical efficacy and safety based on surveillance of 656 patients in 53 centres in Japan. Dig Liver Dis 2009;41:570-7. [PMID: 19211314 DOI: 10.1016/j.dld.2008.11.020] [Cited by in Crossref: 50] [Cited by in F6Publishing: 51] [Article Influence: 3.6] [Reference Citation Analysis]
|
| 429 |
Fujishima S, Takeda H, Kawata S, Yamakawa M. The relationship between the expression of the glucocorticoid receptor in biopsied colonic mucosa and the glucocorticoid responsiveness of ulcerative colitis patients. Clin Immunol. 2009;133:208-217. [PMID: 19646928 DOI: 10.1016/j.clim.2009.07.006] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 430 |
Di Sabatino A, Rovedatti L, Kaur R, Spencer JP, Brown JT, Morisset VD, Biancheri P, Leakey NAB, Wilde JI, Scott L, Corazza GR, Lee K, Sengupta N, Knowles CH, Gunthorpe MJ, Mclean PG, Macdonald TT, Kruidenier L. Targeting Gut T Cell Ca 2+ Release-Activated Ca 2+ Channels Inhibits T Cell Cytokine Production and T-Box Transcription Factor T-Bet in Inflammatory Bowel Disease. J Immunol 2009;183:3454-62. [DOI: 10.4049/jimmunol.0802887] [Cited by in Crossref: 80] [Cited by in F6Publishing: 84] [Article Influence: 5.7] [Reference Citation Analysis]
|
| 431 |
Moschen AR, Geiger S, Gerner R, Tilg H. Pre-B cell colony enhancing factor/NAMPT/visfatin and its role in inflammation-related bone disease. Mutat Res. 2010;690:95-101. [PMID: 19583971 DOI: 10.1016/j.mrfmmm.2009.06.012] [Cited by in Crossref: 49] [Cited by in F6Publishing: 52] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 432 |
Trinder MW, Lawrance IC. Efficacy of adalimumab for the management of inflammatory bowel disease in the clinical setting. J Gastroenterol Hepatol 2009;24:1252-7. [PMID: 19220669 DOI: 10.1111/j.1440-1746.2009.05786.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 433 |
Ozin Y, Kilic MZ, Nadir I, Tayfur O, Ertas A, Ulker A, Sahin B. Presence and diagnosis of amebic infestation in Turkish patients with active ulcerative colitis. Eur J Intern Med 2009;20:545-7. [PMID: 19712863 DOI: 10.1016/j.ejim.2009.05.014] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 434 |
Nishikawa J, Kudo T, Sakata S, Benno Y, Sugiyama T. Diversity of mucosa-associated microbiota in active and inactive ulcerative colitis. Scand J Gastroenterol 2009;44:180-6. [PMID: 18825588 DOI: 10.1080/00365520802433231] [Cited by in Crossref: 95] [Cited by in F6Publishing: 100] [Article Influence: 6.8] [Reference Citation Analysis]
|
| 435 |
Andoh A, Shioya M, Nishida A, Bamba S, Tsujikawa T, Kim-Mitsuyama S, Fujiyama Y. Expression of IL-24, an activator of the JAK1/STAT3/SOCS3 cascade, is enhanced in inflammatory bowel disease. J Immunol. 2009;183:687-695. [PMID: 19535621 DOI: 10.4049/jimmunol.0804169] [Cited by in Crossref: 89] [Cited by in F6Publishing: 92] [Article Influence: 6.4] [Reference Citation Analysis]
|
| 436 |
Nikfar S, Rahimi R, Rezaie A, Abdollahi M. A meta-analysis of the efficacy of sulfasalazine in comparison with 5-aminosalicylates in the induction of improvement and maintenance of remission in patients with ulcerative colitis. Dig Dis Sci 2009;54:1157-70. [PMID: 18770034 DOI: 10.1007/s10620-008-0481-x] [Cited by in Crossref: 67] [Cited by in F6Publishing: 72] [Article Influence: 4.8] [Reference Citation Analysis]
|
| 437 |
Patel H, Barr A, Jeejeebhoy KN. Renal effects of long-term treatment with 5-aminosalicylic acid. Can J Gastroenterol 2009;23:170-6. [PMID: 19319380 DOI: 10.1155/2009/501345] [Cited by in Crossref: 56] [Cited by in F6Publishing: 58] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 438 |
Annaházi A, Gecse K, Dabek M, Ait-Belgnaoui A, Rosztóczy A, Róka R, Molnár T, Theodorou V, Wittmann T, Bueno L. Fecal proteases from diarrheic-IBS and ulcerative colitis patients exert opposite effect on visceral sensitivity in mice. Pain. 2009;144:209-217. [PMID: 19450926 DOI: 10.1016/j.pain.2009.04.017] [Cited by in Crossref: 69] [Cited by in F6Publishing: 73] [Article Influence: 4.9] [Reference Citation Analysis]
|
| 439 |
Bouhnik Y, Attar A, Treton X. Les scores endoscopiques des MICI. Colon Rectum 2009;3:101-106. [DOI: 10.1007/s11725-009-0151-y] [Reference Citation Analysis]
|
| 440 |
Kane S, Lu F, Kornbluth A, Awais D, Higgins PD. Controversies in mucosal healing in ulcerative colitis. Inflamm Bowel Dis 2009;15:796-800. [PMID: 19213060 DOI: 10.1002/ibd.20875] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 441 |
Kudo T, Matsumoto T, Esaki M, Yao T, Iida M. Mucosal vascular pattern in ulcerative colitis: observations using narrow band imaging colonoscopy with special reference to histologic inflammation. Int J Colorectal Dis 2009;24:495-501. [PMID: 19145441 DOI: 10.1007/s00384-008-0631-9] [Cited by in Crossref: 48] [Cited by in F6Publishing: 53] [Article Influence: 3.4] [Reference Citation Analysis]
|
| 442 |
K Kamikozuru, K Fukunaga, S Hirota, N Hida, Y Ohda, K Yoshida, Y Yokoyama, K Tozawa, K Kawa, M Iimuro, K Nagase, A R Saniabadi, S Nakamura, H Miwa, T Matsumoto. The expression profile of functional regulatory T cells, CD4+CD25high+/forkhead box protein P3+, in patients with ulcerative colitis during active and quiescent disease. Clin Exp Immunol 2009;156. [PMID: 19292766 DOI: 10.1111/j.1365-2249.2009.03904.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 443 |
Sherlock ME, Seow CH, Steinhart AH, Griffiths AM. Oral budesonide for induction of remission in ulcerative colitis. Cochrane Database of Systematic Reviews 2009. [DOI: 10.1002/14651858.cd007698] [Reference Citation Analysis]
|
| 444 |
Boye B, Lundin KE, Leganger S, Mokleby K, Jantschek G, Jantschek I, Kunzendorf S, Benninghoven D, Sharpe M, Wilhelmsen I, Blomhoff S, Malt UF, Jahnsen J. The INSPIRE study: do personality traits predict general quality of life (Short form-36) in distressed patients with ulcerative colitis and Crohn's disease? Scand J Gastroenterol 2008;43:1505-13. [PMID: 18777439 DOI: 10.1080/00365520802321196] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 1.9] [Reference Citation Analysis]
|
| 445 |
Gisbert JP, Luna M, González-Lama Y, Pousa ID, Velasco M, Moreno-Otero R, Maté J. Effect of 5-aminosalicylates on renal function in patients with inflammatory bowel disease: 4-year follow-up study. Gastroenterol Hepatol 2008;31:477-84. [PMID: 18928745 DOI: 10.1157/13127088] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 446 |
Zahn A, Giese T, Karner M, Braun A, Hinz U, Stremmel W, Ehehalt R. Transcript levels of different cytokines and chemokines correlate with clinical and endoscopic activity in ulcerative colitis. BMC Gastroenterol 2009;9:13. [PMID: 19203362 DOI: 10.1186/1471-230X-9-13] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 447 |
Tsujikawa T, Andoh A, Ogaẃa A, Sonoda A, Yagi Y, Hata K, Sasaki M, Saito Y, Fujiyama Y. Feasibility of Five Days of Consecutive Leukocytapheresis for the Treatment of Ulcerative Colitis: A Preliminary Study. Therapeutic Apheresis and Dialysis 2009;13:14-8. [DOI: 10.1111/j.1744-9987.2009.00650.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 448 |
Kruis W, Kiudelis G, Rácz I, Gorelov IA, Pokrotnieks J, Horynski M, Batovsky M, Kykal J, Boehm S, Greinwald R, Mueller R; International Salofalk OD Study Group. Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial. Gut 2009;58:233-40. [PMID: 18832520 DOI: 10.1136/gut.2008.154302] [Cited by in Crossref: 140] [Cited by in F6Publishing: 147] [Article Influence: 10.0] [Reference Citation Analysis]
|
| 449 |
Shimada M, Iwase H, Tsuzuki T, Hirashima N, Kobayashi K, Hibino Y, Watanabe H, Ryuge N, Ando T, Goto H. A pilot study of leukocytapheresis efficacy with 1.5 liter blood processing volume in patients with ulcerative colitis. Ther Apher Dial. 2008;12:368-373. [PMID: 18937719 DOI: 10.1111/j.1744-9987.2008.00611.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 450 |
Takeda T, Kamiura S, Kimura T. Effectiveness of the herbal medicine daikenchuto for radiation-induced enteritis. J Altern Complement Med. 2008;14:753-755. [PMID: 18637762 DOI: 10.1089/acm.2007.0748] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 451 |
Ataseven H, Oztürk ZA, Arhan M, Yüksel O, Köklü S, Ibiş M, Başar O, Yilmaz FM, Yüksel I. Cancer antigen 125 levels in inflammatory bowel diseases. J Clin Lab Anal 2009;23:244-8. [PMID: 19623645 DOI: 10.1002/jcla.20323] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 452 |
Hawthorne AB. A Review of Multimatrix System (MMX) Mesalazine in the Management of Ulcerative Colitis. Clinical Medicine Therapeutics 2009;1:CMT.S38. [DOI: 10.4137/cmt.s38] [Reference Citation Analysis]
|
| 453 |
Tillinger W, Jilch R, Jilma B, Brunner H, Koeller U, Lichtenberger C, Waldhör T, Reinisch W. Expression of the high-affinity IgG receptor FcRI (CD64) in patients with inflammatory bowel disease: a new biomarker for gastroenterologic diagnostics. Am J Gastroenterol 2009;104:102-9. [PMID: 19098857 DOI: 10.1038/ajg.2008.6] [Cited by in Crossref: 38] [Cited by in F6Publishing: 40] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 454 |
Cortot A, Maetz D, Degoutte E, Delette O, Meunier P, Tan G, Cazals JB, Dewit O, Hebuterne X, Beorchia S, Grunberg B, Leprince E, D'Haens G, Forestier S, Idier I, Lémann M. Mesalamine foam enema versus mesalamine liquid enema in active left-sided ulcerative colitis. Am J Gastroenterol 2008;103:3106-14. [PMID: 19086960 DOI: 10.1111/j.1572-0241.2008.02152.x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 42] [Article Influence: 2.9] [Reference Citation Analysis]
|
| 455 |
Derici U, Tuncer C, Ebinç FA, Mutluay R, Yakaryilmaz F, Kulaksizoglu S, Soylemezoglu O, Sindel S. Does the urinary excretion of alpha1-microglobulin and albumin predict clinical disease activity in ulcerative colitis? Adv Ther 2008;25:1342-52. [PMID: 19002407 DOI: 10.1007/s12325-008-0109-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 456 |
Kapsoritakis AN, Kapsoritaki AI, Davidi IP, Lotis VD, Manolakis AC, Mylonis PI, Theodoridou AT, Germenis AE, Potamianos SP. Imbalance of tissue inhibitors of metalloproteinases (TIMP) - 1 and - 4 serum levels, in patients with inflammatory bowel disease. BMC Gastroenterol. 2008;8:55. [PMID: 19036126 DOI: 10.1186/1471-230x-8-55] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 457 |
Lawrance IC, Copeland TS. Rectal tacrolimus in the treatment of resistant ulcerative proctitis. Aliment Pharmacol Ther 2008;28:1214-20. [PMID: 18761706 DOI: 10.1111/j.1365-2036.2008.03841.x] [Cited by in Crossref: 51] [Cited by in F6Publishing: 41] [Article Influence: 3.4] [Reference Citation Analysis]
|
| 458 |
Bresci G, Parisi G, Mazzoni A, Scatena F, Capria A. Granulocytapheresis versus methylprednisolone in patients with acute ulcerative colitis: 12-month follow up. J Gastroenterol Hepatol 2008;23:1678-82. [PMID: 18823440 DOI: 10.1111/j.1440-1746.2008.05595.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 459 |
Maiden L, Takeuchi K, Baur R, Bjarnason I, O'Donohue J, Forgacs I, Chung-Faye G, Sanderson J, Bjarnason I. Selective white cell apheresis reduces relapse rates in patients with IBD at significant risk of clinical relapse. Inflamm Bowel Dis 2008;14:1413-8. [PMID: 18521900 DOI: 10.1002/ibd.20505] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 460 |
Sipponen T, Savilahti E, Kärkkäinen P, Kolho KL, Nuutinen H, Turunen U, Färkkilä M. Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti-TNF-alpha therapy for Crohn's disease. Inflamm Bowel Dis 2008;14:1392-8. [PMID: 18484671 DOI: 10.1002/ibd.20490] [Cited by in Crossref: 170] [Cited by in F6Publishing: 145] [Article Influence: 11.3] [Reference Citation Analysis]
|
| 461 |
D’ovidio V, Vernia P, Gentile G, Capobianchi A, Marcheggiano A, Viscido A, Martino P, Caprilli R. Cytomegalovirus infection in inflammatory bowel disease patients undergoing anti-TNFα therapy. Journal of Clinical Virology 2008;43:180-3. [DOI: 10.1016/j.jcv.2008.06.002] [Cited by in Crossref: 64] [Cited by in F6Publishing: 67] [Article Influence: 4.3] [Reference Citation Analysis]
|
| 462 |
Takeda H, Suzuki Y, Takeda Y, Nishise S, Fukui T, Fujishima S, Orii T, Otake S, Sato T, Suzuki K, Nakamuara Y, Kawata S. A multi center study of granulocyte and monocyte adsorption apheresis therapy for ulcerative colitis-clinical efficacy and production of interleukin-1 receptor antagonist. J Clin Apher 2008;23:105-10. [PMID: 18449931 DOI: 10.1002/jca.20164] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 463 |
Andoh A, Tsujikawa T, Ban H, Hashimoto T, Bamba S, Ogawa A, Sasaki M, Saito Y, Fujiyama Y. Monitoring 6-thioguanine nucleotide concentrations in Japanese patients with inflammatory bowel disease. J Gastroenterol Hepatol 2008;23:1373-7. [PMID: 18662197 DOI: 10.1111/j.1440-1746.2008.05419.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 464 |
Pastorelli L, Saibeni S, Spina L, Signorelli C, Celasco G, de Franchis R, Vecchi M. Oral, colonic-release low-molecular-weight heparin: an initial open study of Parnaparin-MMX for the treatment of mild-to-moderate left-sided ulcerative colitis. Aliment Pharmacol Ther 2008;28:581-8. [PMID: 18700898 DOI: 10.1111/j.1365-2036.2008.03757.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 2.1] [Reference Citation Analysis]
|
| 465 |
Miehsler W, Weichselberger M, Offerlbauer-Ernst A, Dejaco C, Reinisch W, Vogelsang H, Machold K, Stamm T, Gangl A, Moser G. Which patients with IBD need psychological interventions? A controlled study. Inflamm Bowel Dis 2008;14:1273-80. [PMID: 18393373 DOI: 10.1002/ibd.20462] [Cited by in Crossref: 59] [Cited by in F6Publishing: 54] [Article Influence: 3.9] [Reference Citation Analysis]
|
| 466 |
Tanaka T, Okanobu H, Yoshimi S, Murakami E, Kogame A, Imagawa H, Numata Y, Kuga Y, Moriya T, Ohya T, Kajiyama G. In patients with ulcerative colitis, adsorptive depletion of granulocytes and monocytes impacts mucosal level of neutrophils and clinically is most effective in steroid naïve patients. Dig Liver Dis 2008;40:731-6. [PMID: 18387860 DOI: 10.1016/j.dld.2008.02.012] [Cited by in Crossref: 49] [Cited by in F6Publishing: 52] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 467 |
Moschen AR, Geiger S, Krehan I, Kaser A, Tilg H. Interferon-alpha controls IL-17 expression in vitro and in vivo. Immunobiology 2008;213:779-87. [PMID: 18926293 DOI: 10.1016/j.imbio.2008.07.022] [Cited by in Crossref: 52] [Cited by in F6Publishing: 50] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 468 |
Muratov V, Ulfgren AK, Engström M, Elvin K, Winqvist O, Löfberg R, Lundahl J. Decreased numbers of FoxP3-positive and TLR-2-positive cells in intestinal mucosa are associated with improvement in patients with active inflammatory bowel disease following selective leukocyte apheresis. J Gastroenterol 2008;43:277-82. [PMID: 18458843 DOI: 10.1007/s00535-007-2156-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 469 |
Seow CH, Benchimol EI, Griffiths AM, Steinhart AH. Type I interferons for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2008;CD006790. [PMID: 18646167 DOI: 10.1002/14651858.cd006790.pub2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 18] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 470 |
Hanai H. Leucocytapheresis for inflammatory bowel disease in the era of biologic therapy. Eur J Gastroenterol Hepatol 2008;20:596-600. [PMID: 18679059 DOI: 10.1097/MEG.0b013e3282f5e9f3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 471 |
Egawa S, Iijima H, Shinzaki S, Nakajima S, Wang J, Kondo J, Ishii S, Yoshio T, Irie T, Nishida T, Kakiuchi Y, Yasumaru M, Yoshihara H, Kanto T, Tsujii M, Tsuji S, Hayashi N. Upregulation of GRAIL is associated with remission of ulcerative colitis. Am J Physiol Gastrointest Liver Physiol 2008;295:G163-9. [PMID: 18467499 DOI: 10.1152/ajpgi.90242.2008] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 472 |
Sakata Y, Iwakiri R, Amemori S, Yamaguchi K, Fujise T, Otani H, Shimoda R, Tsunada S, Sakata H, Ikeda Y, Ando T, Nakafusa Y, Fujimoto K. Comparison of the efficacy of granulocyte and monocyte/macrophage adsorptive apheresis and leukocytapheresis in active ulcerative colitis patients: a prospective randomized study. Eur J Gastroenterol Hepatol 2008;20:629-33. [PMID: 18679064 DOI: 10.1097/MEG.0b013e3282f5e9a4] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 473 |
Canani RB, Terrin G, Rapacciuolo L, Miele E, Siani MC, Puzone C, Cosenza L, Staiano A, Troncone R. Faecal calprotectin as reliable non-invasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel disease. Dig Liver Dis 2008;40:547-53. [PMID: 18358796 DOI: 10.1016/j.dld.2008.01.017] [Cited by in Crossref: 123] [Cited by in F6Publishing: 121] [Article Influence: 8.2] [Reference Citation Analysis]
|
| 474 |
Hirai F, Matsui T. A critical review of endoscopic indices in ulcerative colitis: inter-observer variation of the endoscopic index. Clin J Gastroenterol 2008;1:40-5. [PMID: 26193460 DOI: 10.1007/s12328-008-0018-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 475 |
Stanke-Labesque F, Pofelski J, Moreau-Gaudry A, Bessard G, Bonaz B. Urinary leukotriene E4 excretion: a biomarker of inflammatory bowel disease activity. Inflamm Bowel Dis 2008;14:769-74. [PMID: 18286646 DOI: 10.1002/ibd.20403] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 476 |
Schreiber S, Kamm MA, Lichtenstein GR. Mesalamine with MMX technology for the treatment of ulcerative colitis. Expert Rev Gastroenterol Hepatol 2008;2:299-314. [PMID: 19072380 DOI: 10.1586/17474124.2.3.299] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 477 |
Shinzaki S, Iijima H, Nakagawa T, Egawa S, Nakajima S, Ishii S, Irie T, Kakiuchi Y, Nishida T, Yasumaru M, Kanto T, Tsujii M, Tsuji S, Mizushima T, Yoshihara H, Kondo A, Miyoshi E, Hayashi N. IgG oligosaccharide alterations are a novel diagnostic marker for disease activity and the clinical course of inflammatory bowel disease. Am J Gastroenterol 2008;103:1173-81. [PMID: 18177457 DOI: 10.1111/j.1572-0241.2007.01699.x] [Cited by in Crossref: 61] [Cited by in F6Publishing: 59] [Article Influence: 4.1] [Reference Citation Analysis]
|
| 478 |
Erzin Y, Uzun H, Celik AF, Aydin S, Dirican A, Uzunismail H. Hyperhomocysteinemia in inflammatory bowel disease patients without past intestinal resections: correlations with cobalamin, pyridoxine, folate concentrations, acute phase reactants, disease activity, and prior thromboembolic complications. J Clin Gastroenterol 2008;42:481-6. [PMID: 18344891 DOI: 10.1097/MCG.0b013e318046eab0] [Cited by in Crossref: 39] [Cited by in F6Publishing: 40] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 479 |
Kulnigg S, Stoinov S, Simanenkov V, Dudar LV, Karnafel W, Garcia LC, Sambuelli AM, D'Haens G, Gasche C. A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial. Am J Gastroenterol 2008;103:1182-92. [PMID: 18371137 DOI: 10.1111/j.1572-0241.2007.01744.x] [Cited by in Crossref: 219] [Cited by in F6Publishing: 243] [Article Influence: 14.6] [Reference Citation Analysis]
|
| 480 |
Boye B, Jahnsen J, Mokleby K, Leganger S, Jantschek G, Jantschek I, Kunzendorf S, Benninghoven D, Wilhelmsen I, Sharpe M, Blomhoff S, Malt UF, Lundin KE. The INSPIRE study: are different personality traits related to disease-specific quality of life (IBDQ) in distressed patients with ulcerative colitis and Crohn's disease? Inflamm Bowel Dis 2008;14:680-6. [PMID: 18509900 DOI: 10.1002/ibd.20367] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 481 |
Willert RP, Lawrance IC. Use of infliximab in the prevention and delay of colectomy in severe steroid dependant and refractory ulcerative colitis. World J Gastroenterol 2008; 14(16): 2544-2549 [PMID: 18442203 DOI: 10.3748/wjg.14.2544] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 27] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 482 |
Fabbro E, Rubert L, Quaglia S, Ferrara F, Kiren V, Ventura A, Not T. Uselessness of anti-actin antibody in celiac disease screening. Clinica Chimica Acta 2008;390:134-7. [DOI: 10.1016/j.cca.2008.01.015] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 483 |
Chen CC, Isomoto H, Narumi Y, Sato K, Oishi Y, Kobayashi T, Yanagihara K, Mizuta Y, Kohno S, Tsukamoto K. Haplotypes of PADI4 susceptible to rheumatoid arthritis are also associated with ulcerative colitis in the Japanese population. Clinical Immunology 2008;126:165-71. [DOI: 10.1016/j.clim.2007.09.001] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 484 |
McCormack PL, Robinson DM, Perry CM. Delayed-release Multi Matrix System (MMX) mesalazine: in ulcerative colitis. Drugs 2007;67:2635-42. [PMID: 18034594 DOI: 10.2165/00003495-200767170-00010] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 485 |
Swidsinski A, Loening-Baucke V, Vaneechoutte M, Doerffel Y. Active Crohn's disease and ulcerative colitis can be specifically diagnosed and monitored based on the biostructure of the fecal flora. Inflamm Bowel Dis 2008;14:147-61. [PMID: 18050295 DOI: 10.1002/ibd.20330] [Cited by in Crossref: 205] [Cited by in F6Publishing: 190] [Article Influence: 13.7] [Reference Citation Analysis]
|
| 486 |
Yagi Y, Andoh A, Ogawa A, Bamba S, Tsujikawa T, Sasaki M, Mitsuyama K, Fujiyama Y. Microarray analysis of leukocytapheresis-induced changes in gene expression patterns of peripheral blood mononuclear cells in patients with ulcerative colitis. Ther Apher Dial. 2007;11:331-336. [PMID: 17845392 DOI: 10.1111/j.1744-9987.2007.00495.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 487 |
Langhorst J, Elsenbruch S, Koelzer J, Rueffer A, Michalsen A, Dobos GJ. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices. Am J Gastroenterol 2008;103:162-9. [PMID: 17916108 DOI: 10.1111/j.1572-0241.2007.01556.x] [Cited by in Crossref: 404] [Cited by in F6Publishing: 413] [Article Influence: 26.9] [Reference Citation Analysis]
|
| 488 |
Schoepfer AM, Trummler M, Seeholzer P, Seibold-Schmid B, Seibold F. Discriminating IBD from IBS: comparison of the test performance of fecal markers, blood leukocytes, CRP, and IBD antibodies. Inflamm Bowel Dis 2008;14:32-9. [PMID: 17924558 DOI: 10.1002/ibd.20275] [Cited by in Crossref: 183] [Cited by in F6Publishing: 161] [Article Influence: 12.2] [Reference Citation Analysis]
|
| 489 |
Rizzo R, Melchiorri L, Simone L, Stignani M, Marzola A, Gullini S, Baricordi OR. Different production of soluble HLA-G antigens by peripheral blood mononuclear cells in ulcerative colitis and Crohn's disease: a noninvasive diagnostic tool? Inflamm Bowel Dis 2008;14:100-5. [PMID: 17886287 DOI: 10.1002/ibd.20281] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 490 |
Pandolfino JE, Ghosh SK, Rice J, Clarke JO, Kwiatek MA, Kahrilas PJ. Classifying esophageal motility by pressure topography characteristics: a study of 400 patients and 75 controls. Am J Gastroenterol 2008;103:27-37. [PMID: 17900331 DOI: 10.1111/j.1572-0241.2007.01532.x] [Cited by in Crossref: 323] [Cited by in F6Publishing: 258] [Article Influence: 21.5] [Reference Citation Analysis]
|
| 491 |
Kaiser T, Langhorst J, Wittkowski H, Becker K, Friedrich AW, Rueffer A, Dobos GJ, Roth J, Foell D. Faecal S100A12 as a non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome. Gut 2007;56:1706-13. [PMID: 17675327 DOI: 10.1136/gut.2006.113431] [Cited by in Crossref: 143] [Cited by in F6Publishing: 154] [Article Influence: 8.9] [Reference Citation Analysis]
|
| 492 |
Yoshino T, Nakase H, Ueno S, Uza N, Inoue S, Mikami S, Matsuura M, Ohmori K, Sakurai T, Nagayama S, Hasegawa S, Sakai Y, Chiba T. Usefulness of quantitative real-time PCR assay for early detection of cytomegalovirus infection in patients with ulcerative colitis refractory to immunosuppressive therapies. Inflamm Bowel Dis 2007;13:1516-21. [PMID: 17828781 DOI: 10.1002/ibd.20253] [Cited by in Crossref: 106] [Cited by in F6Publishing: 95] [Article Influence: 6.6] [Reference Citation Analysis]
|
| 493 |
Dai J, Liu WZ, Zhao YP, Hu YB, Ge ZZ. Relationship between fecal lactoferrin and inflammatory bowel disease. Scand J Gastroenterol 2007;42:1440-4. [PMID: 17852860 DOI: 10.1080/00365520701427094] [Cited by in Crossref: 52] [Cited by in F6Publishing: 55] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 494 |
Cucchiara S, Borrelli O. Clinical Trials (Clinical Perspective). Pediatric Inflammatory Bowel Disease. [DOI: 10.1007/978-0-387-73481-1_40] [Reference Citation Analysis]
|
| 495 |
Noble A, Turner D. Clinical Indices for Pediatric Inflammatory Bowel Disease Research. Pediatric Inflammatory Bowel Disease. [DOI: 10.1007/978-0-387-73481-1_39] [Reference Citation Analysis]
|
| 496 |
Moser G. Psychosomatische Aspekte chronisch entzündlicher Darmerkrankungen. Psychosomatik in der Gastroenterologie und Hepatologie. [DOI: 10.1007/978-3-211-69159-5_13] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 497 |
Nikolaus S, Schreiber S. Diagnostics of inflammatory bowel disease. Gastroenterology 2007;133:1670-89. [PMID: 17983810 DOI: 10.1053/j.gastro.2007.09.001] [Cited by in Crossref: 282] [Cited by in F6Publishing: 292] [Article Influence: 17.6] [Reference Citation Analysis]
|
| 498 |
Eliakim R, Tulassay Z, Kupcinskas L, Adamonis K, Pokrotnieks J, Bar-Meir S, Lavy A, Mueller R, Greinwald R, Chermesh I, Gross V; International Salofalk Foam Study Group. Clinical trial: randomized-controlled clinical study comparing the efficacy and safety of a low-volume vs. a high-volume mesalazine foam in active distal ulcerative colitis. Aliment Pharmacol Ther 2007;26:1237-49. [PMID: 17944738 DOI: 10.1111/j.1365-2036.2007.03468.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 499 |
Seow C, Benchimol E, Griffiths A, Steinhart A. Type I interferons for induction of remission in ulcerative colitis. Cochrane Database of Systematic Reviews 2007. [DOI: 10.1002/14651858.cd006790] [Reference Citation Analysis]
|
| 500 |
Schröder O, Naumann M, Shastri Y, Povse N, Stein J. Prospective evaluation of faecal neutrophil-derived proteins in identifying intestinal inflammation: combination of parameters does not improve diagnostic accuracy of calprotectin. Aliment Pharmacol Ther 2007;26:1035-42. [PMID: 17877510 DOI: 10.1111/j.1365-2036.2007.03457.x] [Cited by in Crossref: 66] [Cited by in F6Publishing: 56] [Article Influence: 4.1] [Reference Citation Analysis]
|
| 501 |
Schoepfer AM, Trummler M, Seeholzer P, Criblez DH, Seibold F. Accuracy of four fecal assays in the diagnosis of colitis. Dis Colon Rectum 2007;50:1697-706. [PMID: 17762964 DOI: 10.1007/s10350-007-0303-9] [Cited by in Crossref: 66] [Cited by in F6Publishing: 73] [Article Influence: 4.1] [Reference Citation Analysis]
|
| 502 |
Huber R, Ditfurth AV, Amann F, Güthlin C, Rostock M, Trittler R, Kümmerer K, Merfort I. Tormentil for active ulcerative colitis: an open-label, dose-escalating study. J Clin Gastroenterol 2007;41:834-8. [PMID: 17881930 DOI: 10.1097/MCG.0b013e31804b2173] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 503 |
Kedia P, Cohen RD. Once-daily MMX mesalamine for the treatment of mild-to-moderate ulcerative colitis. Ther Clin Risk Manag 2007;3:919-27. [PMID: 18473016] [Reference Citation Analysis]
|
| 504 |
Pearce CB, Lawrance IC. Careful patient selection may improve response rates to infliximab in inflammatory bowel disease. J Gastroenterol Hepatol 2007;22:1671-7. [PMID: 17845695 DOI: 10.1111/j.1440-1746.2006.04739.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 505 |
Timmer A, Bauer A, Kemptner D, Fürst A, Rogler G. Determinants of male sexual function in inflammatory bowel disease: a survey-based cross-sectional analysis in 280 men. Inflamm Bowel Dis 2007;13:1236-43. [PMID: 17508419 DOI: 10.1002/ibd.20182] [Cited by in Crossref: 56] [Cited by in F6Publishing: 38] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 506 |
Hafer A, Krämer S, Duncker S, Krüger M, Manns MP, Bischoff SC. Effect of oral lactulose on clinical and immunohistochemical parameters in patients with inflammatory bowel disease: a pilot study. BMC Gastroenterol. 2007;7:36. [PMID: 17784949 DOI: 10.1186/1471-230x-7-36] [Cited by in Crossref: 56] [Cited by in F6Publishing: 60] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 507 |
Yilmaz S, Aydemir E, Maden A, Unsal B. The prevalence of ocular involvement in patients with inflammatory bowel disease. Int J Colorectal Dis 2007;22:1027-30. [PMID: 17262200 DOI: 10.1007/s00384-007-0275-1] [Cited by in Crossref: 48] [Cited by in F6Publishing: 51] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 508 |
Emmrich J, Petermann S, Nowak D, Beutner I, Brock P, Klingel R, Mausfeld-Lafdhiya P, Liebe S, Ramlow W. Leukocytapheresis (LCAP) in the management of chronic active ulcerative colitis--results of a randomized pilot trial. Dig Dis Sci 2007;52:2044-53. [PMID: 17410456 DOI: 10.1007/s10620-006-9696-x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 509 |
Langhorst J, Cobelens PM, Kavelaars A, Heijnen CJ, Benson S, Rifaie N, Dobos GJ, Schedlowski M, Elsenbruch S. Stress-related peripheral neuroendocrine-immune interactions in women with ulcerative colitis. Psychoneuroendocrinology 2007;32:1086-96. [PMID: 17933470 DOI: 10.1016/j.psyneuen.2007.09.003] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 510 |
Yokoyama H, Takagi S, Kuriyama S, Takahashi S, Takahashi H, Iwabuchi M, Takahashi S, Kinouchi Y, Hiwatashi N, Tsuji I, Shimosegawa T. Effect of weekend 5-aminosalicylic acid (mesalazine) enema as maintenance therapy for ulcerative colitis: results from a randomized controlled study. Inflamm Bowel Dis 2007;13:1115-20. [PMID: 17455207 DOI: 10.1002/ibd.20158] [Cited by in Crossref: 42] [Cited by in F6Publishing: 38] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 511 |
Kanke K, Hoshino M, Tominaga K, Nakano M, Terano A, Hiraishi H. Selection of Anticoagulants for Leukocytapheresis Therapy in Cases of Active Ulcerative Colitis. Blood Purif 2007;25:370-6. [DOI: 10.1159/000107712] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 512 |
Turner D, Otley AR, Mack D, Hyams J, de Bruijne J, Uusoue K, Walters TD, Zachos M, Mamula P, Beaton DE, Steinhart AH, Griffiths AM. Development, validation, and evaluation of a pediatric ulcerative colitis activity index: a prospective multicenter study. Gastroenterology 2007;133:423-32. [PMID: 17681163 DOI: 10.1053/j.gastro.2007.05.029] [Cited by in Crossref: 694] [Cited by in F6Publishing: 710] [Article Influence: 43.4] [Reference Citation Analysis]
|
| 513 |
Andoh A, Sakata S, Koizumi Y, Mitsuyama K, Fujiyama Y, Benno Y. Terminal restriction fragment length polymorphism analysis of the diversity of fecal microbiota in patients with ulcerative colitis. Inflamm Bowel Dis 2007;13:955-62. [PMID: 17455205 DOI: 10.1002/ibd.20151] [Cited by in Crossref: 86] [Cited by in F6Publishing: 82] [Article Influence: 5.4] [Reference Citation Analysis]
|
| 514 |
Turner D, Steinhart AH, Griffiths AM. Omega 3 fatty acids (fish oil) for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2007;CD006443. [PMID: 17636844 DOI: 10.1002/14651858.cd006443.pub2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 30] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 515 |
Yamamoto T, Saniabadi AR, Maruyama Y, Umegae S, Matsumoto K. Factors affecting clinical and endoscopic efficacies of selective leucocytapheresis for ulcerative colitis. Dig Liver Dis 2007;39:626-33. [PMID: 17532273 DOI: 10.1016/j.dld.2007.04.007] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 516 |
Dincer Y, Erzin Y, Himmetoglu S, Gunes KN, Bal K, Akcay T. Oxidative DNA damage and antioxidant activity in patients with inflammatory bowel disease. Dig Dis Sci 2007;52:1636-41. [PMID: 17393334 DOI: 10.1007/s10620-006-9386-8] [Cited by in Crossref: 64] [Cited by in F6Publishing: 57] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 517 |
Haumer M, Teml A, Dirisamer A, Vogelsang H, Koppensteiner R, Novacek G. Severe ulcerative colitis complicated by an arterial thrombus in the brachiocephalic trunk. Inflamm Bowel Dis 2007;13:937-8. [PMID: 17278129 DOI: 10.1002/ibd.20116] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 518 |
Dilger K, Trenk D, Rössle M, Cap M, Zähringer A, Wacheck V, Remmler C, Cascorbi I, Kreisel W, Novacek G. A clinical trial on absorption and N-acetylation of oral and rectal mesalazine. Eur J Clin Invest 2007;37:558-65. [PMID: 17576207 DOI: 10.1111/j.1365-2362.2007.01809.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 519 |
Clark M, Colombel JF, Feagan BC, Fedorak RN, Hanauer SB, Kamm MA, Mayer L, Regueiro C, Rutgeerts P, Sandborn WJ, Sands BE, Schreiber S, Targan S, Travis S, Vermeire S. American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006. Gastroenterology 2007;133:312-39. [PMID: 17631151 DOI: 10.1053/j.gastro.2007.05.006] [Cited by in Crossref: 160] [Cited by in F6Publishing: 174] [Article Influence: 10.0] [Reference Citation Analysis]
|
| 520 |
Cooney RM, Warren BF, Altman DG, Abreu MT, Travis SP. Outcome measurement in clinical trials for Ulcerative Colitis: towards standardisation. Trials 2007;8:17. [PMID: 17592647 DOI: 10.1186/1745-6215-8-17] [Cited by in Crossref: 89] [Cited by in F6Publishing: 98] [Article Influence: 5.6] [Reference Citation Analysis]
|
| 521 |
Shioya M, Nishida A, Yagi Y, Ogawa A, Tsujikawa T, Kim-Mitsuyama S, Takayanagi A, Shimizu N, Fujiyama Y, Andoh A. Epithelial overexpression of interleukin-32alpha in inflammatory bowel disease. Clin Exp Immunol 2007;149:480-6. [PMID: 17590175 DOI: 10.1111/j.1365-2249.2007.03439.x] [Cited by in Crossref: 160] [Cited by in F6Publishing: 167] [Article Influence: 10.0] [Reference Citation Analysis]
|
| 522 |
Gulubova MV, Manolova IM, Vlaykova TI, Prodanova M, Jovchev JP. Adhesion molecules in chronic ulcerative colitis. Int J Colorectal Dis 2007;22:581-9. [PMID: 17109102 DOI: 10.1007/s00384-006-0236-0] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 523 |
Langhorst J, Mueller T, Luedtke R, Franken U, Paul A, Michalsen A, Schedlowski M, Dobos GJ, Elsenbruch S. Effects of a comprehensive lifestyle modification program on quality-of-life in patients with ulcerative colitis: a twelve-month follow-up. Scand J Gastroenterol 2007;42:734-45. [PMID: 17505996 DOI: 10.1080/00365520601101682] [Cited by in Crossref: 58] [Cited by in F6Publishing: 60] [Article Influence: 3.6] [Reference Citation Analysis]
|
| 524 |
Aoki H, Nakamura K, Yoshimatsu Y, Tsuda Y, Irie M, Fukuda K, Hosoe N, Takada N, Shirai K, Suzuki Y. Adacolumn selective leukocyte adsorption apheresis in patients with active ulcerative colitis: clinical efficacy, effects on plasma IL-8, and expression of Toll-like receptor 2 on granulocytes. Dig Dis Sci 2007;52:1427-33. [PMID: 17394078 DOI: 10.1007/s10620-006-9406-8] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 525 |
Sandborn WJ. Medical management of ulcerative colitis. Inflammatory Bowel Disease: From Bench to Bedside. [DOI: 10.1007/0-387-25808-6_30] [Reference Citation Analysis]
|
| 526 |
Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet 2007;369:1641-57. [PMID: 17499606 DOI: 10.1016/S0140-6736(07)60751-X] [Cited by in Crossref: 1242] [Cited by in F6Publishing: 1298] [Article Influence: 77.6] [Reference Citation Analysis]
|
| 527 |
Bresci G, Parisi G, Mazzoni A, Scatena F, Capria A. Treatment of patients with acute ulcerative colitis: conventional corticosteroid therapy (MP) versus granulocytapheresis (GMA): a pilot study. Dig Liver Dis 2007;39:430-4. [PMID: 17379588 DOI: 10.1016/j.dld.2007.01.001] [Cited by in Crossref: 42] [Cited by in F6Publishing: 46] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 528 |
Gisbert JP, González-lama Y, Maté J. 5-Aminosalicylates and renal function in inflammatory bowel disease. Inflammatory Bowel Diseases 2007;13:629-638. [DOI: 10.1002/ibd.20099] [Cited by in Crossref: 147] [Cited by in F6Publishing: 135] [Article Influence: 9.2] [Reference Citation Analysis]
|
| 529 |
Casellas F, Borruel N, Torrejón A, Varela E, Antolin M, Guarner F, Malagelada JR. Oral oligofructose-enriched inulin supplementation in acute ulcerative colitis is well tolerated and associated with lowered faecal calprotectin. Aliment Pharmacol Ther 2007;25:1061-7. [PMID: 17439507 DOI: 10.1111/j.1365-2036.2007.03288.x] [Cited by in Crossref: 166] [Cited by in F6Publishing: 157] [Article Influence: 10.4] [Reference Citation Analysis]
|
| 530 |
Peyrin-Biroulet L, Laclotte C, Roblin X, Bigard MA. Adalimumab induction therapy for ulcerative colitis with intolerance or lost response to infliximab: An open-label study. World J Gastroenterol 2007; 13(16): 2328-2332 [PMID: 17511032 DOI: 10.3748/wjg.v13.i16.2328] [Cited by in CrossRef: 65] [Cited by in F6Publishing: 72] [Article Influence: 4.1] [Reference Citation Analysis]
|
| 531 |
D’haens G. Importance of mucosal healing in Crohn’s disease and ulcerative colitis. Immunoregulation in Inflammatory Bowel Diseases — Current Understanding and Innovation. [DOI: 10.1007/978-1-4020-5889-9_14] [Reference Citation Analysis]
|
| 532 |
Ricart E, Esteve M, Andreu M, Casellas F, Monfort D, Sans M, Oudovenko N, Lafuente R, Panés J. Evaluation of 5 versus 10 granulocyteaphaeresis sessions in steroid-dependent ulcerative colitis: A pilot, prospective, multicenter, randomized study. World J Gastroenterol 2007; 13(15): 2193-2197 [PMID: 17465500 DOI: 10.3748/wjg.v13.i15.2193] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 533 |
Turner D, Steinhart A, Griffiths A. Omega 3 fatty acids (fish oil) for maintenance of remission in ulcerative colitis. Cochrane Database of Systematic Reviews 2007. [DOI: 10.1002/14651858.cd006443] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 534 |
Luis Cabriada-nuño J, Bernal-martínez A, Hernández-martín A, Antonio Arévalo-serna J, Fernández-prado E. Aféresis leucocitaria en la inducción de la remisión y retirada de corticoides en la colitis ulcerosa corticodependiente. Diálisis y Trasplante 2007;28:47-55. [DOI: 10.1016/s1886-2845(07)71352-8] [Reference Citation Analysis]
|
| 535 |
Biancone L, Gionchetti P, Blanco Gdel V, Orlando A, Annese V, Papi C, Sostegni R, D'Incà R, Petruzziello C, Casa A, Sica G, Calabrese E, Campieri M, Pallone F. Beclomethasone dipropionate versus mesalazine in distal ulcerative colitis: a multicenter, randomized, double-blind study. Dig Liver Dis 2007;39:329-37. [PMID: 17347061 DOI: 10.1016/j.dld.2007.01.012] [Cited by in Crossref: 47] [Cited by in F6Publishing: 43] [Article Influence: 2.9] [Reference Citation Analysis]
|
| 536 |
Moschen AR, Kaser A, Enrich B, Mosheimer B, Theurl M, Niederegger H, Tilg H. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol 2007;178:1748-58. [PMID: 17237424 DOI: 10.4049/jimmunol.178.3.1748] [Cited by in Crossref: 576] [Cited by in F6Publishing: 624] [Article Influence: 36.0] [Reference Citation Analysis]
|
| 537 |
Actis GC, Fadda M, David E, Sapino A. Colectomy rate in steroid-refractory colitis initially responsive to cyclosporin: a long-term retrospective cohort study. BMC Gastroenterol. 2007;7:13. [PMID: 17389040 DOI: 10.1186/1471-230x-7-13] [Cited by in Crossref: 65] [Cited by in F6Publishing: 69] [Article Influence: 4.1] [Reference Citation Analysis]
|
| 538 |
Moss AC, Peppercorn MA. The risks and the benefits of mesalazine as a treatment for ulcerative colitis. Expert Opinion on Drug Safety 2007;6:99-107. [DOI: 10.1517/14740338.6.2.99] [Cited by in Crossref: 33] [Cited by in F6Publishing: 38] [Article Influence: 2.1] [Reference Citation Analysis]
|
| 539 |
Palkovits J, Häfner M, Rand T, Vogelsang H, Kutilek M, Gangl A, Novacek G. Portal vein thrombosis in ulcerative colitis complicated by bleeding from gastric varices. Inflamm Bowel Dis 2007;13:365-6. [PMID: 17206707 DOI: 10.1002/ibd.20034] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 540 |
Miehsler W. A case of refractory proctitis. Falk Symposium. [DOI: 10.1007/1-4020-2912-8_26] [Reference Citation Analysis]
|
| 541 |
Furuta R, Ando T, Watanabe O, Maeda O, Ishiguro K, Ina K, Kusugami K, Goto H. Rebamipide enema therapy as a treatment for patients with active distal ulcerative colitis. J Gastroenterol Hepatol 2007;22:261-7. [PMID: 17295881 DOI: 10.1111/j.1440-1746.2006.04399.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 542 |
Mishima R, Takeshima F, Sawai T, Ohba K, Ohnita K, Isomoto H, Omagari K, Mizuta Y, Ozono Y, Kohno S. High plasma osteopontin levels in patients with inflammatory bowel disease. J Clin Gastroenterol 2007;41:167-72. [PMID: 17245215 DOI: 10.1097/MCG.0b013e31802d6268] [Cited by in Crossref: 50] [Cited by in F6Publishing: 50] [Article Influence: 3.1] [Reference Citation Analysis]
|
| 543 |
Su C, Lewis JD, Goldberg B, Brensinger C, Lichtenstein GR. A meta-analysis of the placebo rates of remission and response in clinical trials of active ulcerative colitis. Gastroenterology 2007;132:516-26. [PMID: 17258720 DOI: 10.1053/j.gastro.2006.12.037] [Cited by in Crossref: 111] [Cited by in F6Publishing: 112] [Article Influence: 6.9] [Reference Citation Analysis]
|
| 544 |
Ullman TA, Palmon R. The certain uncertainty of measuring disease activity in IBD. J Clin Gastroenterol 2007;41:123-5. [PMID: 17245207 DOI: 10.1097/01.mcg.0000225660.15556.4e] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 545 |
D'Haens G, Sandborn WJ, Feagan BG, Geboes K, Hanauer SB, Irvine EJ, Lémann M, Marteau P, Rutgeerts P, Schölmerich J, Sutherland LR. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology 2007;132:763-86. [PMID: 17258735 DOI: 10.1053/j.gastro.2006.12.038] [Cited by in Crossref: 722] [Cited by in F6Publishing: 754] [Article Influence: 45.1] [Reference Citation Analysis]
|
| 546 |
Ewaschuk JB, Tejpar QZ, Soo I, Madsen K, Fedorak RN. The role of antibiotic and probiotic therapies in current and future management of inflammatory bowel disease. Curr Gastroenterol Rep. 2006;8:486-498. [PMID: 17105688 DOI: 10.1007/s11894-006-0039-z] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 547 |
Schreiber S, Keshavarzian A, Isaacs KL, Schollenberger J, Guzman JP, Orlandi C, Hanauer SB. A randomized, placebo-controlled, phase II study of tetomilast in active ulcerative colitis. Gastroenterology 2007;132:76-86. [PMID: 17241861 DOI: 10.1053/j.gastro.2006.11.029] [Cited by in Crossref: 42] [Cited by in F6Publishing: 43] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 548 |
Montalto M, Curigliano V, Santoro L, Armuzzi A, Cammarota G, Covino M, Mentella MC, Ancarani F, Manna R, Gasbarrini A, Gasbarrini G. Fecal calprotectin in first-degree relatives of patients with ulcerative colitis. Am J Gastroenterol 2007;102:132-6. [PMID: 17100982 DOI: 10.1111/j.1572-0241.2006.00884.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 549 |
Timmer A, Bauer A, Dignass A, Rogler G. Sexual function in persons with inflammatory bowel disease: a survey with matched controls. Clin Gastroenterol Hepatol 2007;5:87-94. [PMID: 17234557 DOI: 10.1016/j.cgh.2006.10.018] [Cited by in Crossref: 93] [Cited by in F6Publishing: 98] [Article Influence: 5.8] [Reference Citation Analysis]
|
| 550 |
Ohkawara T, Takeda H, Furukawa S, Kato M, Shimizu Y, Asaka M. Changes in the Plasma Level of Macrophage Migration Inhibitory Factor in Ulcerative Colitis Patients Treated with Selective Granulocyte and Monocyte Apheresis. Intern Med 2007;46:1821-1822. [DOI: 10.2169/internalmedicine.46.0310] [Reference Citation Analysis]
|
| 551 |
Kunzendorf S, Jantschek G, Straubinger K, Heberlein I, Homann N, Ludwig D, Benninghoven D. The Luebeck interview for psychosocial screening in patients with inflammatory bowel disease. Inflamm Bowel Dis 2007;13:33-41. [PMID: 17206637 DOI: 10.1002/ibd.20050] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 552 |
Hanai H. Positions of selective leukocytapheresis in the medical therapy of ulcerative colitis. World J Gastroenterol 2006; 12(47): 7568-7577 [PMID: 17171783 DOI: 10.3748/wjg.v12.i47.7568] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 38] [Article Influence: 1.9] [Reference Citation Analysis]
|
| 553 |
Zhang M, Liu B, Zhang Y, Wei H, Lei Y, Zhao L. Structural shifts of mucosa-associated lactobacilli and Clostridium leptum subgroup in patients with ulcerative colitis. J Clin Microbiol 2007;45:496-500. [PMID: 17151201 DOI: 10.1128/JCM.01720-06] [Cited by in Crossref: 56] [Cited by in F6Publishing: 60] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 554 |
Hanai H, Iida T, Takeuchi K, Watanabe F, Maruyama Y, Andoh A, Tsujikawa T, Fujiyama Y, Mitsuyama K, Sata M, Yamada M, Iwaoka Y, Kanke K, Hiraishi H, Hirayama K, Arai H, Yoshii S, Uchijima M, Nagata T, Koide Y. Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol 2006;4:1502-6. [PMID: 17101300 DOI: 10.1016/j.cgh.2006.08.008] [Cited by in Crossref: 406] [Cited by in F6Publishing: 469] [Article Influence: 23.9] [Reference Citation Analysis]
|
| 555 |
Lucas A, Cobelens PM, Kavelaars A, Heijnen CJ, Holtmann G, Haag S, Gerken G, Langhorst J, Dobos GJ, Schedlowski M. Disturbed in vitro adrenergic modulation of cytokine production in inflammatory bowel diseases in remission. J Neuroimmunol. 2007;182:195-203. [PMID: 17112600 DOI: 10.1016/j.jneuroim.2006.09.011] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 556 |
Suzuki Y, Yoshimura N, Fukuda K, Shirai K, Saito Y, Saniabadi AR. A retrospective search for predictors of clinical response to selective granulocyte and monocyte apheresis in patients with ulcerative colitis. Dig Dis Sci 2006;51:2031-8. [PMID: 17004123 DOI: 10.1007/s10620-006-9199-9] [Cited by in Crossref: 47] [Cited by in F6Publishing: 40] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 557 |
Zahn A, Hinz U, Karner M, Ehehalt R, Stremmel W. Health-related quality of life correlates with clinical and endoscopic activity indexes but not with demographic features in patients with ulcerative colitis. Inflamm Bowel Dis 2006;12:1058-67. [PMID: 17075347 DOI: 10.1097/01.mib.0000234134.35713.d2] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 1.9] [Reference Citation Analysis]
|
| 558 |
Pamuk GE, Vural O, Turgut B, Demir M, Umit H, Tezel A. Increased circulating platelet-neutrophil, platelet-monocyte complexes, and platelet activation in patients with ulcerative colitis: a comparative study. Am J Hematol 2006;81:753-9. [PMID: 16941615 DOI: 10.1002/ajh.20655] [Cited by in Crossref: 51] [Cited by in F6Publishing: 53] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 559 |
Rubio Terrés C, Obrador A, Hinojosa J. Impacto presupuestario del tratamiento de la colitis ulcerosa con dos especialidades de mesalazina equivalentes terapéuticos (Estudio COSTECU). Pharmacoecon Span Res Artic 2006;3:163-171. [DOI: 10.1007/bf03320919] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 560 |
Sakimura K, Omori T, Iwashita E, Yoshida T, Tsuzuki Y, Fujimori K, Konishi F, Yoshida Y, Anzai H, Suzuki H, Sugawara S, Takeda Y, Hiraishi K, Saniabadi AR, Ide T, Miura S, Ota S. Clinical response is associated with elevated plasma interleukin-1 receptor antagonist during selective granulocyte and monocyte apheresis in patients with ulcerative colitis. Dig Dis Sci 2006;51:1525-31. [PMID: 16902810 DOI: 10.1007/s10620-005-9012-1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 561 |
Muratov V, Lundahl J, Ulfgren AK, Elvin K, Fehrman I, Ahlborg N, Ost A, Hittel N, Saniabadi A, Löfberg R. Down-regulation of interferon-gamma parallels clinical response to selective leukocyte apheresis in patients with inflammatory bowel disease: a 12-month follow-up study. Int J Colorectal Dis 2006;21:493-504. [PMID: 16538495 DOI: 10.1007/s00384-005-0069-2] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 562 |
Joos S, Wildau N, Kohnen R, Szecsenyi J, Schuppan D, Willich SN, Hahn EG, Brinkhaus B. Acupuncture and moxibustion in the treatment of ulcerative colitis: a randomized controlled study. Scand J Gastroenterol 2006;41:1056-63. [PMID: 16938719 DOI: 10.1080/00365520600580688] [Cited by in Crossref: 64] [Cited by in F6Publishing: 70] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 563 |
Watanabe K, Oshitani N, Kamata N, Inagawa M, Yamagami H, Higuchi K, Arakawa T. Efficacy and endoscopic prediction of cytapheresis therapy in patients with refractory and steroid-dependent ulcerative colitis. Aliment Pharmacol Ther Symp Series 2006;2:147-52. [DOI: 10.1111/j.1746-6342.2006.00038.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 564 |
Hanai H, Iida T, Yamada M, Sato Y, Takeuchi K, Tanaka T, Kondo K, Kikuyama M, Maruyama Y, Iwaoka Y, Nakamura A, Hirayama K, Saniabadi AR, Watanabe F. Effects of adacolumn selective leukocytapheresis on plasma cytokines during active disease in patients with active ulcerative colitis. World J Gastroenterol 2006; 12(21): 3393-3399 [PMID: 16733857 DOI: 10.3748/wjg.v12.i21.3393] [Cited by in CrossRef: 37] [Cited by in F6Publishing: 40] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 565 |
Zocco MA, dal Verme LZ, Cremonini F, Piscaglia AC, Nista EC, Candelli M, Novi M, Rigante D, Cazzato IA, Ojetti V, Armuzzi A, Gasbarrini G, Gasbarrini A. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 2006;23:1567-74. [PMID: 16696804 DOI: 10.1111/j.1365-2036.2006.02927.x] [Cited by in Crossref: 321] [Cited by in F6Publishing: 329] [Article Influence: 18.9] [Reference Citation Analysis]
|
| 566 |
D'Ovidio V, Aratari A, Viscido A, Marcheggiano A, Papi C, Capurso L, Caprilli R. Mucosal features and granulocyte-monocyte-apheresis in steroid-dependent/refractory ulcerative colitis. Dig Liver Dis 2006;38:389-94. [PMID: 16569521 DOI: 10.1016/j.dld.2005.12.005] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 567 |
Fukunaga K, Fukuda Y, Yokoyama Y, Ohnishi K, Kusaka T, Kosaka T, Hida N, Ohda Y, Miwa H, Matsumoto T. Activated platelets as a possible early marker to predict clinical efficacy of leukocytapheresis in severe ulcerative colitis patients. J Gastroenterol 2006;41:524-32. [PMID: 16868799 DOI: 10.1007/s00535-006-1789-y] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 568 |
Yagi Y, Andoh A, Inatomi O, Bamba S, Tsujikawa T, Fujiyama Y, Mitsuyama K, Yoshida T. Modulation of platelet aggregation responses by leukocytapheresis therapy in patients with active ulcerative colitis. J Gastroenterol 2006;41:540-6. [PMID: 16868801 DOI: 10.1007/s00535-006-1797-y] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 569 |
Kruis W, Dignass A, Steinhagen-Thiessen E, Morgenstern J, Mössner J, Schreiber S, Vecchi M, Malesci A, Reinshagen M, Löfberg R. Open label trial of granulocyte apheresis suggests therapeutic efficacy in chronically active steroid refractory ulcerative colitis. World J Gastroenterol 2005;11:7001-6. [PMID: 16437606 DOI: 10.3748/wjg.v11.i44.7001] [Cited by in CrossRef: 41] [Cited by in F6Publishing: 43] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 570 |
Sutherland L, Macdonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2006;CD000543. [PMID: 16625536 DOI: 10.1002/14651858.cd000543.pub2] [Cited by in Crossref: 42] [Cited by in F6Publishing: 69] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 571 |
Kanai T, Hibi T, Watanabe M. The logics of leukocytapheresis as a natural biological therapy for inflammatory bowel disease. Expert Opinion on Biological Therapy 2006;6:453-66. [DOI: 10.1517/14712598.6.5.453] [Cited by in Crossref: 35] [Cited by in F6Publishing: 37] [Article Influence: 2.1] [Reference Citation Analysis]
|
| 572 |
Bergman R, Parkes M. Systematic review: the use of mesalazine in inflammatory bowel disease. Aliment Pharmacol Ther 2006;23:841-55. [PMID: 16573787 DOI: 10.1111/j.1365-2036.2006.02846.x] [Cited by in Crossref: 82] [Cited by in F6Publishing: 75] [Article Influence: 4.8] [Reference Citation Analysis]
|
| 573 |
Takahashi M, Nakamura K, Honda K, Kitamura Y, Mizutani T, Araki Y, Kabemura T, Chijiiwa Y, Harada N, Nawata H. An inverse correlation of human peripheral blood regulatory T cell frequency with the disease activity of ulcerative colitis. Dig Dis Sci 2006;51:677-86. [PMID: 16614988 DOI: 10.1007/s10620-006-3191-2] [Cited by in Crossref: 69] [Cited by in F6Publishing: 75] [Article Influence: 4.1] [Reference Citation Analysis]
|
| 574 |
Gibson PR, Fixa B, Pekárková B, Bátovský M, Radford-Smith G, Tibitanzl J, Gabalec L, Florin TH, Greinwald R. Comparison of the efficacy and safety of Eudragit-L-coated mesalazine tablets with ethylcellulose-coated mesalazine tablets in patients with mild to moderately active ulcerative colitis. Aliment Pharmacol Ther 2006;23:1017-26. [PMID: 16573804 DOI: 10.1111/j.1365-2036.2006.02861.x] [Cited by in Crossref: 38] [Cited by in F6Publishing: 29] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 575 |
Guslandi M, Petrone MC, Testoni PA. Rifaximin for active ulcerative colitis. Inflamm Bowel Dis 2006;12:335. [PMID: 16633057 DOI: 10.1097/01.MIB.0000215092.85116.6c] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 1.9] [Reference Citation Analysis]
|
| 576 |
Masson S, Nylander D, Mansfield JC. How important is onset of action in ulcerative colitis therapy? Drugs. 2005;65:2069-2083. [PMID: 16225364 DOI: 10.2165/00003495-200565150-00001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 577 |
Poulou AC, Goumas KE, Dandakis DC, Tyrmpas I, Panagiotaki M, Georgouli A, Soutos DC, Archimandritis A. Microproteinuria in patients with inflammatory bowel disease: Is it associated with the disease activity or the treatment with 5-aminosalicylic acid? World J Gastroenterol 2006; 12(5): 739-746 [PMID: 16521187 DOI: 10.3748/wjg.v12.i5.739] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 578 |
Gross V, Bar-Meir S, Lavy A, Mickisch O, Tulassay Z, Pronai L, Kupcinskas L, Kiudelis G, Pokrotnieks J, Kovács A, Faszczyk M, Razbadauskas A, Margus B, Stolte M, Müller R, Greinwald R; International Budesonide Foam Study Group. Budesonide foam versus budesonide enema in active ulcerative proctitis and proctosigmoiditis. Aliment Pharmacol Ther 2006;23:303-12. [PMID: 16393311 DOI: 10.1111/j.1365-2036.2006.02743.x] [Cited by in Crossref: 68] [Cited by in F6Publishing: 63] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 579 |
Andoh A, Tsujikawa T, Inatomi O, Deguchi Y, Hata K, Kitoh K, Sasaki M, Mitsuyama K, Fujiyama Y. Suppression of inflammatory cytokine secretion by granulocyte/monocyte adsorptive apheresis in active ulcerative colitis. Ther Apher Dial. 2005;9:123-127. [PMID: 15828923 DOI: 10.1111/j.1774-9987.2005.00229.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 580 |
Stark R, K??nig H, Leidl R. Costs of Inflammatory Bowel Disease in Germany: . PharmacoEconomics 2006;24:797-814. [DOI: 10.2165/00019053-200624080-00006] [Cited by in Crossref: 86] [Cited by in F6Publishing: 92] [Article Influence: 5.1] [Reference Citation Analysis]
|
| 581 |
Ikeda M, Takeshima F, Ohba K, Ohnita K, Isomoto H, Yamakawa M, Omagari K, Mizuta Y, Kohno S. Flow cytometric analysis of expression of transforming growth factor-beta and glucocorticoid-induced tumor necrosis factor receptor on CD4(+) CD25(+) T cells of patients with inflammatory bowel disease. Dig Dis Sci 2006;51:178-84. [PMID: 16416233 DOI: 10.1007/s10620-006-3105-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 582 |
Andoh A, Yoshida T, Yagi Y, Bamba S, Hata K, Tsujikawa T, Kitoh K, Sasaki M, Fujiyama Y. Increased aggregation response of platelets in patients with inflammatory bowel disease. J Gastroenterol 2006;41:47-54. [PMID: 16501857 DOI: 10.1007/s00535-005-1721-x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 2.1] [Reference Citation Analysis]
|
| 583 |
Saniabadi AR, Hanai H, Suzuki Y, Ohmori T, Sawada K, Yoshimura N, Saito Y, Takeda Y, Umemura K, Kondo K, Ikeda Y, Fukunaga K, Nakashima M, Beretta A, Bjarnason I, Lofberg R. Adacolumn for selective leukocytapheresis as a non-pharmacological treatment for patients with disorders of the immune system: an adjunct or an alternative to drug therapy? J Clin Apher. 2005;20:171-184. [PMID: 15892107 DOI: 10.1002/jca.20046] [Cited by in Crossref: 78] [Cited by in F6Publishing: 86] [Article Influence: 4.3] [Reference Citation Analysis]
|
| 584 |
Elsenbruch S, Langhorst J, Popkirowa K, Müller T, Luedtke R, Franken U, Paul A, Spahn G, Michalsen A, Janssen OE, Schedlowski M, Dobos GJ. Effects of mind-body therapy on quality of life and neuroendocrine and cellular immune functions in patients with ulcerative colitis. Psychother Psychosom 2005;74:277-87. [PMID: 16088265 DOI: 10.1159/000086318] [Cited by in Crossref: 115] [Cited by in F6Publishing: 121] [Article Influence: 6.4] [Reference Citation Analysis]
|
| 585 |
Makiyama K, Takeshima F, Hamamoto T. Efficacy of rebamipide enemas in active distal ulcerative colitis and proctitis: a prospective study report. Dig Dis Sci 2005;50:2323-9. [PMID: 16416182 DOI: 10.1007/s10620-005-3055-1] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 586 |
Langhorst J, Elsenbruch S, Mueller T, Rueffer A, Spahn G, Michalsen A, Dobos GJ. Comparison of 4 neutrophil-derived proteins in feces as indicators of disease activity in ulcerative colitis. Inflamm Bowel Dis 2005;11:1085-91. [PMID: 16306771 DOI: 10.1097/01.mib.0000187980.08686.18] [Cited by in Crossref: 95] [Cited by in F6Publishing: 91] [Article Influence: 5.3] [Reference Citation Analysis]
|
| 587 |
Schröder O, Mickisch O, Seidler U, de Weerth A, Dignass AU, Herfarth H, Reinshagen M, Schreiber S, Junge U, Schrott M, Stein J. Intravenous iron sucrose versus oral iron supplementation for the treatment of iron deficiency anemia in patients with inflammatory bowel disease--a randomized, controlled, open-label, multicenter study. Am J Gastroenterol 2005;100:2503-9. [PMID: 16279906 DOI: 10.1111/j.1572-0241.2005.00250.x] [Cited by in Crossref: 150] [Cited by in F6Publishing: 164] [Article Influence: 8.3] [Reference Citation Analysis]
|
| 588 |
Sands BE, Abreu MT, Ferry GD, Griffiths AM, Hanauer SB, Isaacs KL, Lewis JD, Sandborn WJ, Steinhart AH. Design issues and outcomes in IBD clinical trials. Inflamm Bowel Dis 2005;11 Suppl 1:S22-8. [PMID: 16254479 DOI: 10.1097/01.mib.0000184849.38816.39] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 589 |
Miyata M, Kasugai K, Ishikawa T, Kakumu S, Onishi M, Mori T. Rebamipide enemas-new effective treatment for patients with corticosteroid dependent or resistant ulcerative colitis. Dig Dis Sci 2005;50 Suppl 1:S119-23. [PMID: 16184413 DOI: 10.1007/s10620-005-2816-1] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 590 |
Teml A, Schwab M, Harrer M, Miehsler W, Schaeffeler E, Dejaco C, Mantl M, Schneider B, Vogelsang H, Reinisch W. A prospective, open-label trial of 6-thioguanine in patients with ulcerative or indeterminate colitis. Scand J Gastroenterol 2005;40:1205-13. [PMID: 16265777 DOI: 10.1080/00365520510023369] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 591 |
Nishioka C, Aoyama N, Maekawa S, Shirasaka D, Nakahara T, Tamura T, Fukagawa M, Umezu M, Abe T, Kasuga M. Leukocytapheresis therapy for steroid-naïve patients with active ulcerative colitis: its clinical efficacy and adverse effects compared with those of conventional steroid therapy. J Gastroenterol Hepatol 2005;20:1567-71. [PMID: 16174075 DOI: 10.1111/j.1440-1746.2005.03907.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 592 |
Andoh A, Zhang Z, Inatomi O, Fujino S, Deguchi Y, Araki Y, Tsujikawa T, Kitoh K, Kim-Mitsuyama S, Takayanagi A, Shimizu N, Fujiyama Y. Interleukin-22, a member of the IL-10 subfamily, induces inflammatory responses in colonic subepithelial myofibroblasts. Gastroenterology 2005;129:969-84. [PMID: 16143135 DOI: 10.1053/j.gastro.2005.06.071] [Cited by in Crossref: 361] [Cited by in F6Publishing: 382] [Article Influence: 20.1] [Reference Citation Analysis]
|
| 593 |
Andoh A, Tsujikawa T, Hata K, Araki Y, Kitoh K, Sasaki M, Yoshida T, Fujiyama Y. Elevated circulating platelet-derived microparticles in patients with active inflammatory bowel disease. Am J Gastroenterol 2005;100:2042-8. [PMID: 16128950 DOI: 10.1111/j.1572-0241.2005.50381.x] [Cited by in Crossref: 51] [Cited by in F6Publishing: 51] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 594 |
Costello CM, Mah N, Häsler R, Rosenstiel P, Waetzig GH, Hahn A, Lu T, Gurbuz Y, Nikolaus S, Albrecht M, Hampe J, Lucius R, Klöppel G, Eickhoff H, Lehrach H, Lengauer T, Schreiber S. Dissection of the inflammatory bowel disease transcriptome using genome-wide cDNA microarrays. PLoS Med 2005;2:e199. [PMID: 16107186 DOI: 10.1371/journal.pmed.0020199] [Cited by in Crossref: 147] [Cited by in F6Publishing: 159] [Article Influence: 8.2] [Reference Citation Analysis]
|
| 595 |
Di Sabatino A, Rosado MM, Ciccocioppo R, Cazzola P, Morera R, Corazza GR, Carsetti R. Depletion of immunoglobulin M memory B cells is associated with splenic hypofunction in inflammatory bowel disease. Am J Gastroenterol 2005;100:1788-95. [PMID: 16086716 DOI: 10.1111/j.1572-0241.2005.41939.x] [Cited by in Crossref: 77] [Cited by in F6Publishing: 78] [Article Influence: 4.3] [Reference Citation Analysis]
|
| 596 |
Stremmel W, Merle U, Zahn A, Autschbach F, Hinz U, Ehehalt R. Retarded release phosphatidylcholine benefits patients with chronic active ulcerative colitis. Gut 2005;54:966-71. [PMID: 15951544 DOI: 10.1136/gut.2004.052316] [Cited by in Crossref: 118] [Cited by in F6Publishing: 126] [Article Influence: 6.6] [Reference Citation Analysis]
|
| 597 |
Häuser W, Stallmach A, Kocalevent RD, Rose M, Fliege H. Biopsychosocial predictors of fatigue in quiescent and mild ulcerative colitis - an explorative study. Psychosoc Med 2005;2:Doc07. [PMID: 19742065] [Reference Citation Analysis]
|
| 598 |
Sawada K, Kusugami K, Suzuki Y, Bamba T, Munakata A, Hibi T, Shimoyama T. Leukocytapheresis in ulcerative colitis: results of a multicenter double-blind prospective case-control study with sham apheresis as placebo treatment. Am J Gastroenterol 2005;100:1362-9. [PMID: 15929771 DOI: 10.1111/j.1572-0241.2005.41089.x] [Cited by in Crossref: 103] [Cited by in F6Publishing: 101] [Article Influence: 5.7] [Reference Citation Analysis]
|
| 599 |
Andoh A, Tsujikawa T, Inatomi O, Deguchi Y, Sasaki M, Obata H, Mitsuyama K, Fujiyama Y. Leukocytapheresis Therapy Modulates Circulating T cell Subsets in Patients With Ulcerative Colitis. Therapher Dial 2005;9:270-6. [DOI: 10.1111/j.1774-9987.2005.00270.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 600 |
Hanai H, Iida T, Takeuchi K, Watanabe F, Maruyama Y, Kikuyama M, Tanaka T, Kondo K, Tanaka K, Takai K. Decrease of reactive-oxygen-producing granulocytes and release of IL-10 into the peripheral blood following leukocytapheresis in patients with active ulcerative colitis. World J Gastroenterol 2005; 11(20): 3085-3090 [PMID: 15918195 DOI: 10.3748/wjg.v11.i20.3085] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 22] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 601 |
Häuser W, Janke KH, Stallmach A. Mental disorder and psychologic distress in patients with ulcerative colitis after ileal pouch-anal anastomosis. Dis Colon Rectum 2005;48:952-62. [PMID: 15785887 DOI: 10.1007/s10350-004-0888-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 602 |
Casellas F, Arenas JI, Baudet JS, Fábregas S, García N, Gelabert J, Medina C, Ochotorena I, Papo M, Rodrigo L, Malagelada JR. Impairment of health-related quality of life in patients with inflammatory bowel disease: a Spanish multicenter study. Inflamm Bowel Dis 2005;11:488-96. [PMID: 15867589 DOI: 10.1097/01.mib.0000159661.55028.56] [Cited by in Crossref: 194] [Cited by in F6Publishing: 158] [Article Influence: 10.8] [Reference Citation Analysis]
|
| 603 |
Yamamoto T, Umegae S, Kitagawa T, Matsumoto K. Intraperitoneal cytokine productions and their relationship to peritoneal sepsis and systemic inflammatory markers in patients with inflammatory bowel disease. Dis Colon Rectum 2005;48:1005-15. [PMID: 15785898 DOI: 10.1007/s10350-004-0866-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 604 |
Prantera C, Viscido A, Biancone L, Francavilla A, Giglio L, Campieri M. A new oral delivery system for 5-ASA: preliminary clinical findings for MMx. Inflamm Bowel Dis 2005;11:421-7. [PMID: 15867580 DOI: 10.1097/01.mib.0000158386.25660.1e] [Cited by in Crossref: 108] [Cited by in F6Publishing: 100] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 605 |
Moschen AR, Kaser A, Enrich B, Ludwiczek O, Gabriel M, Obrist P, Wolf AM, Tilg H. The RANKL/OPG system is activated in inflammatory bowel disease and relates to the state of bone loss. Gut 2005;54:479-87. [PMID: 15753532 DOI: 10.1136/gut.2004.044370] [Cited by in Crossref: 169] [Cited by in F6Publishing: 173] [Article Influence: 9.4] [Reference Citation Analysis]
|
| 606 |
Sawada K, Egashira A, Ohnishi K, Fukunaga K, Kusaka T, Shimoyama T. Leukocytapheresis (LCAP) for management of fulminant ulcerative colitis with toxic megacolon. Dig Dis Sci 2005;50:767-73. [PMID: 15844716 DOI: 10.1007/s10620-005-2571-3] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 607 |
Zhang H, Ouyang Q, Wen ZH, Fiocchi C, Liu WP, Chen DY, Li FY. Significance of glucocorticoid receptor expression in colonic mucosal cells of patients with ulcerative colitis. World J Gastroenterol 2005; 11(12): 1775-1778 [PMID: 15793862 DOI: 10.3748/wjg.v11.i12.1775] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 608 |
Janke KH, Klump B, Gregor M, Meisner C, Haeuser W. Determinants of life satisfaction in inflammatory bowel disease. Inflamm Bowel Dis 2005;11:272-86. [PMID: 15735434 DOI: 10.1097/01.mib.0000160809.38611.f7] [Cited by in Crossref: 94] [Cited by in F6Publishing: 79] [Article Influence: 5.2] [Reference Citation Analysis]
|
| 609 |
Costa F, Mumolo MG, Ceccarelli L, Bellini M, Romano MR, Sterpi C, Ricchiuti A, Marchi S, Bottai M. Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease. Gut 2005;54:364-8. [PMID: 15710984 DOI: 10.1136/gut.2004.043406] [Cited by in Crossref: 383] [Cited by in F6Publishing: 417] [Article Influence: 21.3] [Reference Citation Analysis]
|
| 610 |
Marakhouski Y, Fixa B, Holomán J, Hulek P, Lukas M, Bátovský M, Rumyantsev VG, Grigoryeva G, Stolte M, Vieth M, Greinwald R; International Salofalk Study Group. A double-blind dose-escalating trial comparing novel mesalazine pellets with mesalazine tablets in active ulcerative colitis. Aliment Pharmacol Ther 2005;21:133-40. [PMID: 15679762 DOI: 10.1111/j.1365-2036.2005.02312.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 26] [Article Influence: 1.9] [Reference Citation Analysis]
|
| 611 |
Ludwiczek O, Vannier E, Borggraefe I, Kaser A, Siegmund B, Dinarello CA, Tilg H. Imbalance between interleukin-1 agonists and antagonists: relationship to severity of inflammatory bowel disease. Clin Exp Immunol. 2004;138:323-329. [PMID: 15498044 DOI: 10.1111/j.1365-2249.2004.02599.x] [Cited by in Crossref: 93] [Cited by in F6Publishing: 99] [Article Influence: 4.9] [Reference Citation Analysis]
|
| 612 |
Domènech E, Hinojosa J, Esteve-Comas M, Gomollón F, Herrera JM, Bastida G, Obrador A, Ruiz R, Saro C, Gassull MA; Spanish Group for the Study of Crohn's Disease and Ulcerative Colitis (GETECCU). Granulocyteaphaeresis in steroid-dependent inflammatory bowel disease: a prospective, open, pilot study. Aliment Pharmacol Ther 2004;20:1347-52. [PMID: 15606397 DOI: 10.1111/j.1365-2036.2004.02288.x] [Cited by in Crossref: 90] [Cited by in F6Publishing: 74] [Article Influence: 4.7] [Reference Citation Analysis]
|
| 613 |
Raedler A, Behrens C, Bias P. Mesalazine (5-aminosalicylic acid) micropellets show similar efficacy and tolerability to mesalazine tablets in patients with ulcerative colitis--results from a randomized-controlled trial. Aliment Pharmacol Ther 2004;20:1353-63. [PMID: 15606398 DOI: 10.1111/j.1365-2036.2004.02282.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 614 |
Nakamura T, Kawagoe Y, Matsuda T, Ueda A, Ueda Y, Takahashi Y, Tanaka A, Koide H. Effect of granulocyte and monocyte adsorption apheresis on urinary albumin excretion and plasma endothelin-1 concentration in patients with active ulcerative colitis. Blood Purif 2004;22:499-504. [PMID: 15528877 DOI: 10.1159/000081896] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 615 |
Mussell M, Böcker U, Nagel N, Singer MV. Predictors of disease-related concerns and other aspects of health-related quality of life in outpatients with inflammatory bowel disease. Eur J Gastroenterol Hepatol 2004;16:1273-80. [PMID: 15618832 DOI: 10.1097/00042737-200412000-00007] [Cited by in Crossref: 84] [Cited by in F6Publishing: 78] [Article Influence: 4.4] [Reference Citation Analysis]
|
| 616 |
Kruis W, Fric P, Pokrotnieks J, Lukás M, Fixa B, Kascák M, Kamm MA, Weismueller J, Beglinger C, Stolte M, Wolff C, Schulze J. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 2004;53:1617-23. [PMID: 15479682 DOI: 10.1136/gut.2003.037747] [Cited by in Crossref: 851] [Cited by in F6Publishing: 871] [Article Influence: 44.8] [Reference Citation Analysis]
|
| 617 |
Menchén L, Colón AL, Madrigal JL, Beltrán L, Botella S, Lizasoain I, Leza JC, Moro MA, Menchén P, Cos E, Lorenzo P. Activity of inducible and neuronal nitric oxide synthases in colonic mucosa predicts progression of ulcerative colitis. Am J Gastroenterol 2004;99:1756-64. [PMID: 15330915 DOI: 10.1111/j.1572-0241.2004.40065.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 618 |
Miehsler W, Weichselberger M, Offerlbauer-Ernst A, Dejaco C, Reinisch W, Vogelsang H, Machold K, Stamm T, Gangl A, Moser G. Assessing the demand for psychological care in chronic diseases: development and validation of a questionnaire based on the example of inflammatory bowel disease. Inflamm Bowel Dis 2004;10:637-45. [PMID: 15472527 DOI: 10.1097/00054725-200409000-00021] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 619 |
Hanai H, Takeuchi K, Iida T, Kashiwagi N, Saniabadi AR, Matsushita I, Sato Y, Kasuga N, Nakamura T. Relationship between fecal calprotectin, intestinal inflammation, and peripheral blood neutrophils in patients with active ulcerative colitis. Dig Dis Sci 2004;49:1438-43. [PMID: 15481316 DOI: 10.1023/b:ddas.0000042243.47279.87] [Cited by in Crossref: 86] [Cited by in F6Publishing: 77] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 620 |
Maunder RG, Greenberg GR. Comparison of a disease activity index and patients' self-reported symptom severity in ulcerative colitis. Inflamm Bowel Dis 2004;10:632-6. [PMID: 15472526 DOI: 10.1097/00054725-200409000-00020] [Cited by in Crossref: 23] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 621 |
Casellas F, Antolín M, Varela E, García-Lafuente A, Guarner F, Borruel N, Armengol Miró JR, Malagelada JR. Fecal excretion of human deoxyribonucleic acid as an index of inflammatory activity in ulcerative colitis. Clin Gastroenterol Hepatol 2004;2:683-9. [PMID: 15290661 DOI: 10.1016/s1542-3565(04)00291-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 622 |
Hanai H, Watanabe F, Yamada M, Sato Y, Takeuchi K, Iida T, Tozawa K, Tanaka T, Maruyama Y, Matsushita I, Iwaoka Y, Saniabadi A. Correlation of serum soluble TNF-alpha receptors I and II levels with disease activity in patients with ulcerative colitis. Am J Gastroenterol 2004;99:1532-8. [PMID: 15307873 DOI: 10.1111/j.1572-0241.2004.30432.x] [Cited by in Crossref: 60] [Cited by in F6Publishing: 61] [Article Influence: 3.2] [Reference Citation Analysis]
|
| 623 |
Papa A, Pola R, Flex A, Danese S, Armuzzi A, Gaetani E, Guidi L, De Vitis I, Urgesi R, Grillo A, Serricchio M, Proia AS, Fedeli G, Gasbarrini G, Pola P, Gasbarrini A. Prevalence of the K469E polymorphism of intercellular adhesion molecule 1 gene in Italian patients with inflammatory bowel disease. Dig Liver Dis 2004;36:528-32. [PMID: 15334773 DOI: 10.1016/j.dld.2004.03.015] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 624 |
Alcalá MJ, Casellas F, Fontanet G, Prieto L, Malagelada JR. Shortened questionnaire on quality of life for inflammatory bowel disease. Inflamm Bowel Dis 2004;10:383-91. [PMID: 15475746 DOI: 10.1097/00054725-200407000-00009] [Cited by in Crossref: 44] [Cited by in F6Publishing: 34] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 625 |
Janke KH, Raible A, Bauer M, Clemens P, Meisner C, Häuser W, Steder-Neukamm U, Henrich G, Herschbach P, Gregor M, Klump B. Questions on life satisfaction (FLZM) in inflammatory bowel disease. Int J Colorectal Dis 2004;19:343-53. [PMID: 14586630 DOI: 10.1007/s00384-003-0522-z] [Cited by in Crossref: 50] [Cited by in F6Publishing: 55] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 626 |
Pascu M, Roznowski AB, Müller HP, Adler A, Wiedenmann B, Dignass AU. Clinical relevance of transabdominal ultrasonography and magnetic resonance imaging in patients with inflammatory bowel disease of the terminal ileum and large bowel. Inflamm Bowel Dis 2004;10:373-82. [PMID: 15475745 DOI: 10.1097/00054725-200407000-00008] [Cited by in Crossref: 90] [Cited by in F6Publishing: 72] [Article Influence: 4.7] [Reference Citation Analysis]
|
| 627 |
Novacek G, Haumer M, Schima W, Müller C, Miehsler W, Polterauer P, Vogelsang H. Aortic mural thrombi in patients with inflammatory bowel disease: report of two cases and review of the literature. Inflamm Bowel Dis 2004;10:430-5. [PMID: 15475753 DOI: 10.1097/00054725-200407000-00016] [Cited by in Crossref: 49] [Cited by in F6Publishing: 42] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 628 |
Canani RB, Romano MT, Greco L, Terrin G, Sferlazzas C, Barabino A, Fontana M, Roggero P, Guariso G, De Angelis G, Fecarotta S, Polito G, Cucchiara S. Effects of disease activity on anti-Saccharomyces cerevisiae antibodies: implications for diagnosis and follow-up of children with Crohn's disease. Inflamm Bowel Dis 2004;10:234-9. [PMID: 15290917 DOI: 10.1097/00054725-200405000-00009] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 629 |
Pallis AG, Mouzas IA, Vlachonikolis IG. The inflammatory bowel disease questionnaire: a review of its national validation studies. Inflamm Bowel Dis 2004;10:261-9. [PMID: 15290922 DOI: 10.1097/00054725-200405000-00014] [Cited by in Crossref: 55] [Cited by in F6Publishing: 45] [Article Influence: 2.9] [Reference Citation Analysis]
|
| 630 |
Suzuki Y, Yoshimura N, Saniabadi AR, Saito Y. Selective granulocyte and monocyte adsorptive apheresis as a first-line treatment for steroid naïve patients with active ulcerative colitis: a prospective uncontrolled study. Dig Dis Sci 2004;49:565-71. [PMID: 15185858 DOI: 10.1023/b:ddas.0000026299.43792.ae] [Cited by in Crossref: 117] [Cited by in F6Publishing: 97] [Article Influence: 6.2] [Reference Citation Analysis]
|
| 631 |
Tuzun A, Uygun A, Yesilova Z, Ozel AM, Erdil A, Yaman H, Bagci S, Gulsen M, Karaeren N, Dagalp K. Leptin levels in the acute stage of ulcerative colitis. J Gastroenterol Hepatol 2004;19:429-32. [PMID: 15012781 DOI: 10.1111/j.1440-1746.2003.03300.x] [Cited by in Crossref: 58] [Cited by in F6Publishing: 62] [Article Influence: 3.1] [Reference Citation Analysis]
|
| 632 |
Sato S, Oka M, Noguchi Y, Soda H, Tsurutani J, Nakamura Y, Kitazaki T, Mizuta Y, Takeshima F, Murase K, Murata I, Ohtsuka K, Kohno S. Autoimmunity to Heat Shock Protein 40 in Ulcerative Colitis. J Int Med Res 2004;32:141-8. [DOI: 10.1177/147323000403200206] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 633 |
Casellas F, Alcalá MJ, Prieto L, Miró JR, Malagelada JR. Assessment of the influence of disease activity on the quality of life of patients with inflammatory bowel disease using a short questionnaire. Am J Gastroenterol 2004;99:457-61. [PMID: 15056085 DOI: 10.1111/j.1572-0241.2004.04071.x] [Cited by in Crossref: 47] [Cited by in F6Publishing: 47] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 634 |
Ebinger M, Leidl R, Thomas S, Von Tirpitz C, Reinshagen M, Adler G, Konig HH. Cost of outpatient care in patients with inflammatory bowel disease in a German University Hospital. J Gastroenterol Hepatol 2004;19:192-9. [PMID: 14731130 DOI: 10.1111/j.1440-1746.2004.03251.x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 37] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 635 |
Loftus EV Jr, Kane SV, Bjorkman D. Systematic review: short-term adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitis. Aliment Pharmacol Ther 2004;19:179-89. [PMID: 14723609 DOI: 10.1111/j.0269-2813.2004.01827.x] [Cited by in Crossref: 135] [Cited by in F6Publishing: 115] [Article Influence: 7.1] [Reference Citation Analysis]
|
| 636 |
Mittermaier C, Dejaco C, Waldhoer T, Oefferlbauer-Ernst A, Miehsler W, Beier M, Tillinger W, Gangl A, Moser G. Impact of depressive mood on relapse in patients with inflammatory bowel disease: a prospective 18-month follow-up study. Psychosom Med 2004;66:79-84. [PMID: 14747641 DOI: 10.1097/01.psy.0000106907.24881.f2] [Cited by in Crossref: 367] [Cited by in F6Publishing: 390] [Article Influence: 19.3] [Reference Citation Analysis]
|
| 637 |
Suzuki Y, Yoshimura N, Saitoh Y, Saniabadi AR. Granulocyte and monocyte adsorptive apheresis in a case with severe ulcerative colitis unresponsive to conventional medication. J Clin Apher 2003;18:40-2. [PMID: 12717793 DOI: 10.1002/jca.10048] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 638 |
Tilg H, Vogelsang H, Ludwiczek O, Lochs H, Kaser A, Colombel JF, Ulmer H, Rutgeerts P, Krüger S, Cortot A, D'Haens G, Harrer M, Gasche C, Wrba F, Kuhn I, Reinisch W. A randomised placebo controlled trial of pegylated interferon alpha in active ulcerative colitis. Gut 2003;52:1728-33. [PMID: 14633951 DOI: 10.1136/gut.52.12.1728] [Cited by in Crossref: 64] [Cited by in F6Publishing: 73] [Article Influence: 3.2] [Reference Citation Analysis]
|
| 639 |
Sakata H, Kawamura N, Horie T, Ohizumi H, Tamaki T, Kukita K, Meguro J, Yonekawa M, Saitoh M, Kawamura A. Successful Treatment of Ulcerative Colitis with Leukocytapheresis Using Non-woven Polyester Filter. Therapher Dial 2003;7:536-9. [DOI: 10.1046/j.1526-0968.2003.00096.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 640 |
Fliege H, Drandarevski A, Klapp BF, Rose M. Fragebogen zu Ursachenannahmen bei Patienten mit chronisch entzündlichen Darmerkrankungen (URS-CED). Zeitschrift für Klinische Psychologie und Psychotherapie 2003;32:276-85. [DOI: 10.1026/0084-5345.32.4.276] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 641 |
Tamboli CP, Caucheteux C, Cortot A, Colombel JF, Desreumaux P. Probiotics in inflammatory bowel disease: a critical review. Best Pract Res Clin Gastroenterol 2003;17:805-20. [PMID: 14507590 DOI: 10.1016/s1521-6918(03)00076-3] [Cited by in Crossref: 52] [Cited by in F6Publishing: 52] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 642 |
Sutherland L, MacDonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2003;:CD000543. [PMID: 12917894 DOI: 10.1002/14651858.CD000543] [Cited by in Crossref: 22] [Cited by in F6Publishing: 41] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 643 |
Costa F, Mumolo MG, Bellini M, Romano MR, Ceccarelli L, Arpe P, Sterpi C, Marchi S, Maltinti G. Role of faecal calprotectin as non-invasive marker of intestinal inflammation. Dig Liver Dis 2003;35:642-7. [PMID: 14563186 DOI: 10.1016/s1590-8658(03)00381-5] [Cited by in Crossref: 199] [Cited by in F6Publishing: 204] [Article Influence: 10.0] [Reference Citation Analysis]
|
| 644 |
Kapsoritakis A, Sfiridaki A, Maltezos E, Simopoulos K, Giatromanolaki A, Sivridis E, Koukourakis MI. Vascular endothelial growth factor in inflammatory bowel disease. Int J Colorectal Dis 2003;18:418-22. [PMID: 12761641 DOI: 10.1007/s00384-003-0495-y] [Cited by in Crossref: 48] [Cited by in F6Publishing: 50] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 645 |
Campieri M, Adamo S, Valpiani D, D'Arienzo A, D'Albasio G, Pitzalis M, Cesari P, Casetti T, Castiglione GN, Rizzello F, Manguso F, Varoli G, Gionchetti P. Oral beclometasone dipropionate in the treatment of extensive and left-sided active ulcerative colitis: a multicentre randomised study. Aliment Pharmacol Ther 2003;17:1471-80. [PMID: 12823149 DOI: 10.1046/j.1365-2036.2003.01609.x] [Cited by in Crossref: 80] [Cited by in F6Publishing: 80] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 646 |
Reinisch W, Miehsler W, Dejaco C, Harrer M, Waldhoer T, Lichtenberger C, Vogelsang H. An open-label trial of the selective cyclo-oxygenase-2 inhibitor, rofecoxib, in inflammatory bowel disease-associated peripheral arthritis and arthralgia. Aliment Pharmacol Ther 2003;17:1371-80. [PMID: 12786631 DOI: 10.1046/j.1365-2036.2003.01596.x] [Cited by in Crossref: 56] [Cited by in F6Publishing: 58] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 647 |
Foell D, Kucharzik T, Kraft M, Vogl T, Sorg C, Domschke W, Roth J. Neutrophil derived human S100A12 (EN-RAGE) is strongly expressed during chronic active inflammatory bowel disease. Gut 2003;52:847-53. [PMID: 12740341 DOI: 10.1136/gut.52.6.847] [Cited by in Crossref: 201] [Cited by in F6Publishing: 215] [Article Influence: 10.1] [Reference Citation Analysis]
|
| 648 |
Vecchi M, Saibeni S, Devani M, Rondonotti E, De Franchis R. Review article: diagnosis, monitoring and treatment of distal colitis. Aliment Pharmacol Ther 2003;17 Suppl 2:2-6. [PMID: 12786605 DOI: 10.1046/j.1365-2036.17.s2.3.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 649 |
Kiesslich R, Fritsch J, Holtmann M, Koehler HH, Stolte M, Kanzler S, Nafe B, Jung M, Galle PR, Neurath MF. Methylene blue-aided chromoendoscopy for the detection of intraepithelial neoplasia and colon cancer in ulcerative colitis. Gastroenterology 2003;124:880-8. [PMID: 12671882 DOI: 10.1053/gast.2003.50146] [Cited by in Crossref: 616] [Cited by in F6Publishing: 645] [Article Influence: 30.8] [Reference Citation Analysis]
|
| 650 |
Kayaalp C, Nessar G, Akoglu M, Atalay F. Elimination of mucosectomy during restorative proctocolectomy in patients with ulcerative colitis may provide better results in low-volume centers. Am J Surg 2003;185:268-72. [PMID: 12620569 DOI: 10.1016/s0002-9610(02)01376-4] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 651 |
Schroeder KW. Role of mesalazine in acute and long-term treatment of ulcerative colitis and its complications. Scand J Gastroenterol Suppl 2002;:42-7. [PMID: 12408503 DOI: 10.1080/003655202320621445] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 652 |
Andus T, Klebl F, Rogler G, Bregenzer N, Schölmerich J, Straub RH. Patients with refractory Crohn's disease or ulcerative colitis respond to dehydroepiandrosterone: a pilot study. Aliment Pharmacol Ther 2003;17:409-14. [PMID: 12562454 DOI: 10.1046/j.1365-2036.2003.01433.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 653 |
Van Assche G, Dalle I, Noman M, Aerden I, Swijsen C, Asnong K, Maes B, Ceuppens J, Geboes K, Rutgeerts P. A pilot study on the use of the humanized anti-interleukin-2 receptor antibody daclizumab in active ulcerative colitis. Am J Gastroenterol 2003;98:369-76. [PMID: 12591057 DOI: 10.1111/j.1572-0241.2003.07239.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 29] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 654 |
Saniabadi AR, Hanai H, Takeuchi K, Umemura K, Nakashima M, Adachi T, Shima C, Bjarnason I, Lofberg R. Adacolumn, an adsorptive carrier based granulocyte and monocyte apheresis device for the treatment of inflammatory and refractory diseases associated with leukocytes. Ther Apher Dial 2003;7:48-59. [PMID: 12921115 DOI: 10.1046/j.1526-0968.2003.00012.x] [Cited by in Crossref: 198] [Cited by in F6Publishing: 209] [Article Influence: 9.9] [Reference Citation Analysis]
|
| 655 |
Saibeni S, Cattaneo M, Vecchi M, Zighetti ML, Lecchi A, Lombardi R, Meucci G, Spina L, de Franchis R. Low vitamin B(6) plasma levels, a risk factor for thrombosis, in inflammatory bowel disease: role of inflammation and correlation with acute phase reactants. Am J Gastroenterol 2003;98:112-7. [PMID: 12526945 DOI: 10.1111/j.1572-0241.2003.07160.x] [Cited by in Crossref: 119] [Cited by in F6Publishing: 122] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 656 |
Kruis W, Bar-Meir S, Feher J, Mickisch O, Mlitz H, Faszczyk M, Chowers Y, Lengyele G, Kovacs A, Lakatos L, Stolte M, Vieth M, Greinwald R. The optimal dose of 5-aminosalicylic acid in active ulcerative colitis: a dose-finding study with newly developed mesalamine. Clin Gastroenterol Hepatol 2003;1:36-43. [PMID: 15017515 DOI: 10.1053/jcgh.2003.50006] [Cited by in Crossref: 86] [Cited by in F6Publishing: 90] [Article Influence: 4.3] [Reference Citation Analysis]
|
| 657 |
Sandborn WJ. Medical management of ulcerative colitis. Inflammatory Bowel Disease: From Bench to Bedside 2003. [DOI: 10.1007/978-1-4020-3477-0_30] [Reference Citation Analysis]
|
| 658 |
Escher JC, Taminiau JA, Nieuwenhuis EE, Büller HA, Grand RJ. Treatment of inflammatory bowel disease in childhood: best available evidence. Inflamm Bowel Dis 2003;9:34-58. [PMID: 12656136 DOI: 10.1097/00054725-200301000-00006] [Cited by in Crossref: 93] [Cited by in F6Publishing: 98] [Article Influence: 4.7] [Reference Citation Analysis]
|
| 659 |
Casellas F, López-Vivancos J, Casado A, Malagelada JR. Factors affecting health related quality of life of patients with inflammatory bowel disease. Qual Life Res 2002;11:775-81. [PMID: 12482161 DOI: 10.1023/a:1020841601110] [Cited by in Crossref: 138] [Cited by in F6Publishing: 145] [Article Influence: 6.6] [Reference Citation Analysis]
|
| 660 |
Winterkamp S, Weidenhiller M, Otte P, Stolper J, Schwab D, Hahn EG, Raithel M. Urinary excretion of N-methylhistamine as a marker of disease activity in inflammatory bowel disease. Am J Gastroenterol 2002;97:3071-7. [PMID: 12492192 DOI: 10.1111/j.1572-0241.2002.07028.x] [Cited by in Crossref: 68] [Cited by in F6Publishing: 71] [Article Influence: 3.2] [Reference Citation Analysis]
|
| 661 |
Xiao Li F, Sutherland LR. Assessing disease activity and disease activity indices for inflammatory bowel disease. Curr Gastroenterol Rep 2002;4:490-6. [PMID: 12441039 DOI: 10.1007/s11894-002-0025-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 662 |
König HH, Ulshöfer A, Gregor M, von Tirpitz C, Reinshagen M, Adler G, Leidl R. Validation of the EuroQol questionnaire in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol 2002;14:1205-15. [PMID: 12439115 DOI: 10.1097/00042737-200211000-00008] [Cited by in Crossref: 82] [Cited by in F6Publishing: 86] [Article Influence: 3.9] [Reference Citation Analysis]
|
| 663 |
Lamb EJ, Wong T, Smith DJ, Simpson DE, Coakley AJ, Moniz C, Muller AF. Metabolic bone disease is present at diagnosis in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2002;16:1895-902. [PMID: 12390098 DOI: 10.1046/j.1365-2036.2002.01363.x] [Cited by in Crossref: 62] [Cited by in F6Publishing: 63] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 664 |
Fujiya M, Saitoh Y, Nomura M, Maemoto A, Fujiya K, Watari J, Ashida T, Ayabe T, Obara T, Kohgo Y. Minute findings by magnifying colonoscopy are useful for the evaluation of ulcerative colitis. Gastrointest Endosc 2002;56:535-42. [PMID: 12297770 DOI: 10.1067/mge.2002.127101] [Cited by in Crossref: 49] [Cited by in F6Publishing: 47] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 665 |
Tüzün A, Erdil A, Inal V, Aydin A, Bağci S, Yeşilova Z, Sayal A, Karaeren N, Dağalp K. Oxidative stress and antioxidant capacity in patients with inflammatory bowel disease. Clin Biochem 2002;35:569-72. [PMID: 12493587 DOI: 10.1016/s0009-9120(02)00361-2] [Cited by in Crossref: 119] [Cited by in F6Publishing: 125] [Article Influence: 5.7] [Reference Citation Analysis]
|
| 666 |
Hanai H, Watanabe F, Saniabadi AR, Matsushitai I, Takeuchi K, Iida T. Therapeutic efficacy of granulocyte and monocyte adsorption apheresis in severe active ulcerative colitis. Dig Dis Sci 2002;47:2349-53. [PMID: 12395908 DOI: 10.1023/a:1020159932758] [Cited by in Crossref: 67] [Cited by in F6Publishing: 67] [Article Influence: 3.2] [Reference Citation Analysis]
|
| 667 |
Orii F, Ashida T, Nomura M, Maemoto A, Fujiki T, Ayabe T, Imai S, Saitoh Y, Kohgo Y. Quantitative analysis for human glucocorticoid receptor alpha/beta mRNA in IBD. Biochem Biophys Res Commun 2002;296:1286-94. [PMID: 12207914 DOI: 10.1016/s0006-291x(02)02030-2] [Cited by in Crossref: 57] [Cited by in F6Publishing: 61] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 668 |
Actis GC, Bruno M, Pinna-Pintor M, Rossini FP, Rizzetto M. Infliximab for treatment of steroid-refractory ulcerative colitis. Dig Liver Dis 2002;34:631-4. [PMID: 12405249 DOI: 10.1016/s1590-8658(02)80205-5] [Cited by in Crossref: 51] [Cited by in F6Publishing: 54] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 669 |
Dierkes-Globisch A, Mohr H. Pulmonary function abnormalities in respiratory asymptomatic patients with inflammatory bowel disease. Eur J Intern Med 2002;13:385. [PMID: 12225784 DOI: 10.1016/s0953-6205(02)00097-3] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 670 |
Lombardi DA, Feller ER, Shah SA. Medical management of inflammatory bowel disease in the new millennium. Compr Ther 2002;28:39-49. [PMID: 11894442 DOI: 10.1007/s12019-002-0041-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
|
| 671 |
Denton AS, Andreyev HJ, Forbes A, Maher EJ. Systematic review for non-surgical interventions for the management of late radiation proctitis. Br J Cancer 2002;87:134-43. [PMID: 12107832 DOI: 10.1038/sj.bjc.6600360] [Cited by in Crossref: 100] [Cited by in F6Publishing: 110] [Article Influence: 4.8] [Reference Citation Analysis]
|
| 672 |
Daperno M, Sostegni R, Rocca R, Rigazio C, Scaglione N, Castellino F, Ercole E, Pera A. Review article: medical treatment of severe ulcerative colitis. Aliment Pharmacol Ther 2002;16 Suppl 4:7-12. [PMID: 12047253 DOI: 10.1046/j.1365-2036.16.s4.2.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 673 |
Musch E, Andus T, Malek M. Induction and maintenance of clinical remission by interferon-beta in patients with steroid-refractory active ulcerative colitis-an open long-term pilot trial. Aliment Pharmacol Ther 2002;16:1233-9. [PMID: 12144572 DOI: 10.1046/j.1365-2036.2002.01264.x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 37] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 674 |
Vergara M, Casellas F, Badia X, Malagelada JR. Assessing the quality of life of household members of patients with inflammatory bowel disease: development and validation of a specific questionnaire. Am J Gastroenterol 2002;97:1429-37. [PMID: 12094861 DOI: 10.1111/j.1572-0241.2002.05684.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 675 |
Denton A, Forbes A, Andreyev J, Maher EJ. Non surgical interventions for late radiation proctitis in patients who have received radical radiotherapy to the pelvis. Cochrane Database Syst Rev 2002;:CD003455. [PMID: 11869662 DOI: 10.1002/14651858.CD003455] [Cited by in Crossref: 56] [Cited by in F6Publishing: 64] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 676 |
Waetzig GH, Seegert D, Rosenstiel P, Nikolaus S, Schreiber S. p38 mitogen-activated protein kinase is activated and linked to TNF-alpha signaling in inflammatory bowel disease. J Immunol 2002;168:5342-51. [PMID: 11994493 DOI: 10.4049/jimmunol.168.10.5342] [Cited by in Crossref: 297] [Cited by in F6Publishing: 311] [Article Influence: 14.1] [Reference Citation Analysis]
|
| 677 |
Straub RH, Herfarth H, Falk W, Andus T, Schölmerich J. Uncoupling of the sympathetic nervous system and the hypothalamic-pituitary-adrenal axis in inflammatory bowel disease? J Neuroimmunol 2002;126:116-25. [PMID: 12020963 DOI: 10.1016/s0165-5728(02)00047-4] [Cited by in Crossref: 74] [Cited by in F6Publishing: 83] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 678 |
Kazemi-Shirazi L, Gasche CH, Natter S, Gangl A, Smolen J, Spitzauer S, Valent P, Kraft D, Valenta R. IgA autoreactivity: a feature common to inflammatory bowel and connective tissue diseases. Clin Exp Immunol 2002;128:102-9. [PMID: 11982597 DOI: 10.1046/j.1365-2249.2002.01804.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 679 |
García-Martín F, Sánchez Heras M, Sánchez Martínez L, Rodríguez-Zapata M. [Nephrogenic diabetes insipidus secondary to chronic interstitial nephritis associated with mesalazine therapy]. Rev Clin Esp 2002;202:245-6. [PMID: 12003743 DOI: 10.1016/s0014-2565(02)71042-4] [Reference Citation Analysis]
|
| 680 |
Gisbert JP, Gomollón F, Maté J, Pajares JM. Role of 5-aminosalicylic acid (5-ASA) in treatment of inflammatory bowel disease: a systematic review. Dig Dis Sci 2002;47:471-88. [PMID: 11911332 DOI: 10.1023/a:1017987229718] [Cited by in Crossref: 76] [Cited by in F6Publishing: 80] [Article Influence: 3.6] [Reference Citation Analysis]
|
| 681 |
Malchow H, Gertz B; CLAFOAM Study group. A new mesalazine foam enema (Claversal Foam) compared with a standard liquid enema in patients with active distal ulcerative colitis. Aliment Pharmacol Ther 2002;16:415-23. [PMID: 11876694 DOI: 10.1046/j.1365-2036.2002.01199.x] [Cited by in Crossref: 40] [Cited by in F6Publishing: 45] [Article Influence: 1.9] [Reference Citation Analysis]
|
| 682 |
Heuschen UA, Hinz U, Allemeyer EH, Autschbach F, Stern J, Lucas M, Herfarth C, Heuschen G. Risk factors for ileoanal J pouch-related septic complications in ulcerative colitis and familial adenomatous polyposis. Ann Surg 2002;235:207-16. [PMID: 11807360 DOI: 10.1097/00000658-200202000-00008] [Cited by in Crossref: 175] [Cited by in F6Publishing: 187] [Article Influence: 8.3] [Reference Citation Analysis]
|
| 683 |
Bauditz J, Wedel S, Lochs H. Thalidomide reduces tumour necrosis factor alpha and interleukin 12 production in patients with chronic active Crohn's disease. Gut 2002;50:196-200. [PMID: 11788559 DOI: 10.1136/gut.50.2.196] [Cited by in Crossref: 91] [Cited by in F6Publishing: 108] [Article Influence: 4.3] [Reference Citation Analysis]
|
| 684 |
Green JR, Mansfield JC, Gibson JA, Kerr GD, Thornton PC. A double-blind comparison of balsalazide, 6.75 g daily, and sulfasalazine, 3 g daily, in patients with newly diagnosed or relapsed active ulcerative colitis. Aliment Pharmacol Ther 2002;16:61-8. [PMID: 11856079 DOI: 10.1046/j.1365-2036.2002.01150.x] [Cited by in Crossref: 57] [Cited by in F6Publishing: 63] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 685 |
Mansfield JC, Giaffer MH, Cann PA, McKenna D, Thornton PC, Holdsworth CD. A double-blind comparison of balsalazide, 6.75 g, and sulfasalazine, 3 g, as sole therapy in the management of ulcerative colitis. Aliment Pharmacol Ther 2002;16:69-77. [PMID: 11856080 DOI: 10.1046/j.1365-2036.2002.01151.x] [Cited by in Crossref: 55] [Cited by in F6Publishing: 59] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 686 |
Heuschen UA, Hinz U, Allemeyer EH, Lucas M, Heuschen G, Herfarth C. One- or two-stage procedure for restorative proctocolectomy: rationale for a surgical strategy in ulcerative colitis. Ann Surg 2001;234:788-94. [PMID: 11729385 DOI: 10.1097/00000658-200112000-00010] [Cited by in Crossref: 80] [Cited by in F6Publishing: 88] [Article Influence: 3.6] [Reference Citation Analysis]
|
| 687 |
Kruis W, Schreiber S, Theuer D, Brandes JW, Schütz E, Howaldt S, Krakamp B, Hämling J, Mönnikes H, Koop I, Stolte M, Pallant D, Ewald U. Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses. Gut 2001;49:783-9. [PMID: 11709512 DOI: 10.1136/gut.49.6.783] [Cited by in Crossref: 79] [Cited by in F6Publishing: 86] [Article Influence: 3.6] [Reference Citation Analysis]
|
| 688 |
Dejaco C, Mittermaier C, Reinisch W, Gasche C, Waldhoer T, Strohmer H, Moser G. Azathioprine treatment and male fertility in inflammatory bowel disease. Gastroenterology 2001;121:1048-53. [PMID: 11677195 DOI: 10.1053/gast.2001.28692] [Cited by in Crossref: 102] [Cited by in F6Publishing: 106] [Article Influence: 4.6] [Reference Citation Analysis]
|
| 689 |
Vuckovic S, Florin TH, Khalil D, Zhang MF, Patel K, Hamilton I, Hart DN. CD40 and CD86 upregulation with divergent CMRF44 expression on blood dendritic cells in inflammatory bowel diseases. Am J Gastroenterol 2001;96:2946-56. [PMID: 11693331 DOI: 10.1111/j.1572-0241.2001.04686.x] [Cited by in Crossref: 51] [Cited by in F6Publishing: 54] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 690 |
Papa A, De Stefano V, Danese S, Chiusolo P, Persichilli S, Casorelli I, Zappacosta B, Giardina B, Gasbarrini A, Leone G, Gasbarrini G. Hyperhomocysteinemia and prevalence of polymorphisms of homocysteine metabolism-related enzymes in patients with inflammatory bowel disease. Am J Gastroenterol 2001;96:2677-82. [PMID: 11569694 DOI: 10.1111/j.1572-0241.2001.04127.x] [Cited by in Crossref: 61] [Cited by in F6Publishing: 68] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 691 |
Rottembourg D, Labarthe F, Arsene S, Jonville-Béra AP, Maurage C, Rolland JC. Headache during mesalamine therapy: a case report of mesalamine-induced pseudotumor cerebri. J Pediatr Gastroenterol Nutr 2001;33:337-8. [PMID: 11593133 DOI: 10.1097/00005176-200109000-00021] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 692 |
Fraser JS, Muller AF, Smith DJ, Newman DJ, Lamb EJ. Renal tubular injury is present in acute inflammatory bowel disease prior to the introduction of drug therapy. Aliment Pharmacol Ther 2001;15:1131-7. [PMID: 11472315 DOI: 10.1046/j.1365-2036.2001.01041.x] [Cited by in Crossref: 49] [Cited by in F6Publishing: 51] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 693 |
Makins RJ, Cowan RE. 5-amino-salicylate in the management of inflammatory bowel disease. Colorectal Dis 2001;3:218-22. [PMID: 12790962 DOI: 10.1046/j.1463-1318.2001.00265.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 694 |
Casellas F, López-Vivancos J, Badia X, Vilaseca J, Malagelada JR. Influence of inflammatory bowel disease on different dimensions of quality of life. Eur J Gastroenterol Hepatol 2001;13:567-72. [PMID: 11396538 DOI: 10.1097/00042737-200105000-00017] [Cited by in Crossref: 106] [Cited by in F6Publishing: 119 |
